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Abstract 
Metalloglycomics: Investigating the Interactions of Metal Complexes with Heparan Mimetics  
 
By Wyatt E. Johnson 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy in Chemical Biology at Virginia Commonwealth University 
 
Virginia Commonwealth University, 2018 
 
Major Director: Nicholas P. Farrell, Professor, Department of Chemistry 
 
Proteoglycans containing Heparan Sulfate (HS), a sulfated glycosaminoglycan (GAG), play a 
major role in the cell signaling process, interacting with many different proteins. HS is over 
expressed on the surface of many cancer cells. Enzymatic cleavage of HS-GAGs by heparanase 
causes release of angiogenic growth factors leading to tumor cell migration.  Heparanase is also 
over-expressed in tumors with significant correlation between metastatic potential and heparanase 
activity. Proteoglycans and their associated enzymes are thus significant drug targets of high 
biological relevance. 
A functional consequence of strong PPC-HS binding has been shown in proof-of-concept studies 
confirming inhibition of the model pentasaccharide, Fondaparinux, by bacterial Heparinase. Such 
metalloshielding by PPCs may also protect HS from enzymatic cleavage by the mammalian 
heparanase; preventing growth factors from binding to HS and/or preventing release of bound 
growth factors and thus inhibiting the metastatic response in the cancer cells. HS-GAGs are also 
receptors for cellular accumulation of cationic Polynuclear Platinum Complexes (PPCs) through 
high-affinity binding to the highly anionic HS. PPCs competitively inhibit uptake of TAMRA-R9, 
a fluorescent nona-arginine derivative, in CHO cells. 
The previously reported series of Pt(II) complexes were investigated as DNA binders, initiating 
the apoptotic cascade. The result of PPC-DNA binding produces long range inter and intra-strand 
 
 
xii 
 
cross-links, that produce structural and conformational changes. Hydrogen bonding between 
phosphate oxygens and square planar Pt(II) nitrogen results in bidentate complexes by either 
backbone tracking or groove spanning of DNA. This complex forms a clamp like structure, called 
a phosphate clamp, similar to that of the arginine fork. Understanding this clamp allows us to 
investigate the structurally similar sulfate binding between metal complexes and target HSPG. 
HSPGs may allow significant research into both a novel cellular internalization of principal metals 
and “metalloshielding” of heparin by these compounds.  
Previous studies have shown that a wide range of metal ions have high affinity to heparin. The 
trend of metal/heparin affinity is believed to be dependent on parameters consisting of the metal’s 
overall size, spatial orientation of the ligands attached to each metal, the net charge and oxidation 
state of these metals, and number of binding sites. Studies have shown relative affinities of sulfate 
and carboxylate groups for the metal ions. These metal cations play an important role in the 
affinity, specificity, and stability of many protein/heparin interactions. The study of simple 
coordination compounds, like Pt, Mn, V, Ru and Co, will allow preliminary results which will 
extend into the PPCs mode of binding. 
This thesis focuses on the concept of metalloglycomics and reviews the interactions of various 
metal complexes with heparin. The covalent and non-covalent interactions of metal complexes 
with heparin resulting in strong bonding are explained through spectroscopy and calorimetry. The 
cleavage inhibition of heparanase by metal complexes is also described. Sulfate cluster anchoring 
shields the sulfates from loss as seen in mass spectrometry. The study of metalloglycomics offers 
potential understanding into the relevance of metal-heparin interactions and possibilities into the 
development of new compounds as therapeutic agents.  
 
 
 
1 
 
Chapter 1: Introduction 
 
1.1 Platinum Complexes 
 
Cisplatin (cis-diamminedichloroplatinum(II)) was first synthesized in 1845, however, it was not 
until 1965 by Rosenberg that platinum complexes were shown to inhibit cell division and even 
later in 1969 that they were shown to possess anticancer properties.(1,2) Since 1978, cisplatin has 
been in clinical use for treatment in breast, ovarian, bladder, head and neck carcinomas.(3) 
Cisplatin is most well-known as part of the combination therapy that is used in the treatment of 
testicular cancer, with a cure rate over 90%.(3) While twenty-eight direct structural analogues of 
cisplatin have entered clinical trials, only cisplatin, carboplatin and oxaliplatin have been approved 
for use in the United States, Figure 1.1.(4) The remaining platinum complexes have failed to show 
improvement over the efficacy of cisplatin.(3) 
Structurally, cisplatin consists of two inert ammine ligands and two labile chloride ligands. 
Platinum (II) exhibits a square planar geometry with a high affinity for nitrogen and sulfur 
molecules found commonly in proteins and DNA nucleobases. The accepted mechanism of 
cisplatin cytotoxicity is through DNA binding.(3) Extracellularly, replacement of the labile 
chlorides is limited due to the high chloride concentration, ~100 mM. Once cisplatin enters the 
cell, either through passive diffusion or active transport, the labile chlorides are replaced forming 
an aquated active platinum species.(6-9) Cisplatin, following aquation, acts as a soft Lewis acid 
and forms stable complexes with S or N donors found in proteins. Cisplatin forms bifunctional 
intra- or inter-strand cross-links with the N7 on guanine and to a lesser extent adenine bases.(10-
14) The 1,2 intrastrand cross-link bends the DNA helix by 32-34o towards the cisplatin bound in 
the major grove, Figure 1.2.(15) These structural distortions can hinder the replication and 
transcription processes and lead to the initiation of the apoptotic cascade.(16) 
While cisplatin and its analogs have been very successful anticancer drugs, their use is limited by 
developed or intrinsic resistance.(17, 18) Resistances may arise from multiple sources including a  
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Figure 1.1 Structures of FDA approved platinum-based anticancer 
drugs. 
 
 
Figure 1.2 Pathways for GG intrastrand crosslinking of DNA by cisplatin. The insert shows the structure of 
guanine and the position of N7, the major Pt binding site. From Ref. 5 
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decrease in cellular accumulation due to increased efflux, increase in deactivation of cisplatin by 
sulfur-containing molecules, Figure 1.3, and increased recognition and repair of cisplatin-DNA 
adducts, Figure 1.4.(19, 20) Reaction with human serum albumin (HSA), a single chain protein 
containing 17 disulfide bridges and one free thiol at Cys-34, is thought to be the main route for 
inactivation in human blood plasma. Another known biomolecule responsible for cisplatin 
inactivation is glutathione (GSH), an abundant thiol-containing tripeptide, which is present in a 
concentration of 1~10 mM intracellularly. Due to the centrality of DNA in both the development 
of the mechanism of action and resistance, new platinum compounds should produce different 
interactions than cisplatin leading to a greater antitumor efficacy. 
The cis configuration of Pt(II) compounds was extensively studied since the trans configuration 
was shown to be clinically inactive. Structure-activity studies showed that a cis configuration was 
necessary for the Pt(II) complex to exhibit anticancer properties. The trans configuration of Pt(II) 
complexes is inactive due to the fast deactivation of the compound and their inability to induce 
DNA structural distortions. However, replacement of the ammine ligands with sterically hindered 
planar ammine ligands produces an equivalent cytotoxicity as cisplatin.(21) The steric effects of 
these ligands resulted in the formation of structurally unique cross-links, Figure 1.5, exhibiting 
cytotoxic activity toward cisplatin-resistant cell lines.(22-26) While certain trans Pt(II) complexes 
exhibit similar cytotoxicity to cisplatin, the reactivity potential of trans complexes with 
inactivating sulfur-containing nucleophiles increases due to the trans-influencing chlorides.(27) In 
an effort to optimize the pharmacological properties of trans compounds, another innovative 
approach was used, synthesizing cationic polynuclear platinum complexes (PPCs). A 
representative trinuclear complex, BBR364, was the first polynuclear platinum compound to enter 
clinical trials as an anticancer agent, Figure 1.6. BBR3464 binds to DNA through long range inter- 
and intra-strand cross-links, Figure 1.7.(30, 31) These lesions do not significantly bend the DNA 
and are therefore not recognized by high mobility group (HMG) and are a poor substrate for 
nucleotide excision repair (NER).(31) Upon binding to DNA, PPCs are capable of producing a B 
to A or Z transition.(4) Although BBR3464 resulted in a non-cross resistant cytotoxicity with  
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Figure 1.3 Structure of sulfur containing nucleophiles: Cysteine, methionine, and 
glutathione. 
 
Figure 1.4 Resistance pathways for cisplatin and its analogs after DNA binding. From Ref. 8 
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cisplatin by inducing a distinct mode of DNA binding, degradation into inactive metabolites by 
sulfur-containing nucleophiles was no exception for BBR3464 as with other covalently binding 
platinum compounds.(4) Replacement of the reactive chlorides by ammines or dangling ammines, 
Figure 1.8, negated the pharmacokinetic difficulties of inactivation by sulfur-containing 
nucleophiles.(32, 33) Replacement of Pt-Cl by substitution-inert ligands becomes unreactive 
toward sulfur nucleophiles, thus enhancing metabolic stability, and also allows study of non-
covalent contributions. Non-covalent interactions showed a new mode of ligand-DNA recognition 
distinct from the conventional modes of intercalation and groove binding. Hydrogen bonding with 
phosphate oxygens results in either backbone tracking or groove spanning through formation of 
phosphate clamps where the PtN4 coordination sphere forms bidentate N-O-N complexes with 
phosphate oxygen atoms condensing DNA.  
One of the major requirements for the effectiveness of an anticancer therapeutic is the successful 
cellular uptake of the compound. A series of structure-activity relationship rules that define the 
favorable characteristics that a successful therapeutic agent should possess was broadly defined 
as: possess a zero net charge, contain two leaving groups or one bidentate leaving group, have 
chloride leaving groups or similar ligands, leaving groups oriented in the cis-configuration, no 
hydroxy or hydroxo ligands as it  increases toxicity, and have inert non-leaving groups such as 
amines.(34-36) However, the previous assumption that platinum complexes need to be neutral to 
enter cells was contradicted by the higher cellular accumulation of the highly cationic PPCs over 
cisplatin.(37) Polynuclear platinum compounds have a remarkable cellular uptake that appears to 
be based on the charge of the compounds. Recently, the endocytic pathway has been utilized as a 
means to deliver the bioactive structure into the cell.(8) Cell penetrating peptides (CPPs), which 
consist of polycationic arginine rich oligopeptides, are capable of migrating across the membrane 
in a short time with the ability to assist other biomolecular compounds that may not readily migrate 
across the membrane.(34-36) For polyarginine CPPs, the effective arginine residues for cellular 
translocation ranged from 6 to 20 residues, with a maximal uptake of approximately 15 
residues.(12)  A length over 20 arginines increases the association to a level that is too high for the  
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Figure 1.5 Unique cross-links formed by transplatin derivatives. From Ref. 29
 
 
Figure 1.6 Structures of transplatin and BBR3464. 
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effective release of the structure from the membrane. The cell surface contains an array of possible 
anionic binding sites, like phospholipids and polysaccharide constituents. While it has been well 
established that charged compounds do not readily cross the membrane without some sort of 
energetic assistance, which may come in the form of pumps or channels. Arginine rich peptides 
have been heavily studied because of their ability to translocate across the plasma membrane of 
living cells.(14) 
The mechanism of PPCs cellular internalization and reactivity with DNA prompted studies into 
PPCs interactions with extracellular heparan sulfate proteoglycans (HSPG) as the mechanism of 
internalization and expand its studies into other transition metals to lower the cytotoxic profile.  
 
1.2 Other Metal Complexes 
 
In the early development of platinum complex analogs, other transition metals with similar 
reactivities as cisplatin were examined. A wide variety of ruthenium-based complexes exhibited 
anti-cancer properties.(38-43) NAMI-A, Figure 1.9, exerts antimetastatic effects which may occur 
through multiple mechanisms.(41-53) Superoxide dismutase (SOD) with an attached manganese 
performs the role of superoxide detoxification in the mitochondria. M40403, Figure 1.9, a SOD 
mimic, has been used as a cancer co-therapy with interleukin-2 (IL-2), an immune-stimulating 
cytokine drug. IL-2 shows enhanced efficacy when used in combination with M40403.(56-65) 
Metals like vanadium, while not specifically used in cancer treatments, have sparked increasing 
interest over their role in biological systems. The discovery of insulin-like properties of the 
vanadate ions stimulated research into the use of vanadium complexes as insulin mimics.(66-79) 
Many more examples of metal-containing drugs have been reported. Complexes containing gold, 
technetium, rhenium, gadolinium, lithium, bismuth, iron, calcium, lanthanum, gallium, tin, 
arsenic, rhodium, copper, zinc, aluminum, and lutetium have all been used in medicine.(80) More 
recently, cobalt complexes have been found to possess antiviral activity.  
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Figure 1.7 Structures from molecular modeling of the major DNA adducts of BBR3464. From Ref. 29
 
 
Figure 1.8 Structures of platinum complexes. 
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The cobalt (III) ion in vitamin B12 is one of a few organometallic complexes found naturally in the 
human body. Due to cobalt’s role in biological processes, mechanisms have been developed to 
overcome cobalt overload, thus cobalt is less toxic to humans than non-essential metals like 
platinum. Cobalt (III), while normally unstable in water, can be stabilized against reduction by 
chelating ligands. One of the most promising applications of cobalt (III) complexes is the CTC 
series, Figure 1.10, that was shown to inhibit replication of Herpes Simplex Virus Type 1 (HSV-
1).(81-87) Hexamminecoablt(III) chloride (Cohex), Figure 1.10, is an example of a classical 
Werner complex that is kinetically stable in aqueous solutions. While Cohex possesses the ability 
to hydrogen bond with the phosphate backbone of DNA, the mechanism of action is still not fully 
understood. Cohex also exhibits significant antiviral activity and acts at the point of viral entry. It 
is conjectured that the high positive charge density of Cohex allows it to disrupt the interaction of 
Sindbis virus glycoproteins with highly negatively charged, polysulfonated heparan sulfate 
receptors, Figure 1.11.(88, 89)  
The acquired and intrinsic resistances to traditional platinum-based anticancer drugs have 
compelled research into the investigation of the properties of other transition metal-based 
compounds.(90-96) The less cytotoxic anticancer potential of cobalt complexes has been 
extensively studied over the last three decades with much time being devoted to the understanding 
of their mechanisms of action.(97, 98) This stimulated research into investigating cobalt-
containing compounds as less toxic alternatives to platinum-based anticancer drugs. In 1952, the 
first biological studies were conducted with cobalt(III) complexes, verifying the low systemic 
toxicity, while some complexes (99) also exhibiting antibacterial properties, Figure 1.12.(100) 
Cohex has been found to have low to moderate toxicity, much less than cisplatin. The cytotoxicity 
of Cohex was measured against BHK cells and compared to that of cisplatin, Figure 1.13.(101) 
The Cohex cytotoxic effects are observed around 1 mM or higher, whereas cisplatin was cytotoxic 
at even the lowest concentration of 80 µM. 
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Figure 1.9 Structure of NAMI-A (left) and M40403 (right). 
 
Figure 1.10 Structure of CTC (left) and Cohex (right). 
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The most significant medical advancement in terms of cobalt compounds thus far, is the clinical 
development of Doxovir (CTC-96) for Herpes Simplex Virus 1, Figure 1.12.(102) The mechanism 
of action of Doxovir is still unknown, however it is speculated that Doxovir covalently binds to 
histidine residues in the active site of a viral enzyme which is crucial for Herpes replication, Figure 
1.14.(103) The hexamminecobalt (III) cation was also discovered to complex with heparin 
interacting through all three of its valencies, which allowed for accurate determination of the 
content of anionic groups in sulfoglycosaminoglycans.(104)  
Ruthenium complexes have also raised great interest and have been tested against a number of 
cancer cell lines.(105-112) Many Ru(III) compounds contain exchangeable ligands and require 
activation by the tumor microenvironment.(113) The antitumor properties of the Ru(III) 
complexes occur when they are reduced to Ru(II) under biological circumstances of low oxygen 
concentration, acidic pH and high levels of glutathione.(114-116) The first approved ruthenium 
complex in clinical trials, NAMI-A, [trans-RuCl4(DMSO)(Im)] (Im = imidazole, DMSO = 
dimethylsulfoxide), Figure 1.9, has low potency in terms of direct cytotoxicity towards cancer 
cells in vitro; however, in vivo, it has significant efficacy in inhibiting tumor metastasis.(117-122) 
The mechanism of action of NAMI-A remains to be elucidated, but data suggests that NAMI-A is 
capable of binding to DNA and RNA. The fluorescent and photo-activating properties of Ru-
polypyridyl complexes have been used in analyzing the abundance and degree of sulfation of HS 
and evaluating HS-growth factor interactions.(123) Ruthenium red, a polycationic stain, has been 
used to visualize acid polysaccharides on the outer surface of cells.(124) While the fluorescent 
properties of [Ru(bipy)3]
2+ have been used to detect heparin and HS.(125) The application of less 
cytotoxic metal complexes can be expected to produce new patterns of metal ion binding with the 
HS chain. Further investigation is deserved to elucidate these lower cytotoxic complexes and their 
interactions with heparan sulfate. 
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Figure 1.11 Heparan sulfate (HS) can play multiple roles during viral infection. On top of cells that express large 
amount of HS, HS can capture viral particles and facilitate in cis subsequent interaction with specific entry 
receptors. HS from non-permissive cells such as endothelia or epithelia can sequester HIV-1 and then mediate in 
trans infection by presenting the virus to permissive cells. HS can contribute to both attachment and transcytosis 
of HIV-1 through epithelia. From Ref. 88 
 
Figure 1.12. Chemical structures of cobalt(III) coordination complexes used in early biological studies. From Ref. 
100 
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Figure 1.13 Comparison of cytotoxicity of Cohex against BHK cells with cisplatin. From Ref. 87 
Figure 1.14. The proposed mechanism of action of Co(III)-acacen complexes, including Doxovir. It is 
postulated that one of the axial ligands is lost in a dissociative manner, followed by covalent binding to 
histidine residues within the active site of key enzymes or signalling proteins. From Ref. 102 
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1.3 Glycosaminoglycans 
 
Heparan sulfate proteoglycans (HSPGs) are polysulfated linear polysaccharides that are found on 
the cell surface and localized in mast cells.(126) These highly charged polysaccharides are made 
up of repeating 1-4 linked polysulfated disaccharide units comprised of glucosamine and 
hexuronic acid, with up to three sulfate moieties per unit. Two structurally similar polysaccharides, 
heparin and heparan sulfate (HS) are the most complex members of the glycosaminoglycan (GAG) 
family, which also consists of chondrotin sulfate, dermatan sulfate, and keratin sulfate.(127) 
Heparan sulfate is biosynthesized as a proteoglycan and strategically located on the cell surface 
and in the extracellular matrix.(127) The role of HS has been shown to include a variety of 
biological processes consisting of cell adhesion, cell growth regulation, blood coagulation, binding 
of cell surface proteins, and tumor metastasis.(127) 
Heparin chains consist of repeating units of iduronic or glucuronic acids and D-glucosamine which 
may be irregularly substituted at the O- or N-sulfate or N-acetyl positions, Figure 1.15.(128) The 
sulfate residues act as the primary receptors for protein recognition which is affected by shape, 
sulfation pattern, and mobility of the heparin chain.(129) The iduronic acid residue can potentially 
adopt either 1C4 chair or 
2S0 skew boat conformations with flexibility occurring around the 
glycosidic linkage.(130, 131) In heparin the 1C4 to 
2S0 confomers ratio is 60:40 while the ratio in 
Fondaparinux is 40:60, more importantly when these fragments interact with a receptor the most 
favorable conformation is adopted, Figure 1.15.(132-134) 
As with other major classes of macromolecules, the biological roles of glycans extend from 
negligible to crucial for the development, growth, functioning, or survival of the cell, Figure 1.16. 
The biological roles of glycans can be divided into two broad categories: the structural and 
modulatory properties of glycans and the specific recognition of glycans by other molecules either 
mediating cell-cell interactions or recognizing extracellular molecules. When conjugated with 
proteins, the proteoglycans are found in connective tissue with critical functions in cellular 
adhesion and migration. When in the extracellular matrix, proteoglycans form large complexes to  
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Figure 1.15. (a) Major repeating disaccharide unit of (i) heparan sulfate; (ii) heparin; and (iii) variable repeating 
disaccharide unit of heparin and heparan sulfate. (b) Equilibrium between the two major conformations found 
in IdoA(2S) residues of heparin and heparan sulfate. From Refs. 132-134 
16 
 
other proteoglycans, to hyaluronan, and to fibrous matrix proteins such as collagen, affecting the 
activity and stability of proteins and signaling molecules within the matrix. Heparan sulfate is a 
sulfated glycosaminoglycan with numerous important biological activities associated with its 
interaction with diverse proteins, including growth factors, proteases, lipid-binding proteins, and 
adhesion proteins.  
Heparan sulfate interacts with a range of proteins, growth factors, and enzymes. Recognition is 
affected by the glycosidic linkages, conformation, sulfate position, and associated cations.(135) 
Heparin is widely used as an anticoagulant drug based on its ability to accelerate the rate at which 
antithrombin inhibits serine proteases in the blood coagulation cascade. Fondaparinux (FPX), a 
synthetic glycosaminoglycan, is one example of the structure activity relationship required to 
produce an antithrombotic (AT) agent.(136) The variation of number and position of carboxylates 
and sulfates on the FPX chain confirmed these essential features for AT binding. The main 
example of HS–protein interactions is the binding to fibroblast growth factors (FGFs), a family of 
23 structurally related polypeptides involved in developmental and physiological processes 
including cell proliferation, differentiation, morphogenesis and angiogenesis.(135, 136) Fibroblast 
Growth Factors (FGFs) are involved in differentiation, proliferation, and angiogenesis through 
high affinity interactions with their receptors. Heparan sulfate protects FGFs from degradation and 
assists their binding to receptors.(137) Again, heparan sulfate chain length, sulfation pattern, and 
conformation all play integral roles in their attachment to growth factors.(138) Binding of basic 
FGF to cell surface HSPG is necessary for its recruitment of high affinity FGF receptors and for 
its activity. In an initial step, these effects are exerted through binding to four highly related 
transmembrane tyrosine kinase receptors (FGFR1–FGFR4) resulting in FGF–FGFR dimerization, 
Figure 1.17.(139) This results in trans-autophosphorylation of FGFRs at intracellular tyrosine 
residues and the activation of the Ras/mitogen-activated protein kinase and/or phosphoinositide 3-
kinases (PI3K)/Akt signaling networks.(140) Increased stimulation of receptor tyrosine kinases 
(RTKs) by growth factors is associated with the metastatic spread of cancerous cells.(141) 
Furthermore, heparan sulfate can be cleaved at the glycosidic bonds by both mammalian and  
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Figure 1.16: Involvement of heparin and heparan sulfate in important physiological processes.  From Ref. 143 
Figure 1: Proposed mechanism of anti-angiogenesis;  PPC binding to 
heparan sulfate blocks growth factor interaction and heparanase cleavage.
Figure 1.17 Free growth factors bind to the HSPGs and are cleaved by heparanse. Heparan Sulfate then 
mediates the dimerization between the growth factor and its receptor for accumulation into the cancer cell, 
resulting in growth. Proposed mechanism of metastatic and angiogenic hindrance from PPC binding. 
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bacterial enzymes. In the mammalian case, enzymatic degradation by heparanase releases pro-
tumorigenic growth factors.(142) 
Due to the highly anionic nature of heparan sulfate, HS may associate with many physiological 
relevant cations which affects the conformation of the heparan sulfate chain.(143-145) Manganese 
deficiency in animals has significant effects on the production of hyaluronic acid, chondroitin 
sulfate, heparin, and other forms of mucopolysaccharides that are important for growth and 
maintenance of connective tissue, cartilage, and bone.(146) It was found that Mn2+ had the 
strongest afﬁnity toward heparin, in terms of decreasing afﬁnities toward heparin, the relative 
relationships were Mn2+ > Cu2+ > Ca2+ > Zn2+ > Co2+ > Na+ > Mg2+ > Fe3+ > Ni2+ > Al3+ > 
Sr2+.(147) Furthermore, Mn2+ had the second highest number of heparin-binding sites at 66.(147) 
The insulin-like properties of vanadium salts have also attracted much attention in the cases of 
insulin resistances or deficiencies.(148-151) Vanadate’s close resemblance to phosphates enables 
it to inhibit many of the enzymes that are involved in phosphate metabolism.(152) Recently, 
vanadium has been shown to activate the ERK pathway via phosphorylation of the EGF-R.(153, 
154) Cu2+ promotes angiogenesis and modulates vascular endothelium growth factor (VEGF) 
activity.(155, 156) The application of hard and soft acid and base concepts of these simple metals 
can be expected to produce new patterns of metal ion binding with the hard sulfate base on the HS 
chain. 
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1.4 Inhibitors 
 
The development of heparanase inhibitors for the treatment of highly malignant tumors is therefore 
of considerable interest. Heparanase inhibitors are a group of compounds inhibiting/decreasing 
heparanase enzymatic activity, which abolish degradation of heparanase on HS of extracellular 
matrix (ECM) and thus subsequential cascade. As an analog of the natural substrate of heparanase, 
heparin is commonly considered to be a potent inhibitor of heparanase as an alternative enzyme 
substrate. This activity is attributed to the high affinity heparin–enzyme interaction and the limited 
degradation of heparin. Heparin, as well as other sulfated polysaccharides, inhibits tumor cell 
heparanase, however, its use is limited due to its potent anticoagulant activity.(157-159) This 
drawback has stimulated research into the potential use of modified, nonanticoagulant species of 
heparin.(157-159) There are other examples of heparanase inhibitors as heparan sulfate mimics to 
produce an alternative enzyme substrate. Glycol-split N-acetyl heparin shows dramatically 
increased heparanase-inhibiting activity with substantial loss of the anticoagulant activity due to 
cleavage of C-2–C-3 bonds which are essential for binding to antithrombin, Figure 1.18.( 157-159) 
Heparanase enzyme activity can be inhibited by shorter but more extensively sulfated 
oligosaccharides, like PI-88, a highly sulfated phosphosulfomannan, Figure 1.18. The success of 
PI-88 inspired development of additional oligosaccharide-based heparanase inhibitors, mimicking 
GAGs as prototypes, like oligomannurarate sulfate, Figure 1.18. Suramin, Figure 1.18, is a 
polysulfonated naphthyl urea that inhibits heparanase with an IC50 of 48 μM.( 157-159) Synthetic, 
linear, noncarbohydrate polyanionic polymers have also been studied as heparin mimetics. Besides 
heparanase substrate mimetics, development of small-molecular weight compounds directly 
inhibiting heparanase activity was also studied.( 157-159) The structure activity relationship study 
of this class of compounds led to 2-[4-propylamino-5-[5-(4-chloro)phenyl-benzoxazol-2-
yl]phenyl]-2,3-dihydro-1,3-dioxo-1 H-isoindole-5-carboxylic acid, benzoxazol-5-yl-acetic acids, 
and 1,3-bis-[4-(1 H-benzoimidazol-2-yl)-phenyl]-urea, Figure 1.18, which displayed heparanase 
inhibitory activity and antiangiogenic effects.( 157-159) Currently, all heparanase inhibitors raise  
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Figure 1.18: Stuctures of Heparanase Inhibitors. 
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specificity concerns, which gives rise to new approaches that develop effective and highly 
specific heparanase inhibitors. 
The development of Growth Factor-Growth Factor Receptor inhibitors for the treatment of 
uncontrollable tumor growth is also of considerable interest, Figure 1.19.(160-164) This has led to 
the development of targeted agents for cancer treatment to target these pathways, strategies like 
monoclonal antibodies (mAbs) and protein kinase inhibitors that are designed to target the GFRs. 
mAb therapeutics act by directly blocking the function of GFRs and/or by antibody-dependent 
cytotoxicity.(165) Protein kinase inhibitors inhibit the cytoplasmic kinase activity of growth 
receptors and subsequently their downstream signaling cascades by rapidly crossing the cell 
plasma membranes and competing with phosphate donor adenosine tyrosine phosphate (ATP) 
and/or phosphorylation substrates.(166) Similar to heparanase inhibitors, heparin mimetics have 
also been used to inhibit growth factors by offering a different substrate than HSPGs. Resistances 
have been linked to the compensatory pathways mediated by other GFRs or mutations in 
downstream signaling pathways.(167) Targeting multiple GFs/GFRs offers signiﬁcant therapeutic 
potential in cancer therapy, since overexpression of GFRs is also responsible for resistance to 
different drugs. 
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Figure 1.19: Schematic diagrams of membrane bound growth factor receptors and their ligands involve in cancer 
progression. Ligands are shown in boxes. (a) Epidermal growth factor receptor (ErbB/Her); (b) insulin-like growth 
factor receptor; (c) transforming growth factor-beta receptor; (d) vascular endothelial growth factor receptor; (e) 
platelet derived growth factor receptor, and (f) fibroblast growth factor receptor. ErbB2 (HER2) binds no known 
epidermal growth factor-like ligands, and ErbB3 shows no tyrosine kinase activity. They relay signals by forming 
heterodimer with other ErbB proteins from EGFR family. TGFβRIII does not pose any intracellular tyrosine 
kinase domain. From Ref. 161-167 
Figure 1.20 Structural analogies between phosphate and sulfate clamps and the arginine fork. 
From Ref. 170 
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1.5 Metallogylcomics 
 
Heparan sulfate has the highest negative charge density of any known biological macromolecule, 
sometimes referred to as “extracellular DNA”, because of its signaling ability, helical nature and 
high content of negatively charged sulfate and carboxylate groups with an average of 2.7 sulfate 
groups per disaccharide.(168) The highly anionic nature of HS means it associates with 
physiologically relevant cations.(169) Therefore, HS may be a ligand receptor for anti-cancer 
cationic metal complexes revealing a new mechanism of cellular accumulation with implications 
for tumor selectivity.(170, 171) The interaction of PPCs with DNA is through the phosphate clamp, 
analogous to the arginine fork, Figure 1.20.(172) The discovery of the phosphate clamp as a 
biologically relevant binding motif suggested analogies with the isostructural sulfate. While these 
interactions are similar, the sulfate-Pt interactions are weaker due to the negative charge being 
more dispersed on a sulfate monoester from delocalization involving three non-ester oxygen atoms 
compared to the phosphate diester with only two non-ester oxygen atoms.(173) This sulfate clamp 
binding will affect protein recognition in strict analogy to inhibition of protein-DNA interactions 
upon formation of Pt-DNA adducts, allowing extension to the consequences of strong PPC-HS 
binding on the function of HS. Sulfate cluster binding is delocalized but will result in neutralization 
of the sulfate charge and further physically protect the sulfate groups from their receptors. 
“Metalloshielding” of HS by metal complexes through the binding of sulfate clusters, Figure 1.17, 
could act on the processes of tumor growth and metastasis, expanding into the relevance of metal 
complexes with HS. 
Cellular internalization of PPCs are critical to their function as DNA binders. Interestingly, cellular 
accumulation differs dramatically between the 6+ and 8+ congeners.(32, 170) The cellular 
accumulation is higher than for cisplatin and actually increases with charge, further, accumulation 
is higher in transformed mast cells in comparison to the parent cells, suggesting possible tumor 
selectivity and overcoming acquired resistances of reduced platinum accumulation.(170)  
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Discovery of HSPG-mediated cellular accumulation of PPCs has expanded this research to 
understanding PPC–HS interactions and the functional consequences of such binding. 
Metalloshielding could protect HS from the action of glycan-degrading enzymes and/or protein 
recognition, similar to DNA-protein inhibition. Invasiveness of tumor cells involves many events 
including adhesion to basement membrane, degradation of the basement membranes through the 
action of HPSE, and migration in response to growth factors. Cellular invasion through ECM 
requires degradation of the matrix by HPSE, and cell motility in response to growth factors. The 
end-point of inhibition of HPSE activity and growth factor binding to HS through modulation of 
growth factor signaling is the prevention of cell invasion and angiogenesis.  
Understanding the structure activity relationship of metal-heparin binding interactions may extend 
as a model for coordination complexes and their interactions to heparan sulfate. The ability to vary 
oxidation state, coordination number and geometry, and lability of ligands allows investigation 
into the structure and function on heparin. Furthermore, this sulfate-cluster interaction will result 
in neutralization of the sulfate charge and protect the sulfate groups from interacting with their 
receptors. Metalloshielding may prevent HS function through inhibition of enzyme and protein 
recognition to HS. This prevention may occur through two potential approaches either as 
heparanase cleavage inhibition or growth factor binding inhibition, Figure 1.21.  
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Figure 1.21: Potential chemical approaches to inhibition of HS-associated enzyme and protein recognition and 
activation through sulfate masking. From Ref. 103 
Figure 1.22: Left: Absorption spectra of MB solutions at different concentration levels. The concentrations (from 
bottom to top) were as follows: 0.4, 0.8, 1.2, 1.6, 2.0, 2.4, 2.8, 3.2, 3.6, 4.0, 4.4, 4.8, 5.2, 5.6, 6.0, and 6.4 x 10 -5 
mol/L. Right: Absorption spectra of a mixture of MB (2.0 x 10-5 mol/L) and CHS. The concentrations of CHS 
(from above to bottom at 664 nm) were as follows: 0.0, 0.2, 0.4, 0.6, 0.8, 1.0, 1.2, and 1.4 x 10-5 mol/L. From Ref. 
180 
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1.6 My contributions to the field of metalloglycomics 
 
Pt-DNA interactions have been widely studied with much of our understanding of M-HS binding 
arising from these previous studies, for example the phosphate clamp and its isostructural sulfate 
clamp.(173) Pt-DNA interactions undergo a “pre-association” or non-covalent interaction before 
the covalent interaction is observed, this same “pre-association” may be extended to M-HS 
binding.(174) Furthermore, the previous assumption that platinum complexes need to be neutral 
to enter cells was contradicted by the higher cellular accumulation of the highly cationic PPCs 
over cisplatin.(175) The mechanism of PPCs cellular internalization and reactivity with DNA 
prompted studies into PPCs interactions with extracellular heparan sulfate proteoglycans (HSPG) 
as the mechanism of internalization and inhibition of function of HS, Figure 1.21. The less 
cytotoxic anticancer potential of other metal ammine complexes may be examined to elucidate the 
structure-function relationship of interactions with HS.  
In these studies, we chose to examine multiple substrates. We examined multiple types of heparin, 
one maintained specific chain lengths while the other ranged between 3-18 kDa, however, both 
types possessed great heterogeneity of sulfate number and pattern to more closely mimic the 
heterogeneity of mammalian HS. Fondaparinux was chosen as a well-defined substrate in order to 
more accurately obtain binding parameters and association constants with the metal complexes, 
also FPX possesses a single point of cleavage when obtaining heparinase cleavage data.  
Since HS interacts mainly through the sulfate regions, we verified that the key binding sites of our 
metal complexes were also through these sulfate regions. Previously, the interaction of Methylene 
Blue (MB) with heparin has been frequently investigated using spectroscopic techniques.(176-
179) In water, MB aggregates with heparin through charge neutralization, increasing the frequency 
of MB dimer formation through π−π stacking.(180) The MB−heparin aggregation reduces the 
absorbance of the sample since there are fewer MB molecules in solution. Higher heparin 
concentrations disperse the MB−heparin aggregate due to the electrostatic repulsion between 
heparin chains allowing MB to self-aggregate, resulting in an increase in absorbance at 570 nm,  
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Figure 1.23: Sulfate loss in the octasaccharide DP8 by binding to polynuclear platinum complexes at varying ESI-
MS/MS voltages. From Ref. 181 
Figure 1.24. 1H NMR chemical shifts for D-Glucosamine-6-O-sulfate plus 1.3 equivalent Zn (OAc). From 
Ref. 186 
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Figure 1.22.(181) In this work, I developed a competitive assay using MB as a reporter to verify 
interactions with the sulfate regions, increasing the concentration of metal complexes protected 
more heparin/FPX chains from interacting with MB. This inhibition of MB interaction increased 
the amount of free, unbound MB in solution concomitantly increasing the absorbance. This 
absorbance increase allowed for the calculation of IC50s of the concentration of metal complexes 
required to inhibit MB from interacting with heparin/FPX, furthermore, the apparent dissociation 
constants were also calculated.  
Confirming the potential for high-affinity binding to the sulfates of heparin, ESI-MS was 
previously employed on a model DP8 octasaccharide in the presence of the highly charged 6+ 
(AH44) and 8+ (TriplatinNC) ions. (182) This non-covalent interaction is the first demonstration 
of a platinum compound interaction with a sulfated polysaccharide. The sulfate moieties on 
heparin are quite labile and the spectrum of free octasaccharides showed a series of peaks 
corresponding to sequential sulfate loss. In contrast, the initial MS of the Pt-heparin adducts shows 
little loss compared to the unprotected heparin. ESI-MS/MS of the 1:1 adducts at increasing 
energies also shows stabilization toward sulfate loss, Figure 1.23.(181) The stabilization is 
dependent on size and charge of the non-covalent platinum compound with the 8+ compound 
significantly more effective. Various metal ions have also been shown to induce a conformational 
contraction in heparins structure due to the number of metal ion adducts, the ionic radii, and the 
ionic valence of metal ions through TOF-MS.(182) This observation suggests a conformational 
change of heparin induced by metal ions that may alter the interactions of heparin and heparin-
binding proteins. (182) ESMS of heparin fragments as ammonium salts may also provide a 
valuable method for their analysis in combination with binding and inhibition assays providing an 
opportunity to derive structural requirements, such as size, charge density, and sequence, in 
relation to biological activity; while MS/MS analysis may provide complete sequence reporting 
for highly sulfated heparin chains if the precursor molecular ion has its acidic groups deprotonated 
through Na+/H+ exchange.(183, 184) To confirm sulfate interactions with metal complexes, I 
employed ESI-MS in this work to determine stoichiometry and sulfate protection. 
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Figure 1.25. Top Left: 59Co NMR spectrum of 10 mM (+/-)-[Co(en)3]Cl3 solution. Left Bottom: 59Co NMR 
spectrum of 10 mM (+/-)-[Co(en)3]Cl3 solution combined with 50 mM sodium d-tartrate. Right: Structure of d-
tartrate. From Ref. 187 
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NMR has also been used in order to ascertain which residues in heparin may be responsible for its 
metal binding capacities.(185) 1H NMR produced very small shifts of D-Glucosamine-6-O-sulfate 
when interacted with zinc acetate, Figure 1.24.(186) The main shifts were observed at the H6 and 
the anomericprotons, which corresponds to the sulfate as the key binding site.(4) Since 59Co 
possesses a relatively high magnetogyric ratio with a magnetic mixing of its occupied and 
excited d orbitals, it experiences substantial paramagnetic deshielding, >15,000 ppm, that will 
reveal even minute changes in its chemical environment.(187) The cobalt chemical shift for the 
cobalt atom in [Co(en)3]
3+ hydrogen–deuterium isotopomers show about a 5 ppm shift for each 
hydrogen atom that is replaced by a deuterium atom.(188) Furthermore, with a nuclear spin 
number of 7/2 associated with a quadrupole moment that provides a very efficient relaxation 
mechanism, 59Co spectra possess broad solution phase resonances. Therefore, the nuclear 
quadrupole moment of 59Co requires the cobalt atom to occupy a highly symmetric environment 
in order to yield line widths of 100–200 Hz. The cobalt ion in the cobalt complex [Co(en)3]3+ 
resides in an octahedrally symmetric environment and possesses a relatively narrow line width, 
however, when the racemic[Co(en)3]
3+ ion pairs with d-tartrate ion, this results in diastereomeric 
ion pairs having clearly separated 59Co NMR resonances that differ in chemical shift by about 5–
6 ppm, Figure 1.25.(188) In this work, I followed each proton shift of D-glucosamine-6-O-sulfate 
when bound to metal complexes at a 1:1 mixing using 1H NMR. To verify that these cobalt 
compounds may interact covalently with the monomer, I also employed 59Co NMR and compared 
the obtained shifts with previously published spectra. Since we verified that these metal complexes 
interact with heparin/FPX through the sulfate regions, we continued with studies to elucidate the 
mechanism of internalization and inhibition of function on HS. 
Previously, our lab investigated the internalization of PPCs mediated through HSPGs and 
association to the final target of DNA.(189) In this work, we obtained estimations of associations 
between metal complexes on heparin/FPX vs DNA using Fluorescence Polarization (FP) and 
Ethidium Bromide (EtBr). FP demonstrated similar affinities of metal complexes for heparin as 
for DNA. EtBr verified this data through FPX sequestering of the metal complexes from DNA. In  
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Figure 1.26. Competition of TAMRA-R9 internalization and Platinum compound in wt CHO cells. 
Compounds (10 μM) were added 5 min prior to the addition of TAMRA-R9 (1.0 μM) and analyzed by 
fluorescence microscopy. Cells were counterstained with Hoescht 33342. Panels: (A) Control; (B) Cisplatin; 
(C) Oxaliplatin; (D) TriplatinNC; (E) AH44; (F) BBR3464. Bar = 10 μm. From Ref. 189 
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order to probe the metal-HS interaction nonaarginine was chosen since it binds to cell surface HS. 
The interaction of TAMRA-R9 with HS has been investigated using spectroscopic techniques.(189, 
190) Cellular uptake of TAMRA-R9 in the presence of platinum drugs was examined, upon drug 
incubation, TAMRA-R9 cell entry was prevented in a charge-dependent manner, Figure 1.26.(189) 
Furthermore, the affinity of TAMRA–R9 for soluble heparin was also quantitated by direct titration 
monitored by fluorescence spectroscopy.(190) To determine the value of the equilibrium 
dissociation constant (Kd), binding data were fitted by nonlinear regression analysis to the 
equation: Kdn = [heparin][TAMRA–R9]n/[heparin·nTAMRA–R9].(190) Because heparin 
(Mr 3000) and TAMRA–R9 (Mr 1836) are essentially homopolymers of similar mass, the value 
of n is likely to be near unity, for n = 1, Kd = 109 ± 13 nM.(190) In this work, I developed a 
competitive assay using TAMRA-R9 as a reporter to indirectly determine the metalloshielding 
ability of these metal complexes on heparin, increasing the concentration of metal complexes 
protected more heparin chains from interacting with TAMRA-R9. This inhibition of TAMRA-R9 
interaction increased the amount of free, unbound TAMRA-R9 in solution concomitantly 
decreasing the fluorescence. This fluorescence decrease allowed for the calculation of IC50s of the 
concentration of metal complexes required to inhibit TAMRA-R9 from interacting with heparin. 
Direct analysis of metal-heparin/FPX interactions was performed to confirm the strength of 
binding using Isothermal Titration Calorimetry (ITC) and Surface Plasmon Resonance (SPR). 
Previously, growth factor-homogeneous heparin mimetic interactions were measured using ITC, 
Figure 1.27.(191) Binding parameters were obtained with calculated dissociation constants in the 
nM range.(191) While growth factor-heterogeneous heparin mimetic interactions were measured 
using ITC, Figure 1.28, the binding parameters were obtained with calculated dissociation 
constants in the µM range.(192) In this work, I developed and refined the ITC assay to determine 
association constants of metal complexes-heparin/FPX that were in the same range as growth 
factors-HS. SPR was also used to more closely mimic cell surface bound HSPGs and their 
interactions with metal complexes, which were also in the range of previously reported growth 
factors-heparin interactions as calculated from SPR in the nM range.(193) 
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Figure 1.27: ITC titrations of FGF with heparin mimetics. Left: Sample titration of FGF2 with HM8. Top panel: 
raw heating power data; the first peak represents a small pre-injection (5 μl) that is omitted in the integrated 
data. Bottom panel: data after peak integration and concentration normalization. Curve fit of the data to a single 
site binding model. Right:  Isotherms for binding of HM6 (open squares) or HM8 (filled squares) to FGF1, and 
for binding of HM6 (open triangles) or HM8 (filled triangles) to FGF2. Dotted vertical lines indicate the 
equivalence point of the titrations with HM6and HM8 at a molar ratio (HM:FGF) of 1 and 0.5. The sample cell 
contained 5 μM FGF, and HM were titrated from a 65 μM stock solution. From Ref. 191 
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Figure 1.28. Analysis of FGF1-heparin hexasaccharide interaction by direct (a) and reverse (b) titrations. In 
the direct titration, 100 μM FGF1 was titrated into 7 μM hexasaccharide and in the reverse titration, 100 μM 
heparin was titrated into 12.5 μM FGF1. (Upper panel) Calorimetric titration trace with the integrated 
isotherms (shown in lower panel). (Solid lines) Best fit to the noncooperative McGhee-von Hippel model. (c) 
Thermodynamic dissection of the interaction between FGF1 and heparin hexasaccharide. (Shading) Free 
energy of binding (ΔG); (crosshatch) enthalpy of binding (ΔH); (diagonal shading) entropy of binding 
(−TΔS). From Ref. 192 
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HSs are acted upon by the bacterial enzyme heparinase, used to mimic the cleavage of mammalian 
heparanase. Degradation by heparanase releases angiogenic and growth factors leading to tumor 
cell migration, growth, and angiogenesis. Heparanase overexpression is associated with tumor 
progression and there is significant correlation between metastatic potential and heparanase 
activity.(194-197) To examine the efficacy of metalloshielding in blocking heparinase and 
heparanase action on HS-containing proteoglycans we used the sulfated pentasaccharide, 
Fondaparinux as a model HS-like substrate. FPX is a substrate for both bacterial heparinases and 
human heparanase and has been used in assay development for screening the efficiency and 
kinetics of potential heparanase inhibitors.(198, 199) FPX is an ideal substrate because it is 
homogeneous with a single point of cleavage by either enzyme which leads to the formation of 
only two products. 1H NMR and colorimetric assays for enzymatic activity have been 
developed.(199) These assays were adapted to examine the inhibitory effect of metal complexes 
on the enzymatic (heparinase) degradation of Fondaparinux.(200) 1H NMR follows the proton 
shift, mainly the anomeric protons, after cleavage, while the colorimetric assay follows the creation 
of a double bond that absorbs at 584 nm. Furthermore, cellular invasion through the extracellular 
matrix (ECM) requires degradation of the matrix by HPSE, and cell motility in response to growth 
factors. The ability of metal complexes to inhibit cell invasion through matrigel basement 
membrane was also accessed using a Boyden-chamber assay.(201) Previously, inhibition of 
heparinase cleavage is effective in a charge and concentration-dependent manner for the metal 
compounds, Figure 1.29.(200) 
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Figure 1.29. Inhibition of heparinase I Fondiparinux 
cleavage (3h incubation) by polynuclear platinum 
complexes and the arginine-rich R9 protein (1:3 
stoichiometry). From Ref. 200 
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1.7 Thesis Outline 
 
The study of coordination complexes with HS-GAGs has several applications in the field of 
bioinorganic chemistry distinct from the well-studied protein and DNA/RNA interactions. 
Extending from simple to polynuclear, metal complexes were chosen to examine the effects on the 
structure and function of HS, Figure 1.17. The application of hard and soft acid and base concepts 
can be expected to produce new patterns of metal ion binding with the hard sulfate base on the HS 
chain. Further, electrostatic and hydrogen-bonding interactions should provide opportunities for 
“non-covalent” interactions compared to “covalent” interactions. 
Chapter 2 describes work that I collaborated on and that was published in Chemistry: A European 
Journal, investigating the interactions of PPCs with the well-defined pentasaccharide 
fondaparinux. Chapter 3 describes work that I collaborated on and that was published in Inorganic 
Chemistry, investing the interactions of simple metal complexes with heterogeneous heparin. 
Chapter 4 describes work that I collaborated on, investigating the interactions of simple covalent 
cobalt complexes with fondaparinux. Chapter 5 describes work that I collaborated on, investigating 
the interactions of simple non-covalent cobalt complexes with fondaparinux. Chapter 6 describes 
work that I collaborated on, investigating the interactions of simple metal complexes with 
fondaparinux. Chapter 7 details the synthesis and characterization of Werner’s Complex. 
Published work will be included in a format as close as possible to that in which it was published. 
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2.1 Abstract: 
 
Cleavage of heparan sulfate proteoglycans (HSPGs) by the enzyme heparanase modulates tumour-
related events including angiogenesis, cell invasion, and metastasis. Metalloshielding of heparan 
sulfate (HS) by positively charged polynuclear platinum complexes (PPCs) effectively inhibits 
physiologically critical HS functions. Studies using bacterial P. heparinus heparinase II showed 
that a library of Pt complexes varying in charge and nuclearity and the presence or absence of a 
dangling amine inhibits the cleavage activity of the enzyme on the synthetic pentasaccharide, 
Fondaparinux (FPX). Charge-dependent affinity of PPC for FPX was seen in competition assays 
with methylene blue and ethidium bromide. The dissociation constant (Kd) of TriplatinNC for 
FPX was directly measured by isothermal titration calorimetry (ITC). The trend in DFT calculated 
interaction energies with heparin fragments is consistent with the spectroscopic studies. 
Competitive inhibition of TAMRA-R9 internalization in human carcinoma (HCT116) cells along 
with studies in HCT116, wildtype CHO and mutant CHO-pgsA745 (lacking HS/CS) cells confirm 
that HSPG-mediated interactions play an important role in the cellular accumulation of PPCs. 
 
2.2 Introduction: 
 
The heparanase/heparan sulfate proteoglycan (HPSE/HSPG) interaction is central to many 
initiating processes of the angiogenesis cascade.(1, 2) Heparanase degrades heparan sulfate (HS) 
into shorter fragments at the cell surface and within the extracellular matrix through its β‐
endoglycosidase activity. These considerations, combined with glycan overexpression on many 
tumour surfaces make proteoglycans significant drug targets of high biological 
relevance.(1, 2) The sulfate residues are the critical recognition features for HS interaction with 
protein substrates such as growth factors. We have recently shown that sulfate cluster masking, or 
“metalloshielding”, by clinically relevant anticancer polynuclear platinum complexes (PPCs)—
Triplatin (BBR3464) and its substitution‐ inert analogue TriplatinNC—is an effective way to  
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Scheme 2.1. Structures of the Polynuclear Platinum Compounds (PPC Library). Counter‐ anions omitted for 
clarity. All compounds with the exception of [Pt(NH3)4]Cl2 were synthesised and used as nitrate salts. 
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protect HS from the actions of its associated enzymes and proteins.(3-5) By protecting the 
substrate, the shielding concept is a complementary and attractive alternative to the time‐
consuming synthesis of small oligosaccharides, which are generally designed to act as competitive 
inhibitors toward heparanase.(1, 2) In this sense, the substrate protection is analogous to that of 
metal complex–DNA interactions with effects on protein recognition. 
To define the detailed structure–activity relationships involved in inhibition of the HPSE/HSPG 
interaction through sulfate cluster masking by PPCs, it is necessary to consider the role of HS as 
ligand in coordination chemistry. The heterogeneity of heparin and HS, especially with respect to 
sulfation patterns, raises challenges for systematic approaches to this understanding.(6, 7) In this 
respect, we have previously used Fondaparinux (FPX) for mechanistic studies.(3, 4) FPX is a 
well‐ defined, highly sulfated synthetic glycosaminoglycan‐ based fragment that has been used 
clinically as an antithrombotic agent since the 1940s.(8) It is a substrate for both bacterial 
heparinases and human heparanase and is useful in screening the efficiency and reaction kinetics 
of potential heparanase inhibitors.(9-11) Fondaparinux is also an ideal substrate for mechanistic 
studies because it is homogeneous, has low molecular weight, and represents a single point of 
cleavage for both mammalian and bacterial enzymes.(9, 11) The course of FPX hydrolysis can 
conveniently be determined by 1H NMR spectroscopy because the anomeric protons are sensitive 
reporters of the cleavage reaction by both heparanase and the bacterial heparinases.(10, 12) 
To develop structure–activity relationships, we have synthesised a small focused library of PPCs 
(Scheme 2.1) to examine the effects of charge and dangling amine on their interactions with FPX 
and the biological consequences thereof. In this paper we describe cleavage inhibition studies in 
the presence/absence of the PPC library using bacterial heparinase (P. heparinus heparinase II) 
and confirm the generality of the metalloshielding concept for the structurally distinct 
enzymes.3, 4 All complexes except the “control” mononuclear Pt‐ tetraammine 
[Pt(NH3)4]
2+ completely blocked the enzyme activity on FPX. Competition assays with methylene 
blue (MB) and ethidium bromide (EtBr) as reporter molecules describe approaches to measure the 
affinity of each compound for FPX binding and compare the results with the extensively studied  
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Scheme 2.2. Synthesis of MonoplatinNC, DiplatinNC and TetraplatinNC. 
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DNA interactions. The combined data is correlated with calculated energies of interaction for 
PPC–heparin fragments from DFT. These studies contribute to the systematic development of 
metalloglycomics—the study of the effects of metal ions and coordination compounds on 
oligosaccharides—expanding the study of bioinorganic chemistry to the third major biomolecule 
after the well‐ studied proteins and nucleic acids.(13) 
 
2.3 Results and Discussion: 
 
Synthesis of the PPC library 
The library of PPC compounds used in this study is shown in Scheme 2.1. The compounds were 
chosen to examine variation in total positive charge, nuclearity (mono/di/tri Pt units) and the 
presence or absence of a dangling amine. The modular nature of PPCs lends itself to systematic 
synthetic procedures as illustrated for the newly reported compounds MonoplatinNC, DiplatinNC, 
and TetraplatinNC in Scheme 2.2. 
Inhibition of enzyme activity on FPX by PPCs 
Cleavage inhibition studies were performed on the sulfated pentasaccharide Fondaparinux (FPX), 
as a model HS‐ like substrate, using the bacterial enzyme (P. heparinus heparinase II). The assay 
was performed as reported previously, where the effect of enzyme on FPX cleavage was monitored 
by following the anomeric region of the 1H NMR spectrum of FPX.(4, 10) Cleavage of FPX by 
the enzyme results in the formation of a trisaccharide unit and a double‐ bond containing 
disaccharide unit. Consistent with the formation of a double bond after enzyme treatment, the 
signal for HD4 (δ=4.06 ppm in FPX) shifts to δ=5.89 ppm (HD4′) and the signal for HD5 disappears. 
Scheme 2.3 shows the enzymatic cleavage products of FPX when treated with P. 
heparinus heparinase II and Figure 2.1 shows the cleavage of FPX in the absence of Pt compounds 
over 24 h (positive control). 
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Scheme 2.3. Structures of Fondaparinux and cleavage products by P. 
heparinus heparinase II. In the presence of PPCs, cleavage was completely 
inhibited. 
 
 
Figure 2.1. Cleavage of FPX by P. heparinus heparinase II. FPX was incubated with P. heparinus heparinase II, 
and 1H NMR spectra were recorded without enzyme and at different time points after addition of enzyme. 
Decrease of 1H NMR peaks of interest are indicated with asterisks. Olefinic proton at  5.89 ppm obtained due 
to cleavage of Fondaparinux labelled as D4´ (see scheme 1).
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To evaluate the ability of the PPC library to inhibit the enzymatic cleavage of FPX, the substrate 
was pre‐ incubated with each of the Pt complexes in a 1:1 stoichiometric ratio for 10 min prior to 
the addition of the enzyme. Figure 2.2 a shows the anomeric region of the 1H NMR spectra of FPX 
in the presence of one equivalent of each of the Pt complexes. Upon addition of the enzyme to 
each sample, reactions were followed for the next 24 h by 1H NMR spectroscopy (Figure 2.2 b). 
All Pt complexes completely inhibited FPX cleavage, with the exception of the mononuclear 
[Pt(NH3)4]
2+, for which weak signals corresponding to cleavage were observed. MonoplatinNC 
differs from the Pt‐ tetraammine by the presence of dangling amine groups, giving an overall 
higher charge (see Scheme 2.1). The different behaviour of these two mononuclear complexes in 
cleavage inhibition indicates the importance of dangling amines. Following on from our first 
demonstration,4 PPCs can now be considered a class of inhibitors of heparanase/heparinase 
cleavage. Charge dispersion, either through dangling amines or multiple Pt‐ tetraammine 
coordination spheres, is needed for the effective inhibition of enzymatic cleavage of HS substrates.  
Di‐  and tetra‐ saccharide fragments inhibit the function of B. eggerthii heparinase II (bacterial 
enzyme) on FPX.(10) The tetra‐ saccharide completely inhibited FPX cleavage, whereas the di‐
saccharide inhibited the cleavage for the first 60 min of enzyme exposure after which only minor 
levels of cleavage of FPX was observed.(10) Thus, the metalloshielding approach is an attractive 
alternative to the time‐  and material‐ costly synthesis of oligosaccharide mimetics. 
The nature of the PPC–FPX and PPC–HS interactions 
NMR Studies 
The NMR chemical shift changes of FPX in the presence of stoichiometric ratios of PPCs were 
analysed to delineate the critical features for effective metalloshielding (Table 2.1). Highly 
positively charged PPCs induce changes to the chemical shifts of the anomeric protons of 
GlcNS(6S), GlcNS(3S)(6S), IdoA(2S) and GlcNS(6S) residues of FPX (Rings A, C, D and E, 
respectively, Scheme 2.3), suggesting the importance of delocalized positive charge of PPC for 
the favourable interaction with HS fragments. MonoplatinNC produced only slight chemical shift  
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Figure 2.2. Anomeric region of the 1H NMR spectra of 1:1 mixtures of FPX and various PPCs a) 
after 10 min incubation in 20 mM Tris buffer, pH 7.5; b) 24 h after treatment with P. 
heparinus heparinase II enzyme. Peaks indicated with asterisks in (b) represent FPX cleavage 
products in the presence of the mononuclear complex, [Pt(NH3)4]2+.
 
 
Table 2.1. 1H NMR chemical shift changes [Δδ=δ(FPX : PPC)−δ(FPX)] 
after incubation of Pt complexes with FPX for 10 min at 37 °C. 
[a] For assignment of the anomeric protons see Scheme 3. 
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changes whereas no discernible shifts were seen for [Pt(NH3)4]
2+. TriplatinNC and AH44 caused 
the largest changes, with AH44 significantly affecting the anomeric protons of the terminal and 
central glucosamine units, suggesting a favourable interaction between AH44 and sulfate groups 
of Ring A and Ring C, and showing the effect of the third Pt centre, with presumably more 
complex–FPX contacts. The HD1 and HD5 protons of IdoA(2S) (Ring D) are also significantly 
affected by the trinuclear complexes. DiplatinNC, which carries the same 6+ charge as AH44, but 
contains dangling amine groups on both the Pt centres, induces significant shifts only to these two 
protons. IdoA(2S) residues of HS are highly conformationally flexible and can adopt both 
the 1C4 chair and 
2S0 skew boat conformations, whereas GlcNS residues prefer only 
4C1 chair 
conformation.(14, 15) The ratio of 1C4 and 
2S0conformers of the IdoA(2S) residue of FPX in 
solution is about 35:65.(14-16) The results suggest that PPCs change the ring conformation and/or 
induce conformational changes to the important glycosidic linkages of the IdoA(2S) residue. The 
NMR changes observed for the FPX anomeric protons in the 1:1 adducts of FPX–PPC validate the 
reasons for effective inhibition of the enzymatic cleavage. 
Protection of FPX against sulfate loss 
Previous ESI‐MS studies showed that AH44 (6+) and TriplatinNC (8+) protect the sulfate groups 
of an octasaccharide (DP8) against dissociation through the formation of sTable 2.1:1 adducts.3 In 
the present work we used ESI‐MS to study the protection from sulfate loss of 1:1 PPC–FPX 
adducts in the gas phase (Figure 2.3). The most abundant charge state observed in previous MS 
studies of FPX was 3−, with three sulfo groups being cleaved and cation/H+ exchange reducing 
SO3 loss.(17) Under our conditions, ESI‐MS spectra of free FPX also showed the sequential loss 
of three sulfate moieties, whereas under the same conditions and in the presence of PPCs, sulfate 
groups of FPX are protected in a manner dependent on charge and number of Pt centres. Consistent 
with the high affinity FPX binding of TriplatinNC, no significant sulfate loss occurred. The same 
was true for AH44, whereas for 1:1 FPX adducts of DiplatinNC (6+) there was also significant 
protection, with only peaks of low intensity observed corresponding to loss of one and two 
60 
 
SO3 groups. For the lower charged MonoplatinNC (4+), loss of two and three sulfate groups is 
observed, but again by far the most dominant peak was the parent ion. 
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Figure 2.3. ESI-MS with inset showing actual isotopic distribution (top) and theoretical isotopic 
distribution (bottom). A) Free FPX showing sequential sulfate loss. B) 1:1 adduct of FPX-
TriplatinNC showing no sulfate loss. C) FPX-AH44 showing no sulfate loss. D) FPX-DiplatinNC 
showing sequential loss of two sulfates. E) FPX-MonoplatinNC showing sequential loss of three 
sulfates. 
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Figure 2.3. ESI-MS with inset showing actual isotopic distribution (top) and theoretical isotopic 
distribution (bottom). A) Free FPX showing sequential sulfate loss. B) 1:1 adduct of FPX-
TriplatinNC showing no sulfate loss. C) FPX-AH44 showing no sulfate loss. D) FPX-DiplatinNC 
showing sequential loss of two sulfates. E) FPX-MonoplatinNC showing sequential loss of three 
sulfates. 
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Figure 2.3. ESI-MS with inset showing actual isotopic distribution (top) and theoretical isotopic 
distribution (bottom). A) Free FPX showing sequential sulfate loss. B) 1:1 adduct of FPX-
TriplatinNC showing no sulfate loss. C) FPX-AH44 showing no sulfate loss. D) FPX-DiplatinNC 
showing sequential loss of two sulfates. E) FPX-MonoplatinNC showing sequential loss of three 
sulfates. 
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Figure 2.4. ESI-MS of Free FPX showing multiple charge states with sequential sulfate loss.  
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Figure 2.4. ESI-MS of Free FPX showing multiple charge states with sequential sulfate loss.  
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Figure 2.4. ESI-MS of Free FPX showing multiple charge states with sequential sulfate loss.  
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Figure 2.5. ESI-MS of FPX + AH78 showing multiple charge states with sulfate loss.  
 
 
Figure 2.6. ESI-MS of FPX + AH44 showing multiple charge states with contamination of AH78 
from previous runs.  
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Figure 2.7. ESI-MS of FPX + DiPtNC showing multiple charge states.  
 
 
Figure 2.8. ESI-MS of FPX + MonoPtNC showing multiple charge states with sequential sulfate loss, 
and a 1:2 FPX:Pt binding stoichiometry.  
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Figure 2.8. ESI-MS of FPX + MonoPtNC showing multiple charge states with sequential sulfate loss, 
and a 1:2 FPX:Pt binding stoichiometry.  
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DFT modelling of PPC–HS interactions 
DFT studies were performed to delineate the effect of structural differences of PPCs in their 
binding to various heparin fragments.(4) Interaction energies and comparison with individual 
phosphate and sulfate are given in Table 2.2. Based on the previously reported interactions of the 
heparin trimer with [Pt(NH3)4]
2+, and heparin hexamer with TriplatinNC,(4) we have now 
modelled the association of MonoplatinNC and DiplatinNC with a heparin tetramer [IdoA(2S)‐
Glc(NS)(6S)]2, as well as the association of AH44 with the analogous heparin hexamer 
[IdoA(2S)‐ Glc(NS)(6S)]3. As previously described,4 the model fragments were derived from the 
NMR‐ based structure PDB1HPN of the heparin dodecamer, comprising repeats of the 
disaccharide units.(14, 18) The interaction energies as measured by DFT increase in the order Pt‐
tetraammine < MonoplatinNC < DiplatinNC < AH44 < TriplatinNC. 
The heparin tetramer–MonoplatinNC model was designed such that the carbon chain of one of the 
dangling amine groups stretched over the hydrophobic groove that is formed in the middle by the 
hydrocarbon rings of the tetramer. The trans geometry of the Pt coordination sphere in 
MonoplatinNC means that the other dangling amine is placed at the edge of the helix, with the free 
amine (‐ CH2NH3+) interacting with N‐ sulfate of GlcNS(6S), which is in the middle of two 
IdoA(2S) residues. The optimised structure is shown in Figure 2.9 a. The hydrocarbon chain along 
the groove is seen to be involved in establishing van der Waals contact with hydrogen atoms from 
two of the sugar residues. Moreover, the chain stretches all the way to the other side of the helix, 
facilitating interaction of the free amine with N‐ sulfate and O‐ sulfate of terminal GlcNS(6S) and 
IdoA(2S) residues, respectively, and also with a carboxylate group of the middle IdoA(2S) residue. 
The interaction energy of the complex is −142 kcal mol−1 and is almost three times that of the 
previously reported Pt‐ tetraammine‐ trimer interaction (Table 2.2).(4) The higher interaction 
energy of MonoplatinNC compared to that of the Pt‐ tetraammine again emphasises the 
importance of favourable interactions arising from the dangling amine ligands. 
Based on the above structure, the interaction of DiplatinNC with heparin tetramer was designed 
by introducing the second Pt centre at the dangling amine that traverses the groove. The optimised  
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 Table 2.2. Interaction energies of isolated phosphate and sulfate anions and heparin fragments with Pt 
coordination spheres in the PPC library (see Scheme 1). [a] From Ref. 4. [b] [GlcNS(6S)‐ IdoA(2S)‐
GlcNS(6S)]. [c] [IdoA(2S)‐ GlcNS(6S)]2. [d] [IdoA(2S)‐ GlcNS(6S)]3. 
72 
 
structure of this interaction and the surface maps are shown in Figure 2.9 b. The second Pt centre 
forms H‐ bonds with the N‐ sulfate of the terminal GlcNS(6S), the carboxylate of the middle 
IdoA(2S) and O‐ sulfate of the terminal IdoA(2S) residues of the tetramer. The calculated 
interaction energy is −171 kcal mol−1. The overlay of the optimised structures of the association  
 complexes formed by the tetramer with MonoplatinNC and DiplatinNC and the free tetramer 
reveals the structural change that results following the interactions (Figure 2.10). It is noticeable 
that, compared to free tetramer, the outer rings have moved in towards the Pt complex to facilitate 
the interactions. MonoplatinNC induces more bending than DiplatinNC because the bulkier second 
Pt centre needs to be accommodated among the negatively charged sulfate groups of the terminal 
residues of the tetramer.  
The structure of AH44 with hexamer reveals that the introduction of a third Pt centre, rather than 
the dangling ammine of DiplatinNC, results in strong cluster binding with three sulfate groups 
from terminal GlcNS(6S) and the central IdoA(2S) and GlcNS(6S) residues (Figure 2.9 c). The 
interaction energy of this model is −202 kcal mol−1, which is greater than the interaction energies 
of MonoplatinNC and DiplatinNC models (Table 2.2), indicating the favourable interaction of the 
third Pt centre. For AH44, the hydrogen bonding cluster formation results in tighter binding 
compared with the cluster formation involving free amine (‐ CH2NH3) groups of DiplatinNC. 
As shown in the surface maps (Figure 2.9), electrostatic and hydrophobic interactions facilitate the 
tight fit of PPCs with heparin fragments. Although the tetramer and hexamer sequences do not 
match exactly that of FPX, the observation of sulfate clusters involving the IdoA(2S) residue is 
consistent with the chemical shift changes observed and suggest that the Pt coordination spheres 
may reside close to this residue. 
Measurement of the FPX–PPC binding interaction 
The NMR studies of the FPX–PPC interaction show significant chemical shift changes indicative 
of strong binding, which is sufficient to inhibit cleavage of FPX by heparinase. To assess the 
strength of the noncovalent FPX–PPC interaction for the different compounds in the PPC library, 
two different competitive inhibition assays were developed (Figure 2.11 a). The first was based on  
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Figure 2.9. a) Left: Optimised structure of heparin tetramer (stick) interacting with MonoplatinNC (ball 
and stick): hydrogen bonding interactions of the free amine of the dangling amine are represented by 
green dashed lines. The favourable van der Waals interactions among the hydrogens can be 
inferred. Right: Solvent accessibility maps using a probe of 1.4 Å: These shows how well the Pt complex 
fits the pockets and grooves in heparin. b) Left: Optimised structure of heparin tetramer (stick) interacting 
with DiplatinNC (ball and stick): hydrogen bonding interactions of the second Pt centre are represented 
by green dashed lines. Right: Solvent accessibility maps using a probe of 1.4 Å: Top, bottom and side 
views show how well the Pt complex fits the pockets and grooves of the heparin unit. c) Left: Optimised 
structure of heparin hexamer (stick) interacting with AH44 (ball and stick). Right: Solvent accessibility 
maps using a probe of 1.4 Å: These maps show the relationship of AH44 (magenta) to the heparin 
hexamer (green). 
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a spectroscopic investigation of the interaction of methylene blue (MB) with heparin and 
HS.(6, 19) The second measured the displacement of intercalated ethidium bromide (EtBr) from 
DNA, which is a useful assay to gauge the relative strengths of coordination compounds to 
oligosaccharides (heparin/HS) versus oligonucleotides (DNA/RNA).(4, 6) To confirm the direct 
strength of the FPX–PPC interactions, isothermal titration calorimetry (ITC) assays were also 
performed. 
Methylene blue reporter assay 
The cationic dye methylene blue (MB) has been used to quantify sulfate content on heparin.(19-
22) The MB absorbance at 664 nm decreases proportionally with increasing heparin concentration, 
allowing the calculation of binding constants.(6, 19) The addition of increasing concentrations of 
FPX to a solution containing MB also resulted in the gradual decrease of MB absorbance (Figure 
2.11 b, left). The association constant between MB and FPX was determined by the Scatchard plot 
and the value (4.0±0.1×104 M−1) is two orders of magnitude lower compared with the previously 
reported association constant between MB and the chondroitin sulfate (CS) polymer 
(1.73×106 M−1).(19) We then studied the effect of metalloshielding on the MB–FPX interaction by 
adding aliquots of MB to a solution containing FPX pre‐ incubated with varying concentrations 
of PPCs. PPCs are competitive inhibitors of the MB–FPX interaction, as evidenced by the higher 
absorbance of MB with increasing platinum complex concentration (Figure 2.11 b and Figure 
2.12). The ability of PPCs to metalloshield FPX against MB binding may be reported as an 
IC50 value, the concentration required to inhibit 50 % binding of MB to FPX. By using MB as a 
reporter, the apparent dissociation constant (Kd(app)) between PPCs and FPX may then be 
calculated. The results are shown in Table 2.3 and illustrate the systematic decrease in IC50 with 
increase in positive charge. TriplatinNC, having the highest overall charge (8+), required the 
lowest concentration to inhibit 50 % of MB binding to FPX, and the lowest apparent dissociation 
constant. Slightly higher affinity was again also correlated with the number of Pt centres. Both 
AH44 and DiplatinNC have the same 6+ charge, but AH44 with one more Pt centre gave slightly 
lower IC50 and Kd(app) values. 
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 Figure 2.10. Overlay of optimized free heparin tetramer (pink), 
heparin tetramer (turquoise) in complex with MonoplatinNC 
(purple) and heparin tetramer (green) in complex with DiplatinNC 
(violet). The alignment was centred at the middle two rings. 
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Ethidium bromide (EtBr) reporter assay 
To compare the PPC–FPX interactions with the well‐ studied PPC–DNA interactions(5, 23, 24)an 
ethidium bromide (EtBr) competition assay was developed applying EtBr as the reporter.(4)This 
assay exploits the decrease in fluorescent properties when the intercalator is removed from DNA 
under the influence of DNA–PPC binding. Upon FPX addition to the EtBr–PPC–DNA system, the 
intercalator binds back to DNA as FPX sequesters the PPC (Figure 2.11 a).(4) The comparative 
binding of different PPCs for DNA and FPX was estimated based on the FPX concentrations 
required to sequester the PPC from DNA, thus allowing EtBr to intercalate, with a concomitant 
increase in its fluorescence. Given that the ability to displace EtBr from DNA differs amongst the 
complexes themselves, the concentration for any individual PPC required to produce an initial 
≥50 % decrease in fluorescence was normalised as the modified EtBr–PPC–DNA fluorescence 
([PPCd]) and 100 % fluorescence was control EtBr–DNA. The data are presented in the form of an 
EC50 value, which reflects the concentration of FPX, [FPXr], required to restore EtBr fluorescence 
to 50 % of the control EtBr–DNA sample in the absence of either PPC or FPX (Figure 2.11 c and 
Table 2.3). Note that FPX has no effect on EtBr–DNA fluorescence. This allows a discussion of 
the EC50 as a ratio index of [PPCd]/[FPXr] (Table 2.3). The ratio index suggests that above 1, PPCs 
have more affinity for FPX than DNA, whereas below 1 PPCs have more affinity for DNA than 
FPX. Thus, AH44 has similar affinities for DNA as FPX, with ratio index of 0.97, while 
MonoplatinNC, DiplatinNC, and TriplatinNC all had slightly higher affinities for FPX than DNA. 
[Pt(NH3)4]
2+ has a very high ratio index but this reflects its very weak binding to DNA(25) and 
thus was eliminated from the comparison of strongly binding DNA compounds (Figure 2.13).  
 
Isothermal titration calorimetry (ITC) 
ITC assays were performed to determine the binding constants between FPX and different PPCs. 
Hydrogen bonding and electrostatic interactions contribute to the enthalpy term, whereas changes 
in conformational freedom and solvation upon complex formation contribute to the entropy 
term.(26, 27) The entropic term reflects the desolvation as a principal contributor.(27) Figure  
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Figure 2.11. PPC–HS binding interaction as measured by EtBr and methylene blue (MB) reporter assays. a) 
Schematic representation of PPC competitive inhibition of MB binding to FPX and sequestering of DNA bound 
PPC by FPX. b) A; absorption spectra of a mixture of MB (18.6 μM) and FPX. The concentrations of FPX 
(from top to bottom at 664 nm) were as follows: 0, 1, 2, 3, 5, 10, and 15 μM. B; absorption spectra of a mixture 
of MB (18.6 μM), FPX (15 μM), and TriplatinNC. The concentrations of TriplatinNC (from above to bottom at 
664 nm) were as follows: 14, 10, 5, and 0.5 μM. c) Curve graph for the EC50 values measured by EtBr reporter 
assay showing the preference of PPCs for FPX, samples were normalised to the controls (no FPX as 0 % and 
EtBr–DNA as 100 %). TriplatinNC data was taken from Ref. 4. 
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2.14 shows the ITC analysis by direct titration for the binding of FPX to TriplatinNC, with similar 
plots for other compounds from the PPC library shown in Figure 2.14. The derived dissociation 
constants are given in Table 2.4  and the derived thermodynamic binding parameters are given in 
Table 2.4. The PPCs follow the same trend seen in the MB assay. The dissociation constants again 
show the same charge‐ dependency with the Kd value for TriplatinNC approximately three orders 
of magnitude higher than that of [Pt(NH3)4]
2+ and AH44 having slightly greater affinity than 
DiplatinNC. Few ligand–heparin(HS) data have been reported. ITC has been used in heparin‐
growth factor interaction assays and in defining the thermodynamic parameters obtained from 
these interactions. The Kd of a synthetic hexasaccharide with a homogeneous sulfation pattern 
interacting with FGF1 and FGF2 gave values of 54 to 855 nM, respectively.(28) On the other hand, 
a mixture of heterogeneous heparin chains showed a Kd of 1.1 to 3 μM for interaction with FGF‐
1.(29, 30) Considering the Kd for FPX–TriplatinNC from Table 2.4 as approximately 40 nM (0.4 
μM), the strength of this interaction is broadly similar to that seen for FGF–oligosaccharide 
interactions. 
Summary 
Indirect and direct assays give an estimate of the strength of the FPX–PPC interaction. The set of 
assays developed give an estimate of strength of binding and relative FPX(HS)/DNA affinities. 
Given clear variations in the quantitation of dissociation constants, care should be taken in 
extrapolating across the assays discussed due to the inherent differences in the nature of these 
assays. Thus, whereas ITC is a “two‐ body” system, the MB and EtBr competition assays become 
“three‐ body and four‐ body” systems, respectively, and are consequently more difficult to 
interpret. Nevertheless, the trends are consistent within each assay and strongly reflect a charge 
dependence. In general, we suggest that use of complementary assays in this manner should be 
encouraged to provide an overall picture of the metal complex–heparin(HS) interaction.(13) 
Correlation of FPX binding with HSPG‐ mediated cellular accumulation of PPCs 
The nature of the PPC–FPX interactions may also be relevant in considering the molecular details 
of PPC cellular accumulation mediated by HS proteoglycans. Polyarginine cellular uptake is  
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 Table 2.3. FPX–PPC dissociation constants as measured by methylene blue (MB), ethidium bromide (EtBr) 
reporter assays and isothermal titration calorimetry (ITC).  
 [a] MB IC50 indicates PPC concentration required to competitively inhibit 50 % of the MB dye from binding to 
FPX. Association constants were calculated from the MB assay for PPCs binding to FPX using a two ligand‐ one 
binding site Scatchard model. [b] ITC analysis reported in Table S1. [c] TriplatinNC data was taken from Ref. 4. 
[d] EC50 is the concentration of FPX required to restore EtBr–DNA fluorescence, and was calculated from the 
normalisation of 0 μM FPX as 0 % and DNA–EtBr only as 100 %. [e] Ratio index calculated from the 
[PPCd]/[FPXr] where [PPCd] is the concentration required to produce an initial <50 % decrease in fluorescence 
and [FPXr] is the concentration required to restore EtBr fluorescence to 50 % of the control EtBr–DNA sample in 
absence of either PPC or FPX (see text). 
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mediated by cell surface heparan sulfate proteoglycans (HSPGs).(31, 32) The conceptualization 
of PPCs as “polyarginine mimics” led to the inhibition of the HSPG‐ mediated cellular 
internalisation and nucleolar localization of the fluorescent‐ labelled nona‐ arginine peptide 
(TAMRA‐ R9) and identification of HSPGs as receptors for PPC cellular 
internalisation.(33, 34) In contrast to the mononuclear clinical platinum agents such as cisplatin 
and oxaliplatin, PPCs uniquely utilise this internalisation mechanism, which could provide an 
approach for selective uptake into tumours with high levels of HSPGs.(34, 35) 
TAMRA‐ R9 entry into human colorectal carcinoma (HCT 116) cells was examined in the 
presence of different PPCs, which prevented cell entry of the peptide in a charge‐ dependent 
manner (Figure 2.15 a). A complete inhibition of TAMRA‐ R9 fluorescence was observed in the 
cells containing TetraplatinNC (10+) and TriplatinNC (8+), whereas the lesser‐ charged analogues 
AH44 (6+) and DiplatinNC (6+) reduced the fluorescence somewhat. MonoplatinNC (4+) failed 
to reduce any fluorescence. Differential accumulation of PPCs into wild type CHO‐ K1 and mutant 
CHO‐ 745 (lacking HS and CS) confirmed the proteoglycan mediation (Figure 2.16).  
The relative cellular accumulation of the PPC library in HCT 116 cells suggest the involvement of 
dangling amine‐ dependent and size‐ dependent mechanisms (Figure 2.15 b). TriplatinNC′s 
higher cellular accumulation compared with AH44 is consistent with previous 
results.(34, 36) DiplatinNC, TriplatinNC, and TetraplatinNC showed similar cellular 
accumulation, even though their overall charges ranged from 6+ to 10+, suggesting an influence 
of the dangling amine. There is no strict correlation between TAMRA‐ R9 inhibition and cellular 
accumulation—as evidenced in the comparison between DiplatinNC and AH44 (Figure 2.15 a and 
b). Likewise, although MonoplatinNC failed to inhibit TAMRA‐ R9internalisation, it showed the 
highest cellular accumulation compared with the other PPCs, and showed higher accumulation 
into wildtype compared with mutant CHO cells (Figure 2.S7). The smaller size may allow it to use 
multiple entry pathways including a size‐ dependent one.(37, 38) Small mononuclear platinum 
drugs like cisplatin, carboplatin, and oxaliplatin reportedly use the hCTR1 copper influx 
transporter for cell entry.(39) Furthermore, the cellular accumulation and cytotoxicity of the  
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 Figure 2.12. Absorption spectra of a mixture of MB (18.6 µM), FPX (15 µM), and PPCs. A) The concentrations 
of [AH44] (from above to bottom at 664 nm) were as follows: 30, 20, 15, 12, 6, and 1 µM; B) The concentrations 
of [DiplatinNC] (from above to bottom at 664 nm) were as follows: 30, 20, 15, and 10 µM; C) The concentrations 
of [MonoplatinNC] (from above to bottom at 664 nm) were as follows: 50, 30, 20, 10, and 1 µM; D) The 
concentrations of [Pt(NH3)4]2+ (from above to bottom at 664 nm) were as follows: 250, 100, 50, and 20 µM. 
Charges omitted for clarity. 
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Figure 2.13. Competitive inhibition of PPC-DNA binding by FPX as measured by EtBr reporter assay with 12.5 
μM EtBr, 10μM ct-DNA and PPC (12.5μM TriplatinNC, 125μM AH44, 62.5μM DiplatinNC, 125μM 
MonoplatinNC and 500μM Pt tetraammine) were incubated for 1h and then increasing concentrations of FPX 
from 10-640μM were added and incubated again for an another 1h and read at 530/590 nm. 
 TriplatinNC data was taken from Peterson et al. 2017. Plot was normalized to 0µM FPX as 0 % and DNA-EtBr 
only as 100%. 
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covalently binding Triplatin (BBR3464) is also affected by copper status.(40 The relative 
cytotoxicity of the PPC library in HCT 116 cells was investigated using MTT viability assays 
(Figure 2.15 c). The PPC cytotoxicity was unpredictably related to their cellular uptake (Table 
2.5).  
Summary 
This section extrapolated the enzyme inhibition and biophysical studies of the FPX–PPC 
interaction to correlate with HSPG‐ mediated PPC cellular accumulation, considering FPX as a 
small but well‐ defined HS model.(6, 34) Although there is clear evidence of proteoglycan 
mediation for this class of molecules, there is no strict correlation with cellular accumulation. In 
general, while HSPGs clearly affect cellular internalisation, the results emphasise that multiple 
complementary pathways exist for small molecule internalisation and, for platinum complexes, no 
single pathway is “all or nothing”.(36-38) The proteoglycan mediation is unique to the PPC class 
and, coupled with the overexpression of glycans on many tumour cell surfaces,(1, 35) the results 
do suggest potential avenues for tumour selectivity of PPC agents based on differential uptake. 
 
2.4 Conclusions: 
 
The results presented in this study demonstrate that the library of PPC complexes, with the 
exception of the mononuclear [Pt(NH3)4]
2+, completely inhibits cleavage of the model HS substrate 
(FPX) by the bacterial P. heparinus heparinase II enzyme. Combined with previous results using 
both bacterial heparinase I and human heparanase,(3, 4) PPCs are a structurally distinct class of 
broad‐ spectrum heparanase cleavage inhibitors acting through metalloshielding. Oligosaccharide 
mimetics have been widely studied for their ability to act as inhibitors of the heparanase enzyme, 
and a number have entered clinical trials.(41, 42)Metalloshielding is an attractive alternative to 
design of heparanase inhibitors and indeed the Phase I and Phase II clinical results of Triplatin 
could be reinterpreted in light of these new glycan‐ related findings.(5, 13) 
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Figure 2.14. ITC analysis of FPX by direct titration of A) [TriPlatinNC], B) [AH44], C) [DiPlatinNC], D) 
[MonoPlatinNC], and E) [Pt(NH3)4]2+. A trace of calorimetric titration (upper panel) and integrated isotherms 
(lower panel). The first peak represents a pre-injection that was omitted in the binding calculations. 
 
 TriplatinNC data was taken from Peterson et al. 2017. Plot was normalized to 0µM FPX as 0 % and DNA-EtBr 
only as 100%. 
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The focused small library studied here begins to elucidate structure–activity relationships. The 
stark contrast between [Pt(NH3)4]
2+ and MonoplatinNC in inhibiting the HS cleavage emphasises 
the importance of dangling amine moieties as well as increased charge dispersion. The relative 
efficacy of the polynuclear set again shows that positive charge dispersion through dangling 
amines and Pt coordination spheres play important roles in masking the HS fragments and 
protecting them against enzymatic cleavage. The ability to form a “sulfate clamp” from the 
interaction of am(m)ines in a Pt coordination unit are a priori likely to be more effective in masking 
than the single positive charge of the dangling amine—nevertheless the two structural features do 
contribute to the overall effect. 
As part of our approach to metalloglycomics, we have developed direct and indirect assays to study 
the nature and strength of “noncovalent” interactions on the biomolecule.(6, 13)Consistent trends 
emerge—affinity is related to charge and in general these substitution‐ inert complexes show 
broadly similar affinity to FPX and DNA. Heparin is often considered as having higher negative 
charge density compared with that of polyanionic DNA, with an average negative charge of 2.7 
per disaccharide compared to that of two negative charges per base pair for DNA.(7) 
In this latter aspect, at least for substitution‐ inert complexes, the approaches to inhibition of HS 
or DNA function are formally analogous—both protect the “substrate” from enzyme and/or protein 
processing. High‐ affinity DNA binding through the phosphate clamp efficiently inhibits 
transcription factors such as TBP (TATA box binding proteins) and restriction 
enzymes.(5, 23, 33) The Kd values found for PPC–FPX interactions are broadly similar to those 
found for growth factor–oligosaccharide interactions.(28-30) This suggests that metalloshielding 
will also be effective in inhibition of oligosaccharide‐ protein function as shown for the effect of 
TriplatinNC on FGF‐ heparin interactions.(4) Overall, the results demonstrate the utility of the 
metalloglycomics concept in developing new classes of molecules for study of glycan structure 
and function. It is clear that oligosaccharides represent a viable alternative cellular target to 
oligonucleotides and the results further emphasise the unique dual‐ function nature of the PPC 
series compared with the mononuclear clinical agents. 
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Table 2.4. ITC analysis showing the obtained binding parameters: dissociation constants (Kd); free energy of 
binding (ΔG); enthalpy of binding (ΔH); and entropy of binding (-TΔS) between PPCs and FPX, best fit to a one 
site model. The standard error from 3 measurements is indicated. 
[a] Kd measured in µM 
[b] Kd measured in nM 
[c] Gibbs Free Energy calculated from the enthalpy and entropy of binding 
 
 
 
 TriplatinNC data was taken from Peterson et al. 2017. Plot was normalized to 0µM FPX as 0 % and DNA-EtBr 
only as 100%. 
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2.5 Experimental Section: 
 
Synthesis and materials 
[Pt(NH3)4]Cl2 was prepared by published methods.(43) TriplatinNC and AH44 (as nitrate salts) 
were prepared as described previously.(23, 24) Fondaparinux (GlcNS(6S)‐ GlcA‐
GlcNS(3S)(6S)‐ IdoA(2S)‐ GlcNS(6S)‐ OMe) was sourced from Sigma–Aldrich. 
Synthesis of new compounds 
MonoplatinNC: A mixture of trans‐ diamminedichloro‐ platinum (1 mmol) and AgNO3 (1.98 
mmol) in anhydrous DMF (18 mL) was stirred overnight with protection from light, and AgCl was 
then filtered off. A solution of the mono‐ Boc‐ 1,6‐ hexanediamine (2.2 mmol) in anhydrous 
DMF (2 mL) was added to the filtrate. The mixture was stirred for three days at ambient 
temperature, protected from light. The solvent was then removed under reduced pressure and the 
residue was dissolved in H2O (100 mL) at 50 °C and filtered through a membrane filter to remove 
any reduced silver and platinum. The filtrate was evaporated to dryness and the residue was 
suspended in 0.5 M HNO3 (25 mL) and stirred for two days at room temperature. The mixture was 
filtered through Celite to remove any unreacted starting materials and reduced silver/platinum. The 
volume of the filtrate was reduced to almost dryness and acetone was added to force the 
precipitation of the product. The formed precipitate (92.3 % yield) was filtered off then washed 
with acetone and dried under vacuum. 1H NMR (300 MHz, D2O): δ=3.00 (t, J=6.6 Hz, 4H 4 H), 
2.67 (t, J=7.2 Hz 4 H), 1.67 (m, 8 H), 1.39 ppm (m, 8 H); 195Pt NMR (300 MHz D2O): δ=−2658 
ppm; elemental analysis calcd (%) for C12H40N10O12Pt: C 20.25, H 5.67, N 19.68; found: C 20.20; 
H 5.54; N 19.44. 
DiplatinNC‐ Boc: The nitrate salt of [{trans‐ PtCl(NH3)2}2{μ‐ H2N(CH2)6NH2}]2+ (1,1/t,t) was 
synthesised from trans‐ diamminedichloroplatinum as previously reported.(44) To 1,1/t,t (1 
mmol) dissolved in DMF (50 mL), AgNO3 (1.98 equiv) was added. The reaction was protected 
from light and stirred for 16 h, then AgCl was removed by filtering through Celite. Mono‐ Boc‐
1,6‐ hexanediamine (2.2 equiv) was added to the filtrate and the reaction was stirred for two days  
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Figure 2.15. An evaluation of PPCs cell uptake, accumulation, and overall cytotoxicity 
in colorectal carcinomas cells (HCT 116). a) PPCs (10 μM) competition with 
TAMRA‐ R9(1 μM) uptake was compared by the presence of fluorescence dye using 
flow cytometry. b) Cellular accumulation of PPCs (10 μM) at 3 and 6 h prior to 
collection was analysed using ICP‐ MS for Pt content. Pt readings were normalised 
to cell number and number of Pt‐ centres for each compound. c) MTT assays were 
employed to determine overall cytotoxicity of PPCs for a 72 h compound incubation. 
 
 TriplatinNC data was taken from Peterson et al. 2017. Plot was normalized to 0µM 
FPX as 0 % and DNA-EtBr only as 100%. 
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at room temperature. The solution was evaporated to dryness under reduced pressure and the 
residue was dissolved in H2O (100 mL) at 60 °C and filtered through Celite to remove any reduced 
platinum and silver. The filtrate was evaporated to dryness and acetone was added to precipitate 
the product. The precipitate was collected through filtration then washed with acetone and dried 
under vacuum to obtain the product (64 % yield). 1H NMR (300 MHz, D2O): δ=3.05 (t, J=9.0 Hz 
4 H), 2.65 (m, 8 H), 1.60 (m, 12 H), 1.40 ppm (m, 30 H). 
DiplatinNC: DiplatinNC‐ Boc (0.1 mmol) was suspended in 0.1 M HNO3 (25 mL) and stirred for 
four days at 50 °C, at which time the suspension had turned into a clear almost colourless solution. 
Completion of Boc‐ deprotection was confirmed by 1H NMR spectroscopic analysis. The solution 
was filtered through Celite to remove any unreacted starting material. The filtrate was evaporated 
to almost dryness and acetone was added to force the precipitation of the product. The residue was 
collected through filtration and washed with methanol and acetone. The crude product (yield 93 %) 
was recrystallised in water. 1H NMR (600 MHz, D2O): δ=3.00 (t, J=9.9 Hz 4 H), 2.65 (m, 8 H), 
1.65 (m, 12 H), 1.37 ppm (m, 12 H); 195Pt NMR (600 MHz, D2O): δ=−2651 ppm; elemental 
analysis calcd (%) for C18H62N16O18Pt2: C 18.31, H 5.29, N 18.98; found: C 18.51, H 5.27, N 
18.47. 
Tetraplatin: A mixture of trans‐ diamminedichloroplatinum (2.2 mmol) and AgNO3 (1.1 mmol) 
in anhydrous DMF (18 mL) was stirred overnight at −20° C in the dark to produce, upon warming 
to room temperature and filtration, mono‐ activated transplatin. This solution was then added to a 
mixture of DiplatinNC (1 mmol) and N,N‐ diisopropylethylamine (DIPEA) (2.2 mmol) in DMF 
(20 mL). The reaction mixture was stirred for two days at ambient temperature. The solution was 
then evaporated to dryness under reduced pressure. The residue was dissolved in a minimum 
amount of H2O and filtered through a syringe filter to remove any unreacted starting materials. 
The filtrate was then evaporated to ca. 1 mL under reduced pressure and acetone (25 mL) was 
added to precipitate the product. The precipitate (46 % yield) was collected through filtration, 
washed with acetone and dried under vacuum. 1H NMR (300 MHz, D2O): δ=2.62 (m, 12 H), 1.61 
(m, 12 H), 1.13 ppm (m, 12 H); 195Pt NMR (300 MHz, D2O): δ=−2405, −2663 ppm; elemental  
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Figure 2.16. Cellular accumulation of PPCs in wt (CHO K1) and mutant CHO-pgsA-745 cells (lack of both 
heparan sulfate and chondrotin sulfate). Platinum complexes were incubated for 1 and 3 hours prior to cell 
collection for Pt detection on ICP-MS. Pt readings were normalized to cell number and number of Pt-centers per 
compound. See Materials and Methods. 
 
 
 TriplatinNC data was taken from Peterson et al. 2017. Plot was normalized to 0µM FPX as 0 % and DNA-EtBr 
only as 100%. 
Table 2.5. Cytotoxicity of noncovalent PPCs in HCT116 cells (n=2). 
 
 TriplatinNC data was taken from Peterson et al. 2017. Plot was 
normalized to 0µM FPX as 0 % and DNA-EtBr only as 100%. 
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analysis calcd (%) for C18H72Cl2N20O18Pt4: C 12.66; H 4.25; N 16.40; found: C 13.04; H 4.20; N 
16.36. 
TetraplatinNC: To Tetraplatin (1 mmol) dissolved in DMF (20 mL), AgNO3 (1.98 equiv) was 
added. The reaction was protected from light and stirred for 16 h, then AgCl formed during the 
reaction was removed by filtering through Celite. Mono‐ Boc‐ 1,6‐ hexanediamine (2.2 equiv) 
was added to the filtrate and the mixture was stirred for two days at room temperature. The solution 
was evaporated to dryness under reduced pressure and the residue was dissolved in H2O (100 mL) 
at 60 °C and filtered through Celite to remove any reduced platinum and silver. The filtrate was 
evaporated to dryness. The residue was suspended in 0.1 M HNO3 (25 mL) and stirred for four 
days at 50 °C, at which time the suspension had turned into a clear almost colourless solution. 
Completion of Boc‐ deprotection was confirmed by 1H NMR spectroscopic analysis. The solution 
was filtered through Celite to remove any unreacted starting material. The filtrate was evaporated 
to almost dryness and acetone was added to force the precipitation of the product. The residue was 
collected through filtration and washed with methanol and acetone. The crude product (yield 84 %) 
was recrystallised in water. 1H NMR (300 MHz, D2O): δ=2.95 (t, J=8.4 Hz 4 H), 2.62 (m, 16 H), 
1.61 (m, 20 H), 1.35 ppm (m, 20 H); 195Pt NMR (D2O): δ=−2652 ppm; elemental analysis calcd 
(%) for C30H106N28O30Pt4: C 17.00; H 5.04; N 18.50; found: C 17.27; H 5.02; N 18.21. 
Molecular modelling and DFT calculations 
All DFT computations were performed using the Guassian 09 suite of programs, with the 
dispersion corrected density functional MO6L, as described in detail elsewhere.(4) The heparin 
models were constructed based on the NMR structure, 1HPN.(14, 18) There are two models in the 
original PDB file, each corresponding to all the iduronic acid residues in either 
a 2S0 or 
1C4 conformation. The structure resulting from the IdoA(2S) in a 
2S0 form has sulfate 
groups well separated compared to the structure from the 1C4 conformation of IdoA(2S). Through 
an initial visual assessment of a crude model, the 2S0 form was found to be more suitable for Pt‐
tetraammine interactions,4 and the structure containing all the IdoA(2S) residues 
in 2S0 confirmation has been used to study the interactions of PPC library with heparin. 
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NMR cleavage inhibition assay 
1H NMR spectroscopy was performed in 250 μL Shigemi tubes with an Avance 600 MHz 
Ultrashield NMR spectrometer (Bruker) with a 1H/13C/15N gradient cryoprobe system; data were 
collected and analysed with the TOPSPIN software (Bruker). The HDO signal was suppressed 
using a 2 s rf‐ field during the relaxation delay. The assay was performed according to the previous 
reports.(4, 10) FPX (300 μM) was pre‐ incubated for 10 min with each of the Pt compounds (300 
μM) in the PPC library (Scheme 2.1) and then was incubated with P. heparinus heparinase II (0.4 
U, 4 μL, Sigma–Aldrich) at 37 °C in deuterated Tris buffer (Tris‐ D11 (20 mM), NaCl (100 mM) 
and CaCl2⋅2H2O (10 mM)), pH 7.5. 1H NMR spectra were recorded for each sample prior to 
addition of enzyme and at different time points thereafter. A control experiment was performed 
under the same conditions in the absence of PPC library to confirm the activity of the enzyme on 
FPX. 
Competitive binding assays 
FPX–PPC binding (methylene blue reporter method) 
All binding studies were performed in triplicate with an Agilent 8453 diode array 
spectrophotometer in a sub‐ micro quartz cuvette with a path length of 10 mm. Aqueous solutions 
of methylene blue chloride (at a constant concentration of 18.6 μM) and fondaparinux (1–15 μM) 
were prepared for determination of optimal MB‐ FPX binding. A concentration of 15 μM of FPX 
was then used for evaluating the inhibition of MB binding by PPCs. Varying concentrations of 
PPCs were incubated with constant concentration of FPX (15 μM) for 15 min at 23 °C. To each 
sample was added MB to a final concentration of 18.6 μMand the absorbance was measured. 
The Scatchard model(19) was applied to calculate the binding constant between MB and FPX by 
plotting  versus n, where  , [L]=concentration of free methylene blue, and n is 
average number of binding sites [Eq.1]: 
(1) 
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where Δϵ is the calculated difference in molar absorptivity between free and bound methylene blue 
in water at 664 nm; Cx
=concentration of heparin added. 
IC50 and Ka(app) values for binding of PPCs to FPX were calculated by converting the MB 
absorption values into a normalised value (minimum and maximum absorbance) and 
the Ka(app) was determined by using Equation 2 
(2) 
where KdL is the dissociation constant for the labelled ligand (MB) and binding site (FPX), SL is 
the total concentration of the labelled ligand, and (BL)o is the equilibrium of labelled ligand value 
when competitor concentration is zero. 
FPX competition with PPC–DNA (EtBr reporter method) 
All samples were read in a 96 well plate at 530/590 nm using a microplate reader (BioTek 
instruments). Ethidium bromide (EtBr) at 5 mM in water was diluted in HEPES buffer (80 
mMHEPES, pH 7.2) and incubated with calf thymus (ct) DNA for 5 min at 25 °C to a final control 
concentration of 12.5 μM EtBr and 10 μM DNA in a final volume of 100 μL. In separate wells, the 
concentration of each individual PPC (dissolved in water and diluted in HEPES buffer) needed 
to decrease EtBr fluorescence by at least or greater than 50 % after 1 h incubation was calculated 
to be the following: TriplatinNC 12.5 μM, DiplatinNC 62.5 μM, AH44 125 μM, MonoplatinNC 
125 μM, and [Pt(NH3)4]2+ 500 μM and denominated as [PPCd]. This concentration was normalised 
as the modified (0 %) EtBr–PPC–DNA fluorescence and 100 % fluorescence was the control 
EtBr‐ DNA. Next, 10 μL of varying concentrations of FPX (0–640 μM) in HEPES buffer were 
added to 90 μL of a combined solution of platinum complex, DNA and EtBr such that the final 
concentrations were [PPCd], 12.5 μM (EtBr) and 10 μM (DNA). After 1 h, the fluorescence was 
read, allowing the calculation of [FPXr], the concentration of FPX required to restore EtBr 
fluorescence to 50 % of the control EtBr‐ DNA sample. Samples were normalised to the controls 
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([PPCd] and no FPX as 0 % and EtBr‐ DNA only as 100 %) to calculate EC50 values using Prism 
software as per Table 2.3. The ratio index was calculated from the drug concentration divided by 
the EC50 value. 
Isothermal titration calorimetry 
ITC data were collected with a VP‐ ITC Microcalorimeter (MicroCal, LLC). All samples were 
degassed for 5 min with a ThermoVac (MicroCal, LLC). For all titrations, injections of Pt 
complexes were pipetted automatically into the reaction cell containing 1.3 mL of FPX at 300 s 
intervals from a 300 μL syringe, while stirring at 75 rpm. In all experiments, 100 mMcacodylate 
buffer (pH 7.4) was used at 25 °C and the thermal reference cell contained 1.3 mL of 100 
mM cacodylate buffer (pH 7.4). Integration of the thermogram peaks was carried out using the 
software supplied with the calorimeter (Origin 7.0). The heats were fitted to a one‐ site model 
using Origin 7.0 to determine Kd, ΔH, and ΔS. ΔG was obtained by using the Gibbs free energy 
equation. 
Mass spectrometry 
Mass spectra were acquired with a Thermo Electron Corporation Orbitrap Velos mass 
spectrometer (Waltham, MA). Samples were introduced by flow injection at flow rates of 0.5 to 
0.7 μL min−1 by using a syringe pump. Electrospray source conditions were kept constant with a 
capillary temperature of 230 °C and capillary voltage between 2.3 and 2.5 kV. FPX and Pt 
compounds were reconstituted in deionised water to a stock concentration of 40 μM. Samples were 
mixed at a 1:1 molar ratio and were incubated at room temperature for 20 min. Samples were 
diluted with addition of Milli‐ Q methanol for a final concentration of 1:10 methanol/water. 
Biological Evaluation 
Cell lines and cell culture 
The human colorectal cancer cell line HCT 116 was obtained from the American Type Tissue 
Collection. HCT116 cells were cultured in RPMI 1640 media (Invitrogen) with 10 % fetal bovine 
serum (FBS) and 1 % penicillin/streptomycin (Gibco) at 37 °C with 5 % CO2. 
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MTT cell viability assay 
HCT116 cells were seeded in 96‐ well plates (5×103 cells/well) in supplemented media (100 μL). 
After incubation overnight, the cells were treated with varying concentrations of the indicated Pt 
compound, in sets containing four replicates for each concentration. After drug exposure for 72 h, 
1 mM MTT (3‐ (4,5‐ dimethylthiazol‐ 2‐ yl)‐ 2,5‐ diphenyltetrazolim bromide) (Sigma) was 
added to each well and incubated for 4 h. The MTT reagent was removed, and 100 μL of DMSO 
was added to each well. All incubations were performed at 37 °C with 5 % CO2. 
Spectrophotometric readings were determined at 570 nm with a microplate reader (Bio‐ Tek 
instruments). Percentage cell survival was determined as treated/untreated controls × 100. Data 
are reported as the average of two independent experiments ± SD. 
Cellular accumulation 
HCT116 cells were seeded in 100 mm dishes (1×106 cells/dish) in supplemented media (20 mL). 
After incubation for 24 h, cells were treated with 10 μM of the indicated Pt compounds for 3 and 
6 h incubations (37 °C with 5 % CO2). The cells were then washed twice with PBS, harvested with 
0.25 % trypsin (Gibco), and washed with 10 mL of PBS. The cell pellets were digested in 1 mL of 
nitric acid for 72 h and diluted with H2O (2 mL). The solutions were filtered through a 0.45 GHP 
filter. Platinum analysis was performed with a Varian 820 inductively coupled plasma mass 
spectrometer (ICP‐ MS). The standards were prepared with K2PtCl4 in concentrations of 10, 50, 
100, 150, and 250 ppb. The blank was 7 % nitric acid. Data was normalized to number of platinum 
centres per drug. 
Cellular internalization 
HCT116 cells were seeded in 6‐ well plates (5×105 cells/well) in supplemented media (3 mL). 
After incubation for 24 h, cells were treated with 10 μM of the indicated Pt compounds and 
incubated for 5 min before the addition of TAMRA‐ R9 (1.0 μM) and further incubation for 1 h at 
37 °C with 5 % CO2. Cells were washed three times with PBS, harvested with 0.25 % trypsin 
(Gibco), and washed twice with cold PBS. The cells were passed through a cell strainer (40 
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μMFlowmi) and then analysed at 488 nm (excitation) and 585±42 nm bandwidth emission with a 
Becton Dickinson FACSCanto II Analyzer flow cytometer (BD Biosciences). 
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3.1 Abstract: 
 
We present spectroscopic and biophysical approaches to examine the affinity of metal–ammine 
coordination complexes for heparin as a model for heparan sulfate (HS). Similar to nucleic acids, 
the highly anionic nature of heparin means it is associated in vivo with physiologically relevant 
cations, and this work extends their bioinorganic chemistry to substitution-inert metal–ammine 
compounds (M). Both indirect and direct assays were developed. M compounds are competitive 
inhibitors of methylene blue (MB)–heparin binding, and the change in the absorbance of the dye 
in the presence or absence of heparin can be used as an indirect reporter of M–heparin affinity. A 
second indirect assay uses the change in fluorescence of TAMRA-R9, a nonaarginine linked to a 
fluorescent TAMRA moiety, as a reporter for M–heparin binding. Direct assays are surface 
plasmon resonance (SPR) and isothermal titration calorimetry (ITC). The Kd values for 
TriplatinNC–heparin varied to some extent depending on the technique from 33.1 ± 2 nM (ITC) 
to 66.4 ± 1.3 nM (MB absorbance assay) and 340 ± 30 nM (SPR). The differences are explained 
by the nature of the technique and the use of heparin of differing molecular weight. Indirect probes 
using the displacement of ethidium bromide from DNA or, separately, fluorescently labeled 
oligonucleotide (DNA-Fl) can measure the relative affinities of heparin and DNA for M 
compounds. These assays showed essentially equivalent affinity of TriplatinNC for heparin and 
DNA. The generality of these methods was confirmed with a series of mononuclear cobalt, 
ruthenium, and platinum compounds with significantly lower affinity because of their smaller 
overall positive charge but in the order [Co(NH3)6]
3+ > [Ru(NH3)6]
3+ > [Pt(NH3)4]
2+. The results 
on heparin can be extrapolated to glycosoaminoglycans such as HS, emphasizing the relevance of 
glycan interactions in understanding the biological properties of coordination compounds and the 
utility of the metalloglycomics concept for extending bioinorganic chemistry to this class of 
important biomolecules. 
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Figure 3.1. (a) Proposed structural analogy of the phosphate clamp to DNA (top) and the sulfate 
clamp to heparin or a sulfated glycan (bottom) formed by PPCs. (b) Blue circles on the 
repeating IdoA(2S)–GlcNS(6S) dimer in heparin (right) and 2′-deoxyguanosine 5′-
monophosphate (left) in DNA indicating possible electrostatic interaction sites, and a red arrow 
showing the favored GuanineN7 site of covalent binding. (c) DNA (PDB: 309D) and heparin 
(PDB: 1HPN) having high negative charge densities, and glycans such as HS having different 
protein recognition and signaling pathways (blue boxes). Inhibition of these pathways results 
in different biological consequences (red boxes). 
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3.2 Introduction: 
 
Glycosaminoglycans (GAGs) such as heparan sulfate (HS) are linear polysaccharides composed 
of repeating disaccharide units of alternating uronic acid and hexosamine residues. When 
conjugated with proteins, heparan sulfate proteoglycans (HSPGs) are found on the cell surface and 
extracellular matrix with critical functions in cellular adhesion and migration.(1,2) HS is 
structurally related to heparin, a free GAG chain produced by mast cells that may be deployed as 
an immune defense mechanism.(3,4) Heparin usually remains highly sulfated, whereas HS 
displays varying degrees of sulfation.(1,2) HS has a multitude of protein partners, mediated 
through hydrogen-bonding and electrostatic interactions between sulfated regions of the 
polysaccharide and the basic amino acids of the protein.(5−7) Specifically, HSPGs interact with 
pro-angiogenic growth factors such as fibroblast growth factor (FGF) to induce dimerization for 
subsequent activation of its receptor.(5,8) FGF-2 directly stimulates tumor and endothelial cell 
proliferation, migration, and survival.(6) In addition to protein interactions, heparin and HSPGs 
are cleaved at glycosidic bonds by bacterial and mammalian enzymes (heparinase and heparanase, 
respectively). This HS cleavage leads to degradation of the extracellular matrix and release of 
growth factors for tumor angiogenesis.(9) Heparanase has a high abundance in many tumors, 
correlating with increased metastatic potential and poor clinical prognosis.(10−12) HSPGs and 
their associated proteins and enzymes are thus attractive drug targets because of their promotion 
of tumor progression at multiple levels: proliferation, invasion, angiogenesis, and metastasis.(3−7) 
The highly anionic nature of heparin and HS means they are associated in vivo with 
physiologically relevant cations, similar to nucleic acids.(13−15) Cation association affects the 
biomolecule conformation and, in some cases, facilitates heparin–protein interactions such as 
Ca2+-dependent heparin–annexin A2 binding.(16) More broadly, Cu2+ promotes angiogenesis, 
although the detailed mechanism is not defined.(17,18) Growth factors are also copper-dependent, 
with a slightly higher affinity for FGF-1 compared to FGF-2.(19,20) Aquated Ca2+, Mg2+, Fe3+, 
and Zn2+ ions, at higher than physiological concentrations, reduce FGF-1 interactions with HS– 
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Figure 3.2. Structures of TriplatinNC and metal–ammine compounds used 
in this study. Counterions are omitted for clarity. 
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heparin.(13) For heparin and HS, there are no strong donor atoms such as the heterocycle nitrogen 
atoms of purines and pyrimidines or even sulfur and nitrogen donors of amino acids such as 
cysteine and histidine available for binding to metal centers, suggesting that harder acids may 
preferentially bind and/or the oligosaccharides can enter into “noncovalent” electrostatic or 
hydrogen-bonding interactions (Figure 3.1). In recent papers, we have suggested that 
metalloglycomics, defined as the study of metal ion–oligosaccharide interactions, can be expanded 
beyond the study of physiologically relevant aquated metal cations to use defined coordination 
compounds.(21−24)  
Using coordination compounds, alteration of the oxidation state, coordination number, and 
geometry and substitution lability of ligands allows for the study of a wide variety of structural 
types to examine the structure and function of sulfated oligosaccharides, extending bioinorganic 
chemistry to this third major class of biomolecules after DNA/RNA and proteins. Specifically, 
HSPGs act as receptors for cellular accumulation of the highly cationic polynuclear platinum 
complexes (PPCs).(21) Molecular recognition of a compound such as TriplatinNC (Figure 3.2) is 
effected through electrostatic and hydrogen-bonding interactions with the sulfate groups on the 
HS chains, analogous to the phosphate clamp formed by the same complex on DNA (Figure 
3.1a,b).(22−24) This high-affinity sulfate binding, or metalloshielding, has functional 
consequences including stabilization of the sulfate moieties, in a defined sequence octasaccharide, 
from dissociation in the gas phase.(23) In biophysical studies, PPC metalloshielding inhibits 
oligosaccharide backbone cleavage by both bacterial (heparinase I) and mammalian (heparanase) 
enzymes.(22,23) Growth factor binding to HS is inhibited in the presence of TriplatinNC with 
consequent effects on downstream kinase signaling.(22) Overall, these interactions lead to the 
inhibition of cellular angiogenesis and eventually the inhibition of in vivo metastasis (Figure 
3.1c).(25,26)  
The molecular-level explanation of these events requires a detailed understanding of PPC–glycan 
interactions. The identity and conformation of the sugar and the number and positions of sulfation 
make GAGs highly complex systems, with significantly more variability than DNA, also with  
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Figure 3.3. MB competition assay for assessment of heparin MW ∼18000 binding. (a) 
The absorbance of a constant concentration of free MB ([AbsMB]) at 664 nm decreases 
with increasing heparin concentration (from top to bottom with 0–15 μM) with a 
concomitant increase in the absorbance of [MB][Hep] at 560 nm. (b) At a constant 
concentration of 15 μM heparin in the presence of varying concentrations of 
TriplatinNC (from bottom to top with 0–5 μM), MB binding is inhibited, reflected in 
the change of [AbsMB]. (c) The percent inhibition of MB (18.6 μM) binding to heparin 
(15 μM) by TriplatinNC (5 μM) in the presence of physiologically relevant 
concentrations of cations is observed at 664 nm. Charges are omitted for clarity. 
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respect to non-bond-forming interactions. As polyelectrolytes, heparin and DNA have strong 
electrostatic interactions that, for heparin and other glycans such as HS, are influenced by the 
positions and amount of sulfation. Heparin is often used as a model for a highly sulfated HS and 
is considered to have the highest negative charge density of any biomolecule at an average of 2.7 
sulfate groups per disaccharide.(3) This paper evaluates spectroscopic and biophysical approaches 
to examine metal ion–heparin interactions, especially in the case of substitution-inert PPCs such 
as TriplatinNC. The fundamental unit of TriplatinNC is the mononuclear 
tetraam(m)ineplatinum(II), and charge-related effects may be examined by a comparison of 
mononuclear and poly(tri)nuclear species. The generality of these approaches is exemplified by 
extension to other mononuclear metal–ammine complexes based on cobalt and ruthenium. The 
fluorescent properties of [Ru(bpy)3]
2+ and its analogues have been used as analytical probes to 
examine the heparin concentration and even content in cells.(27−29) In this paper, we therefore 
compared the relative reactivities of the chosen set of compounds toward both biomolecules (DNA 
and heparin) and in a novel competition assay showed that heparin is a competitor for metal 
complex–DNA binding. The overall results emphasize the relevance of glycan interactions for 
understanding the biological properties of coordination compounds and the potential for extending 
bioinorganic chemistry to this important class of biomolecules. 
 
3.3 Results and Discussion: 
 
We first examined the binding of TriplatinNC and subsequently extended the studies to the cobalt 
and ruthenium systems (Figure 3.2). 
 
The Case of TriplatinNC 
Indirect Assays: Methylene Blue (MB) Competition (Absorbance) 
The cationic dye MB has been used to quantify heparin content and examine heparin binding 
interactions.(30−32) MB interaction with heparin causes a concentration-dependent reduction in  
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(a) 
The Scatchard model was applied to calculate the association constant of MB to heparin by 
plotting 
𝑛
[𝐿]
 versus n, using 
𝑛
[𝐿]
=
(𝐴𝑚𝑎𝑥−𝐴)
(A−𝐴𝑚𝑖𝑛)𝐶𝑥
 , where [L] was the concentration of free MB, and 
where n was the average number of binding sites (𝑛 =
(𝐴𝑚𝑎𝑥−𝐴)
ΔƐ𝐶𝑥
; ΔƐ was the calculated 
difference in molar absorptivity between free and bound methylene blue in water at 664 nm, 
and Cx was the concentration of heparin added).
1   
 
(b) 
To determine the Ka(app) of metal complexes-heparin, the absorbance values were converted to 
the percentage of the control (minimum and maximum absorbance) and a competitive model 
of  
1
𝐾𝑎(𝑎𝑝𝑝)
= 𝐼𝐶50 ×
2𝐾𝑑𝐿[𝑆𝐿−(𝐵𝐿)𝑜] 
[(𝐵𝐿)𝑜
  2
+2𝑆𝐿𝐾𝑑𝐿−3𝑆𝐿(𝐵𝐿)𝑜]
, (KdL is the dissociation constant for the labeled 
ligand (MB) and binding site (heparin), SL is the total concentration of the labeled ligand, and 
(BL)o is the labeled ligand equilibrium value when competitor concentration is zero 
(BL)o=Bmax).
2 
 
(c) 
To determine the Kd of TAMRA-R9 to heparin, the fluorescence data was fitted to a sigmoidal 
plot using the equation 𝐹 =
𝑎−√𝑎2−4[𝑅𝑇 ][𝐿𝑇]
2[𝐿𝑇]
 (where 𝑎 = 𝐾𝑑 + [𝑅𝑇] + [𝐿𝑇], and F is the 
measured fluorescence, Kd is the dissociation constant for the fluorescent probe (TAMRA-R9) 
and binding site (heparin), RT is the total concentration of the heparin, and LT is the total 
concentration of the TAMRA-R9.
3 
 
Equation 3.1. The dissociation constants and apparent binding constants were calculated by the Scathcard model1 
for (a) MB-heparin binding, the competitive model2 for (b) metal-ammine compounds-heparin binding using MB 
as a reporter, and  the nonlinear curve fitting3 for (c) TAMRA-R9 -heparin binding. 
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its absorbance. With increasing heparin concentration, the MB absorbance at 664 and 614 nm 
decreases while that at 570 nm increases, allowing for calculation of the affinity constants (Figure 
3.3a).(30) The Scatchard model (eq 1a) gave a dissociation constant (Kd) value for the MB–heparin 
interaction of 351 nM, comparable to a previously reported value of 578 nM (reported originally 
as the association constant) measured between MB and chondroitin sulfate (another type of 
GAG).(33)  
In the presence of heparin bound to varying concentrations of TriplatinNC, the absorbance of 
added MB dye (at a constant concentration) varies depending on how much TriplatinNC is released 
due to competitive dye binding: [Hep][TriplatinNC] + MB ⇌ [Hep][MB] + TriplatinNC (Figure 
3.3b). The disruption of TriplatinNC binding by MB can be reported as IC50, the concentration of 
the complex necessary to give 50% of free dye, as monitored by MB absorbance (Table 3.1). By 
using MB as a reporter for competitive inhibition in a three-species system, the Kdvalue between 
TriplatinNC and heparin was calculated to be 66.4 ± 1.3 nM (Table 3.1 and eq 1b). 
We also evaluated the competitive binding interactions between TriplatinNC and MB in the 
presence of other physiologically relevant cations. The presence of physiological concentrations 
of other cations affects the absorbance of the dye in the MB–heparin interaction.(34) The change 
in absorbance varies depending on the degree of cation release due to competitive dye binding, 
and this release is based on the concentration, charge, and ionic radius of the cations.(34) High 
concentrations of Na+ showed the greatest effect on MB binding, followed by Ca2+ > Mg2+ > 
K+(Figure 3.3). With the addition of TriplatinNC (at a constant concentration), MB binding is 
further inhibited with no observed difference from the TriplatinNC–heparin binding in the 
presence of other cations, although the increase in inhibition is consequently smaller in the case of 
the highest concentrations of Na+ at 150 mM. There is a difference between the Na+ effects on 
DNA, where concentrations above 600 mM were needed to completely restore condensed DNA 
to the relaxed form in the presence of TriplatinNC, which is a very effective DNA condensing 
agent.(35,36) We note that the SPR data to be discussed below were obtained in the presence of  
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Figure 3.4. Observed absorbance change of binding between MB and heparin with a constant concentration of 
18.6 µM MB, 15 µM heparin, 5 µM TriplatinNC, and physiological relevant concentrations of cations; absorbance 
changes with added concentrations of cations, while no change between the Pt and heparin binding was observed. 
Aqueous solutions of methylene blue chloride (at a constant final concentration of 18.6 µM), heparin MW 18000 
(at a constant final concentration of 15 µM), and TriplatinNC (at a constant final concentration of 5 µM) were 
used for evaluating the absorbance change of MB-heparin binding by physiological relevant concentrations of 
cations (Sodium Chloride: 150 mM, Potassium Chloride: 5 mM, Calcium Chloride: 1.3 mM, and Magnesium 
Chloride: 1 mM). 
Table 3.1. IC50 and Kd values of TriplatinNC and Metal-ammine compounds in competitive 
inhibition assays using MB or TAMRA-R9. 
aThe IC50 value was determined as the concentration of complex required for half-maximal 
binding of the dye (18.6 μM or 100 nM) to heparin MW ∼18000 (15 or 625 μM) for MB or 
TAMRA-R9 binding assays, respectively. 
bDissociation constants were calculated from the MB assay for TriplatinNC and metal–
ammine compound binding to heparin MW ∼18000 using a competitive inhibitor model. 
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150 mM NaCl, confirming that TriplatinNC is capable of binding to heparin at physiologically 
relevant concentrations of small cations. 
Indirect Assays: TAMRA-R9 Competition (Fluorescence) 
TAMRA-R9 is a polycationic, nona-L-arginine peptide linked to a fluorescent TAMRA moiety. In 
this case, the fluorescence of TAMRA-R9 at 590 nm (emission) increases with increasing heparin 
concentration, and a Kd value of 109 nM for TAMRA-R9–heparin binding has been previously 
reported.(37) In our hands, we obtained a Kd value of 405.9 nM, and the difference may be 
attributed to the use of a larger heparin (MW 18000) than that previously reported (Figure 3.5a). 
There is also slight variability in the Kd values under similar conditions because heparin 
preparations can be very heterogeneous.(3,37) We have previously used the fluorescence of 
TAMRA-R9 as a reporter to identify HSPGs as receptors for platinum complex cellular 
internalization.(21) Analogous to the enhanced fluorescence of an intercalator such as ethidium 
bromide (EtBr) upon DNA binding, TAMRA-R9 fluorescence increases when bound to heparin. 
Again, in the presence of heparin bound to varying concentrations of TriplatinNC, the addition of 
TAMRA-R9 (at a constant concentration) results in the observation of fluorescence proportional 
to the amount of TAMRA-R9–heparin binding with TriplatinNC release: [Hep][TriplatinNC] + 
TAMRA-R9 ⇌ [Hep][TAMRA-R9] + TriplatinNC (Figure 3.5b). The ability of TriplatinNC to 
compete with TAMRA-R9 for heparin binding can be reported as the IC50 required to produce 50% 
fluorescence compared to control of heparin dye in the absence of the complex (Table 3.1). 
Direct Assays: Surface Plasmon Resonance (SPR) 
For direct analysis, SPR was used to estimate the TriplatinNC–heparin affinity. SPR is a label-
free, real-time quantification of the interaction between the immobilized ligand on the sensor chip 
and the analyte being injected in a continuous flow over the ligand.(38) When the ligand and 
analyte interact, the refractive index changes, and the response is reported as response units (RU). 
SPR has been used for determining the heparin concentration, metal–heparin binding, and metal–
heparin binding effects on the growth factor and growth factor receptor recognition.(13,39) A 
mixture of metal ions reduced the affinity of FGF-1 binding to heparin from Kd = 22 to 350  
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Figure 3.5.  TAMRA-R9 competition assay with metal-ammine compounds binding to heparin. (a) Normalized 
fluorescence spectra of TAMRA-R9 (100 nM) changes with various concentrations of heparin. TAMRA-R9 
binding to heparin is inhibited with increasing concentrations of metal complex.  Normalized Fluorescence 
spectra of TAMRA-R9 were changed to a percentage of maximum and minimum fluorescence with % inhibition 
correlated to a decrease in fluorescence. (b) Concentrations for TriplatinNC were the following: 125, 62.5, 31.3, 
15.6, and 7.8 µM. (c) Concentrations for metal-ammines were the following (red) Co(NH3)6]3+; (purple) 
[Pt(NH3)4]2+; (blue) [CoCl(NH3)5]2+; and (green) [RuCl(NH3)5]2+: 2500, 1250, 625, 312.5, 156.3, 78.1, 39.1, and 
19.5 µM. 
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nM.(13)In the study of heparin–protein interactions by SPR, heparin is preferentially immobilized 
onto the sensor chip rather than the protein because this more closely mimics natural biological 
systems, where HS is found at the cell surface as a proteoglycan and binds to target 
proteins.(40,41) A common method for heparin immobilization is to use a biotinylated heparin and 
a streptavidin-coated sensor chip.(40) The high charge of TriplatinNC caused significant 
nonspecific binding to both the dextran sensor chip surface and streptavidin. Therefore, in 
collaboration with Reichert Technologies, a Neutravidin-coated mixed self-assembled monolayer 
(mSAM) sensor chip was used to minimize the background noise and resulted in significantly 
lower nonspecific binding of TriplatinNC to the sensor surface, although there is still some binding 
to the reference, causing some distortion in the binding curves (Figure 3.6). At the lowest 111 nM 
concentration, there was a large (repeatable) decrease in the signal, which may be due to random 
adsorption of the highly charged molecule in the system. An analysis of the binding curves for the 
interaction between heparin and TriplatinNC was generated using the TraceDrawer program. 
Although a global fit was not possible, a one-site model and 1:1 TriplatinNC–heparin stoichiometr, 
gave a Kd value of 340 ± 30 nM (Figure 3.6). Because the immobilized heparin had MW 15000, it 
is plausible that there could be multiple binding sites, which may affect the estimated Kd values.  
Direct Assays: Isothermal Titration Calorimetry (ITC) 
ITC accurately determines the thermodynamic contributions of both enthalpy (ΔH) and entropy 
(−TΔS) changes to the free energies of binding (ΔG). ITC measures the heat released or absorbed 
into the system upon the binding of two molecules and is proportional to the overall strength of 
binding.(42) ITC has been used in heparin growth factor assays and in defining the thermodynamic 
parameters from these interactions.(43,44) A mixture of heterogeneous heparin chains interacting 
with FGF-1 gave Kd values of 1.1–3 μM.(45) Using a smaller (MW 3000) heparin, we studied the 
heparin–TriplatinNC interaction by ITC. As TriplatinNC was titrated into the reaction cell 
containing heparin (Figure 3.7), the produced peaks were integrated to yield the heat released per 
titration. Using a one-site model for TriplatinNC–heparin gave a Kd value of 33.1 ± 2 nM (Figure 
3.7). The enthalpy term reflects the strong electrostatic and hydrogen-bonding interactions  
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Figure 3.6. Determination of the TriplatinNC–heparin binding affinity by SPR using a 
biotinylated heparin (MW ∼15000) immobilized to Neutravidin on a planar mSAM chip. (a) 
After injection of 5, 1, 0.333, and 0.111 μM of TriplatinNC, the solution was allowed to flow 
over the chip for 5 min to allow binding; a buffer was then injected, and after flowing for 5 min, 
dissociation was assessed. (b) The amount of TriplatinNC bound at equilibrium was corrected 
for background and plotted versus input TriplatinNC concentration. Analysis by equilibrium 
parameters using a 1:1 binding model yielded a Kd value of 340 ± 30 nM. 
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occurring between the sulfates and ammines, while the entropic term reflects the possible release 
of water molecules as well as the loss of conformational mobility of the iduronic acid 
ring.(42) This loss of conformational mobility results in a high entropy value and commonly 
reflects the phenomenon of entropy–enthalpy compensation.(46) Overall, the interactions 
observed produce a spontaneous and favorable binding between TriplatinNC and heparin (ΔG = 
−10.1 ± 0.1 kJ/mol). 
Summary 
Overall, the results from MB and TAMRA-R9 reporter assays demonstrated strong TriplatinNC–
heparin interactions, which were confirmed by SPR and ITC. MB and TAMRA-R9 dyes had 
similar estimated Kd values for binding to heparin itself, 351 and 405.9 nM, respectively. The 
TriplatinNC–heparin binding gave similar Kd values of 66.4 ± 1.3 and 33.1 ± 2 nM from the MB 
assay and ITC system, respectively, whereas the SPR system displayed a magnitude weaker 
affinity (340 ± 30 nM). Because the SPR system measured TriplatinNC interacting with heparin 
immobilized to the surface of the sensor chip, this immobilization may reduce the degrees of 
freedom of the heparin molecule to interact and thus affect the kinetics and affinity of the 
TriplatinNC–heparin interaction.(47) However, the heparin immobilization more closely mimics 
natural biological systems where the HS chains are covalently attached to core proteins as HSPGs. 
There are few small molecule–heparin binding data for comparison by SPR and ITC because the 
majority of studies have been on protein–heparin interactions. 
Comparison of the PPC–Heparin and PPC–DNA Affinities 
The Kd values with heparin from the indirect reporter assays and the direct SPR and ITC 
techniques raise questions about the relative affinity of TriplatinNC for DNA or heparin. 
TriplatinNC and substitution-inert complexes in general bind with high affinity to DNA with a 
measured Kd(app)value of 17.7 nM (reported as Ka(app)).(48) Given the highly anionic nature of both 
biomolecules, what are the relative affinities of a molecule such as TriplatinNC for DNA or 
heparin? As mentioned, heparin is considered to have an average of 2.7 sulfate 
groups per disaccharide compared to that of two phosphate groups per base pair for DNA. We  
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a b c 
d e f 
Figure 3.7.  Isothermal titration calorimetry measured the heat released by titrations of (a) TriplatinNC, (b) 
[Co(NH3)6]3+ , (c) [Ru(NH3)6]3+ , (d) [Pt(NH3)4]2+ , (e) [CoCl(NH3)5]2+ , and (f) [RuCl(NH3)5]2+ into the heparin 
solution. 
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therefore developed a number of competitive binding assays to answer this question and to 
complement the indirect and direct HS–PPC assays. Fluorescence polarization, EtBr, and circular 
dichroism (CD) competition assays compared the ability of heparin to compete with DNA for the 
binding of charged metal complexes. 
DNA Competition Assay 
A fluorescence polarization assay measures the tumbling motion of molecules to describe binding 
events. Typically, the assay incorporates a small fluorescently labeled molecule, such as a DNA 
oligonucleotide, and an interacting molecule of similar or higher molecular weight, such as a 
protein. Upon binding, the rotation of the fluorescent molecule decreases, which is measured by 
emission fluorescence passing through parallel and perpendicular polarized light paths.(38) For 
our purposes, we examined whether changes in the rotation of a small fluorescently labeled DNA 
hairpin (DNA-Fl; 23nt; MW 7705) could be detected upon binding of the lower-molecular-weight 
metal complex, TriplatinNC (MW 1650). 
Reproducible saturation binding curves were established with the concentration of drug required 
for half-maximal binding determined to be EC50 = 1.92 μM (Figure 3.8a and Tables 3 and 4). 
When the same unlabeled DNA hairpin was subsequently titrated into the reactions, a predicTable 
3.shift of the curve occurred as unlabeled DNA competed with labeled DNA for binding of 
TriplatinNC with concomitant increases in the apparent EC50 values (Figure 3.8a and Table4). The 
fold changes of the apparent EC50 values were 1.1, 1.9, and 11.6 with changing DNA/DNA-Fl 
ratios of 0.2:1, 2.11:1, and 21.2:1, respectively (Table 3.4). When heparin MW ∼3000 was used 
as the competitor ligand, the EC50 values similarly increased relative to the control DNA-Fl (Figure 
3.8b and Table 3.3). In comparison, the fold increases in the EC50 values were 1, 2.1, and 10.3 
upon the addition of increasing concentrations (0.2–21.2 μM) of heparin, closely comparable to 
the DNA/DNA-Fl ratios used. These results therefore suggest a similar affinity for TriplatinNC 
between low-molecular-weight heparin and DNA substrates. 
For a second competition assay, we used an adaptation of the well-known EtBr fluorescence assay 
to measure the binding affinities of metal complexes.(22,48) The fluorescence from intercalator  
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Table 3.2. A comparison of dissociation constants and Gibbs free energy by the 
enthalpy and entropy of the calorimetric data fitted to a single site-binding model for 
TriplatinNC and metal-ammine complexes. 
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binding to DNA is quenched when the intercalator is displaced upon TriplatinNC–DNA binding. 
Upon the addition of increasing concentrations of heparin, TriplatinNC is sequestered and the 
nucleic acid now becomes available to bind the intercalator, with a resultant increase in 
fluorescence (Table 3.5). From Figure 3.8c, we can see that a concentration of 12.5 μM 
TriplatinNC reduced EtBr fluorescence to approximately 25% of the control value. A 
concentration of 20.5 μM heparin increases fluorescence to approximately 50%, while full 
fluorescence is restored in the 35–40 μM range. The experiment allows us to define EC50 as the 
sequestration concentration of heparin required to restore 50% EtBr binding (Table 3.5). This 
experiment again confirms the similar affinities of the two biomolecules for TriplatinNC. 
CD Assay 
The competitive binding of heparin and DNA can also be easily envisaged by CD spectroscopy 
monitoring of the conformational changes during each event. The CD spectrum of the DNA 
structure influenced by its environment and changes such as TriplatinNC binding can be monitored 
without the need for labels. The positive CD band of DNA centered at approximately 270 nm is 
decreased in the presence of TriplatinNC (Figure 3.9). Upon the addition of heparin to the DNA–
TriplatinNC mixture, the positive band is restored in a heparin concentration-dependent manner 
through sequestration of TriplatinNC and restoration of DNA to its original conformation. Neither 
heparin nor heparin–TriplatinNC mixtures show any CD absorbance in the 250–280 nm range, 
and thus the changes observed are direct visualizations of competitive binding. 
Summary 
Electrostatic and hydrogen-bonding interactions with noncovalent metal complexes observed on 
DNA translate to heparin–HS interactions. To determine the relative affinity of TriplatinNC for 
heparin and/or DNA, competition assays were used with reporters for the TriplatinNC–DNA 
interaction. Fluorescence polarization and EtBr competition assays showed that TriplatinNC has a 
broadly similar affinity for both unlabeled heparin and DNA. 
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Figure 3.8. Heparin, a competitive inhibitor of TriplatinNC–
DNA binding. (a) Unlabeled DNA (0–21.2 μM) competed with 
fluorescently labeled DNA (23nt and MW 7705) for 
TriplatinNC binding. (b) Analogously, the binding of 
TriplatinNC to the fluorescently labeled-DNA was reduced upon 
the addition of heparin MW ∼3000 (0–21.2 μM). (c) EtBr bound 
to ct-DNA was displaced upon the addition of TriplatinNC, 
while increasing the concentration of heparin MW ∼18000 
sequestered TriplatinNC from DNA, allowing EtBr–DNA 
binding to occur. EtBr bound to DNA was normalized to 100% 
with EtBr only as 0%. 
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Affinity of HS Binding to Metal–Ammine Complexes 
Trinuclear complexes are modular in nature, and the strong interactions of TriplatinNC with 
heparin led us to explore the individual contributions of the mononuclear 
tetraam(m)ineplatinum(II) units and further compare charge-related effects based on cobalt and 
ruthenium analogues (Figure 3.1). While, in principle, the chloropentaammine complexes of 
cobalt(III) and ruthenium(III) can enter into covalent interactions through Co–Cl or Ru–Cl 
substitution, the nature of the assays developed and the kinetic inertness of substitution on the 
cobalt(III) and ruthenium(III) centers suggests that any trends observed across the series of 
compounds will be most likely due to simple differences in charge. 
MB Assay 
In MB assay, [Co(NH3)6]
3+ and [Ru(NH3)6]
3+ of the mononuclear metal–ammine compounds 
exhibited the highest affinity to heparin, although the IC50 values were significantly higher than 
that for TriplatinNC (Table 3.1 and Figure 3.10). The efficacy of inhibition is charge-dependent, 
and the 2+ compounds [Pt(NH3)4]
2+, [RuCl(NH3)5]
2+, and [CoCl(NH3)5]
2+ required over 10-fold 
more compound for inhibition than [Co(NH3)6]
3+ with increasing IC50 (Table 3.1). Similar trends 
were observed for TAMRA-R9 assay (Table 3.1 and Figure 3.5c). 
ITC Assay 
The ITC titrations of metal–ammine species to heparin did not give well-defined isotherms, 
perhaps because of the inherently lower affinity as measured by the MB reporter assay, and were 
not analyzed in detail. Affinity values derived from ITC can also vary depending on the nature of 
the heparin as noted above.(45) 
DNA Competition Assays  
Metal-ion interactions with nucleic acids have been widely studied;(49) more specifically, the 
chosen cobalt and ruthenium complexes bind tightly to DNA.(50−54) Thus, we compared the 
affinities of metal–ammine compounds for DNA and heparin. Using the fluorescently labeled 
DNA-Fl, as was previously done, and heparin MW ∼3000 as the competitor, we examined the 
relative binding affinity of metal–ammines for these two substrates. Overall, the metal–ammine  
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Table 3.3.  Fluorescence Polarization Assays Showing That Heparin Is a Competitor for Metal–Ammine 
Compound Binding to DNA 
aEC50 was determined as the concentration of the complex required for half-maximal binding to fluorescently 
labeled DNA using heparin MW ∼3000 as a competitor. 
bThe fold change EC50 was calculated as (EC50 of the sample with a competitor)/(EC50of the sample without a 
competitor). 
 
 
 
 
Table 3.4. TriplatinNC bound to fluorescently labeled DNA 
competes with “cold” unlabeled DNA. Upon addition of 
unlabeled-DNA, the EC50 of TriplatinNC binding to labeled-
DNA increases. The EC50 was determined as the concentration 
of complex required for half-maximal binding to DNA. The fold 
change EC50 is calculated as the (EC50 of sample with 
competitor)/ (EC50 of the sample without competitor). 
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compounds exhibited at least a 2-fold increase in EC50 for the highest heparin–DNA ratios, with 
the largest fold increase of 5.1 observed for [Co(NH3)6]
3+ (Table 3.2 and Figure 3.11). Compared 
to TriplatinNC, the EC50 values of the metal–ammine compounds binding to DNA were higher 
(TriplatinNC8+ < [Co(NH3)6]
3+ < [CoCl(NH3)5]
2+ < [Pt(NH3)4]
2+ ≈ [RuCl(NH3)5]2+), indicating the 
expected lower binding affinity to DNA. Upon competition with heparin, the higher fold increase 
in EC50 is a measure of the higher heparin affinity, independent of the actual concentrations used 
for each compound to achieve half-maximal DNA binding. In this case, the trend suggests a strong 
charge effect, with TriplatinNC8+ and [Co(NH3)6]
3+ showing the highest relative affinities. The 
(smaller) one to 2-fold changes for the lower-charged species may reflect inherently stronger 
binding to DNA rather than a diminished heparin affinity, as can be seen in indirect MB and 
TAMRA-R9 assays (Table 3.1). 
Because previous studies demonstrated [Pt(NH3)4]
2+- and [Co(NH3)6]
3+-induced DNA 
conformational change using CD,(53,54) we employed this method to observe metal–ammine 
compound binding to DNA and then the effects of the addition of heparin observed by the return 
of the DNA conformation. The potential covalent metal–ammine compounds (up to a 
concentration of 500 μM) did not change the DNA conformation at 280 nm, indicating little 
interaction, even in comparison to the square-planar [Pt(NH3)4]
2+ (data not shown). 
For EtBr competition assay, at a concentration identical with that of the intercalator, a much larger 
concentration of 500 μM was needed for the mononuclear metal–ammine compounds to displace 
the EtBr compared to TriplatinNC (12.5 μM; Table 3.5 and Figure 3.12). Care must be taken in 
analyzing these trends across a range of compounds because the inherent affinities of the 
compounds themselves for DNA as a starting point differ widely. Further, the different assays 
themselves represent different phenomena. The dangers in extrapolating across a series such as the 
one studied here is demonstrated for [Pt(NH3)4]
2+, which has demonstrably low affinity for 
DNA.(55) In principle, charge effects (2+) should be the same as those for the [CoCl(NH3)5]
2+ and 
[RuCl(NH3)5]
2+ compounds, as seen in fluorescence polarization assay (Table 3.3 and Figure 3.8). 
An apparently higher affinity for heparin in EtBr assay compared to fluorescence polarization  
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Table 3.5. EtBr Competition Assay for Comparison of Metal–Ammine Binding to DNA and 
Heparin 
aEC50 is defined as the sequestration concentration of heparin MW ∼18000 required to return 50% 
EtBr binding to DNA from the bound metal–ammine compound. EtBr bound to DNA was 
normalized to 100%, with EtBr only as 0%. 
 
Figure 3.9. CD spectra of ct-DNA in presence and absence of heparin and metal-ammine compounds (0-82µM 
for TriplatinNC, and 0-1000µM for metal-ammines, MW 18000).  DNA-compound conformation (measured by 
the 280nm absorbance specific for ct-DNA) is restored upon increasing heparin concentrations. HEPES buffer 
effects are observed below 230nm for DNA. 
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assay may reflect its reduced ability to displace the intercalator, perhaps because of its smaller 
square-planar geometry versus the octahedral geometry of the cobalt and ruthenium systems, 
giving an apparently (but false) higher heparin affinity. This anomaly emphasizes the need to 
employ more than one approach to assess accurately the questions of relative affinity of heparin 
and DNA for coordination compounds. 
Summary 
We observed broadly similar trends for metal–ammine compound interaction with heparin across 
the dye reporter techniques and DNA comparison assays. Slight discrepancies can be accounted 
for by the nature of the technique. Another caveat is the complexity across the experiments where 
the ITC system is a simple two-species system, heparin–dye reporter assays are three-species 
system, and DNA comparison assays are four-species systems. Given these caveats, these results 
are a testament to the relative accuracy of these methods for determining trends of coordination 
compound interaction with heparin. 
 
3.4 Conclusions: 
 
Overall, oligosaccharide interactions with metal-based compounds are understudied in 
bioinorganic chemistry. Molecular crowding in the interior of the cell breeds an environment in 
which molecules must compete with each other,(56) and small molecules such as cisplatin may 
encounter many possible binding partners, affecting biodistribution and metabolism, a reflection 
perhaps of the accepted fact that such a small fraction (<5%) of administered drug is considered 
to bind to its DNA target.(24) The overall results discussed here suggest comparable affinities for 
heparin relative to DNA for charged substitution-inert coordination compounds, regardless of their 
intrinsic nucleic acid affinity. This comparison should be capable of extrapolation to 
glycosoaminoglycans such as HS. The presence of HS on the cell surface and its relatively similar 
affinity to DNA would suggest that glycan binding is thus a competitive cellular event for many 
coordination compounds.(21) These results extend our understanding of the importance of the  
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Figure 3.10. Metal-ammine compounds inhibit methylene blue from binding to heparin.  Concentrations for 
metal-ammines were the following from top to bottom at 664 nm with highest and lowest concentrations shown: 
(a) [Co(NH3)6]3+ 40, 35, 30, 25, 20, 15, and 1 µM; (b) [Ru(NH3)6]3+ 70, 60, 50, 40, 30, 20, and 10 µM; (c) 
[Pt(NH3)4]2+ 500, 375, 250, 100 and 50 µM; (d) [CoCl(NH3)5]2+ 1250, 1000, 750, 500, 250, and 100 µM; (e) 
[RuCl(NH3)5]2+ 1750, 1500, 1250, 1000, 750, 500, 250, 100, and 25 µM. 
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interactions of physiologically relevant aquated metal cations with heparin to defined coordination 
compounds. The available coordinating moieties on HS–heparin are the oxygen-donor atoms of 
the hard carboxylate and sulfate bases. New patterns of metal-ion binding can be achieved by the 
interplay and application of hard–soft acid–base concepts. Further, in considering the concept of 
metalloglycomics, a phrase first coined by Codd,(57) coordination compounds can be manipulated 
to modify the oxidation state, ligand lability, and coordination number and geometry to produce a 
diverse inorganic library. 
 
3.5 Experimental: 
 
Materials 
Heparin sodium salts from porcine intestinal mucosa of MW 3000 and 18000, 
pentaamminechlorocobalt(III) chloride, hexaammineruthenium(III) chloride, and 
hexaamminecobalt(III) chloride were purchased from Sigma-Aldrich (USA). 
Pentaamminechlororuthenium(III) chloride was purchased from Aithace Chemical Corp. (USA). 
TAMRA-R9 and methylene blue chloride were purchased from Anaspec (USA) and Fisher 
Scientific (USA), respectively. TriplatinNC and tetraammineplatinum(II) chloride were 
synthesized according to published methods from refs (58) and (59), respectively. The 
concentrations of heparin were calculated using the dimer IdoA(2S)–GlcNS(6S) with a molecular 
weight of 609.46 g/mol unless otherwise noted. 
MB Binding Assay 
All heparin–MB binding studies were performed in triplicate on an Agilent 8453 diode-array 
spectrophotometer in a submicrometer quartz cuvette with a path length of 10 mm. Aqueous 
solutions of methylene blue chloride (at a constant final concentration of 18.6 μM) and heparin 
MW 18000 (1–25 μM) were prepared for determination of the optimal heparin–MB binding. A 
final concentration of 15 μM heparin was used for evaluating the inhibition of MB binding by  
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Figure 3.11. Heparin, a competitor for DNA binding 
to metal–ammine compounds. The binding of metal–
ammine compounds to fluorescently labeled DNA is 
reduced upon the addition of MW ∼3000 heparin (0–
21.2 μM). 
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TriplatinNC (1–5 μM), whereas the metal–ammine compounds were studied at the higher 1 μM to 
1.75 mM range. The heparin and metal complexes were incubated at room temperature for 15 min 
before the addition of methylene blue chloride. Aqueous solutions of methylene blue chloride (at 
a constant final concentration of 18.6 μM), heparin (MW 18000; at a constant final concentration 
of 15 μM), and TriplatinNC (at a constant final concentration of 5 μM) were used to evaluate the 
inhibition of TriplatinNC–heparin binding by physiological relevant concentrations of cations 
(sodium chloride, 50, 100, and 150 mM; potassium chloride, 5 mM; calcium chloride, 1.3 mM; 
magnesium chloride, 1 mM). 
TAMRA-R9 Binding Assay 
All heparin–TAMRA-R9 binding studies were carried out in triplicate. Solutions of TAMRA-
R9 (100 nM) and heparin 18000 MW (3 μM to 10 mM) in cacodylate buffer (200 mM, pH 7.4) 
were prepared to determine the heparin concentration for optimal fluorescence. Heparin (625 μM) 
and metal–ammine compounds (in the range 7.8 μM to 2.5 mM) were incubated for 15 min at 
room temperature for compound–heparin binding before the addition of TAMRA-R9 (100 nM) 
and measurement of the fluorescence. 
SPR 
Binding experiments were carried out at 25 °C on a Reichert Technologies (Depew, NY) 
SR7500DC two-channel system equipped with a Neutravidin-coated mSAM sensor chip (Reichert 
Technologies, part 13306065) using 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), 150 mM NaCl, and 0.005% Tween-20 (HBST) as the running buffer. Prior to heparin 
capture, the Neutravidin-coated mSAM sensor chip was preconditioned with three consecutive 
injections of 50 mM NaOH for 1 min, respectively. Biotinylated heparin (MW ∼15000, Sigma) at 
a concentration of 100 μg/mL was subsequently injected onto the avidin surface on the left channel 
and captured to a level of 110 μRIU (∼110 RU), whereas the right channel was left as the bare 
avidin surface to serve as a reference for nonspecific binding of TriplatinNC. Under a flow rate of 
25 μL/min, TriplatinNC was injected over both channels at concentrations of 5, 1, 0.33, and 0.11  
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Figure 3.12. Ethidium bromide competition assay for comparison of 
metal-ammine compounds binding to ct-DNA and heparin (MW ~18000).  
EtBr displaced by metal-ammine compound-DNA binding rebinds to 
DNA upon the concentration-dependent sequestration of the metal-
ammine compound (500 µM) by heparin. EtBr bound to DNA was 
normalized to 100% with EtBr only as 0%. 
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mM, respectively, for 2 min followed by a 5 min dissociation in a HBST running buffer. The 
kinetic data were analyzed using TraceDrawer (Ridgeview Instruments) with a 1:1 model, while 
the equilibrium data were fit using Scrubber (Biologic Software) to a 1:1 binding model. 
ITC 
Calorimetric data were collected using a VP-ITC microcalorimeter (MicroCal, LLC). All samples 
were degassed for 5 min using a ThermoVac (MicroCal, LLC). For all titrations, injections of 
TriplatinNC and metal–ammine compounds (0.546 and 4 mM, respectively) were pipetted 
automatically into the reaction cell containing 1.3 mL of heparin MW 3000 (0.1 and 0.4 mM) at 
300 s intervals from a 300 μL syringe with stirring at 75 rpm. In all experiments, a 100 mM 
cacodylate buffer (pH 7.4) was used at 25 °C, and the thermal reference cell contained 1.3 mL of 
100 mM cacodylate buffer (pH 7.4). Integration of the thermogram peaks was carried out using 
the software supplied with the calorimeter (Origin 7.0). The heat released was fitted using Origin 
7.0 to determine Ka, ΔH, and ΔS. ΔG was obtained using Gibbs free energy equation. 
Fluorescence Polarization 
50 μL binding reactions were carried out at room temperature in 96-well, low-binding, black plates 
(Greiner) using 100 nM to 25 μM of each compound in 1.25 mM NaCl, 0.125 mM HEPES (pH 
7.2), and 1 μM 3′ fluorescein-labeled hairpin DNA (GGGGCGACTGGTGAGTACGCCCC; MW 
= 7705; Sigma). Readings were recorded immediately after mixing (for no competitor readings). 
Subsequently, 1 μL of 10 μM heparin (MW = approximately 3000; Sigma) was titrated into each 
reaction. Readings were recorded immediately. This was followed by titrations of 1 μL of 100 μM 
heparin and then 1 μL of 1 mM heparin, with immediate readings after each addition. The 
EC50calculation was based on the average of three separate experiments. 
Ethidium Bromide (EtBr) Displacement Assay with Heparin 
Calf-thymus DNA (ct-DNA) was dissolved and dialyzed in HEPES buffer (80 mM HEPES, pH 
7.2). Buffer exchanges occurred three times every 12 h. The DNA concentration was determined 
by UV–vis with absorbance at 260 nm and the average molecular weight of a nucleotide (333 
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g/mol). EtBr at 5 mM in water was diluted in HEPES buffer and incubated with ct-DNA in HEPES 
buffer for 5 min at room temperature. An aliquot of 1 mM TriplatinNC (4 mM for other 
compounds) in water was diluted in HEPES buffer and incubated for 1 h to reduce fluorescence to 
approximately 30% (20–25% for other compounds). Finally, increasing concentrations of heparin 
MW 18000 in buffer from 20.5 to 82 μM final (100–1000 μM final for other compounds) were 
incubated for an additional 1 h. Final concentrations were the following: EtBr, 12.5 μM; ct-DNA, 
10 μM; TriplatinNC, 12.5 μM (500 μM for other compounds). All samples were read (after a total 
of 2 h 5 min) in a 96-well plate at 530/590 nm using a microplate reader (Bio-Tek instruments). 
Samples were normalized to the controls (EtBr only as 0% and EtBr–DNA as 100%). All 
incubations were done at 37 °C. 
CD Studies 
TriplatinNC (ri = 0.075 compound/DNA ratio) or metal–ammine compounds (ri = 5) were 
incubated with 100 μM ct-DNA for 1 h at 37 °C in HEPES buffer (80 mM HEPES, pH 7.2). Then 
heparin MW ∼18000 was added with 10.25–230 μM final concentrations (only 10.25–82 μM are 
shown) and incubated for an additional 1 h at 37 °C. Final concentrations after heparin addition 
were the following: 100 μM ct-DNA and 7.5 μM TriplatinNC (ri = 0.075) or 500 μM (ri = 5). After 
the incubations, samples were placed in a 10 mm submicro cuvette to record the CD spectra at 
room temperature using a Jasco J600 spectropolarimeter. 
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4.1 Abstract 
 
Spectroscopic and biophysical approaches were developed to examine the affinity and 
stoichiometry of simple cobalt complexes for Fondaparinux (FPX) as a model for Heparan Sulfate 
(HS). HSs play vital roles in both cancer cell proliferation, angiogenesis, metastasis, and 
differentiation; and viral particle attachment. Cobalt containing complexes, like CTC-96, were 
shown to inhibit Herpes Simplex Virus 1 replication through HS binding, and this work extends 
FPX binding to these simple cobalt complexes. Cobalt complexes are competitive inhibitors of 
methylene blue (MB)–FPX binding, and the change in absorbance of the dye in the presence or 
absence of sulfated FPX was used as an indirect reporter of cobalt-FPX affinity. The dissociation 
constant (Kd) was also directly measured using Isothermal Titration Calorimetry (ITC). 
Stoichiometry and sulfate protection was determined using electrospray ionization mass 
spectrometry (ESI-MS). Cleavage of HS by the enzyme heparanase also modulates tumor 
angiogenesis, cell invasion, and metastasis. Metalloshielding of HS cleavage by these cobalt 
complexes will effectively inhibit tumor-related events. Studies using P. heparinus heparanase I 
showed that these cobalt complexes inhibit the cleavage activity of the enzyme. These results will 
further the understanding of the metalloglycomics concept into the third important class of 
biomolecules from the well-studied protein and DNA/RNA and their interactions. 
 
4.2 Introduction 
 
Proteoglycans containing Heparan Sulfate (HS), a sulfated glycosaminoglycan, play a major role 
in the cell signaling process, adhesion and migration.(1,2) Heparan sulfate proteoglycans (HSPGs) 
are HSs conjugated with proteins and can be found on the cell surface or in the extracellular 
matrix.(1,2) HSPGs are over-expressed on the surface of many cancer cells.(3,4) The sulfate 
residues on HS are the recognition site for many different protein substrates including pro-
angiogenic growth factors, similar to the phosphate clamp-arginine fork motif.(5-10) Fibroblast  
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Figure 4.1. Structures of cobalt complexes used. Counterions are omitted for clarity.  
Figure 4.2. Structures of D-Glucosamine-6-O-sulfate, Fondaparinux, and cleavage products 
by P. heparinum heparinase I. In the presence of cobalt complexes, cleavage was inhibited. 
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growth factors (FGF) directly stimulates the cancer cell’s growth, metastasis and survival.(6) 
Enzymatic cleavage of HSPG at the glycosidic linkages by heparanase (HPSE) causes release of 
angiogenic growth factors initiating the angiogenic cascade.(11-13) HPSE is also over-expressed 
in tumors with significant correlation between metastatic potential and heparanase activity.(14) 
Furthermore, HS plays a vital role in the attachment of viral envelope glycoproteins to the cell 
surface.(15) Viral particles attach to HS by their glycoproteins causing subsequent interactions 
with specific cell entry receptors leading to viral cell replication.(15) Cobalt containing complexes 
binding HS has been shown to disrupt synthesis of viral structural proteins.(15) HS is thus an 
attractive drug target to inhibit tumor cell progression and viral replication. We have shown that 
“metalloshielding” or sulfate cluster masking of HS by metal complexes protect HS from 
enzymatic cleavage by the mammalian heparanase, prevents growth factors from binding to HS 
and/or prevents release of bound growth factors.(6, 7) We hypothesize that such binding by cobalt 
complexes may also act at the point of viral entry; preventing viral particle attachment and thus 
inhibiting the replication of the viral cells.   
In order to determine the importance of structure-activity relationship on the “metalloshielding” 
potential of the metal complex library, affinity and cleavage inhibition studies were performed on 
Fondaparinux, as a model HS-like substrate. Fondaparinux is a well-defined, octasulfated 
pentasaccharide with a single point of cleavage for both bacterial and human HPSE.(11,13) We 
have previously presented spectroscopic and biophysical approaches to examine the affinity of 
metal−ammine coordination complexes for heparin.(16) Metal−ammine compounds are 
competitive binders to heparin. Results have shown that simple cobalt compounds bind with 
relatively high affinity, even greater than that of the simple platinum compound, 
tetraammineplatinum(II).(16) To further explore the less cytotoxic cobalt, as compared to 
platinum, and its interactions with HS, the differences between covalent and non-covalent 
interactions will be examined. New patterns of cobalt-heparin binding can be achieved by the 
application of hard–soft acid–base concepts. 
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Figure 4.3. A) Fondaparinux cleavage by heparinase I. B) Pentamminechlorocobalt (III) 
inhibits heparinase I cleavage of fondaparinux more effectively than t-
dichlorobis(ethylenediamine)cobalt (III) or tris(ethylenediamine)cobalt (III). 
Figure 4.4. Pentamminechlorocobalt (III) inhibits the heparinase I induced invasion of 
matrigel by MDA-MB231 cells more than t-dichlorobis(ethylenediamine)cobalt(III) or 
tris(ethylenediamine)cobalt (III). 
B A 
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To develop the structure-activity relationships, we have chosen a small library of cobalt complexes 
to examine the effects of covalent and non-covalent interactions on their interactions with FPX.  
In this paper, we describe cleavage inhibition studies in the presence/absence of the cobalt library 
using bacterial HPSE.(17) A competition assay using methylene blue (MB) as a reporter describes 
an approach to measure the affinity of each compound for FPX and compare that to a direct 
titration of each cobalt complex into FPX using isothermal titration calorimetry (ITC). Binding 
stoichiometry and type of binding to compare covalent and non-covalent interactions were 
examined using mass spectrometry (MS) and nuclear magnetic resonance (NMR). The overall 
results emphasize the importance of understanding the properties of glycan interactions with 
coordination complexes. 
 
4.3 Results and Discussion 
 
The library of simple cobalt compounds is shown in Figure 4.1. The compounds were chosen to 
study the covalent interactions between hard base oxygens on the glycan chain with the hard acid 
cobalt metal. These covalent interactions will also be compared to a non-covalent compound to 
determine strength of binding and overall stoichiometry.  
The cleavage patterns for bacterial heparinase I (often used as a model for the mammalian enzyme) 
are shown in Figure 4.2. Colorimetric assays for enzymatic activity and inhibitor screening have 
been developed.(18) We therefore adapted the assay to examine the inhibitory effect of cobalt 
complexes on the enzymatic (heparinase) degradation of Fondaparinux. The pentasaccharide 
substrate was incubated with cobalt complex prior to enzyme exposure and cleavage measured 
versus control in absence of added complex. Inhibition of heparinase cleavage is effective for the 
non-covalent compound, pentaamminechlorocobalt(III), followed by the covalent t-
dichlorobis(ethylenediamine)cobalt(III), Figure 4.3. 
Cellular invasion through the extracellular matrix (ECM) requires degradation of the matrix by 
HPSE, and cell motility in response to growth factors. The ability of cobalt complexes to inhibit  
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Figure 4.5. A) 1H NMR spectra of 1:1 mixtures of D-glucosamine-6-O-sulfate and 
various cobalt complexes from top to bottom: tris(ethylenediamine)cobalt(III), t-
dichlorobis(ethylenediamine)cobalt(III), pentaamminechlorocobalt(III), and D-
glucosamine-6-O-sulfate. B) 59Co NMR spectrum of tris(ethylenediamine)cobalt(III) 
(bottom) and 1:1 mixture of D-glucosamine-6-O-sulfate and 
tris(ethylenediamine)cobalt(III) (top). C) 59Co NMR spectrum of 1:1 mixture of D-
glucosamine-6-O-sulfate and t-dichlorobis(ethylenediamine)cobalt(III) (top) and 1:1 
mixture of D-glucosamine-6-O-sulfate and pentaamminechlorocobalt(III) (bottom). 
A B 
C 
Table 4.1. 1H and 59Co chemical shift changes (Δδ = δ(monomer : Co) – 
δ(monomer/Co)) after incubation of Co complexes with D-glucosamine-6-O-sulfate. 
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cell invasion through matrigel basement membrane was accessed using a Boyden-chamber 
assay.(19) Serum-starved cells were seeded into the top chamber onto a matrigel membrane with 
heparinase I or without (migration control). Complex was added to the top chamber in serum-free 
media. The bottom chamber was filled with media containing 10% serum (no drug). In Figure 4.4, 
pentaamminechlorocobalt(III) shows minimal cell migration at the 50 μM. The results of the two 
heparinase cleavage assays clearly distinguishes that the pentaamminechlorocobalt(III) exhibits 
the greatest inhibition of heparinase cleavage followed by t-
dichlorobis(ethylenediamine)cobalt(III) with minimal inhibition by the 
tris(ethylenediamine)cobalt(III).  
The NMR chemical shift changes of D-glucosamine-6-O-sulfate (monomer) in the presence of 
cobalt complexes were investigated to delineate the binding interactions. Addition of cobalt 
complexes shifted the protons of the monomer, Figure 4.5 A. Upon measurements performed from 
the freshly prepared 1:1 Co:Monomer complexed mixture, distinct shifts were observed due to fast 
interactions. It is readily apparent that only small downfield shifts (.000 to .018 Δppm) are 
observed disregarding t-dichlorobis(ethylenediamine)cobalt(III), Table 4.1. These weaker shifts 
are due to the non-covalent interactions produced by these cobalt complexes. However, t-
dichlorobis(ethylenediamine)cobalt(III) produced shifts (-.034 to -.049 Δppm) that were at least 4 
fold greater than any other cobalt complex shift. The covalent interactions produced larger shifts 
by coordination of the cobalt to the sulfate or any other oxygen on the monomer. Due to the lack 
of solubility pentaamminechlorocobalt(III) peaks did not shift considerably. 
59Co NMR spectra of cobalt complexes with monomer were also obtained. 
Tris(ethylenediamine)cobalt(III) peak was observed similar to previously published data, Table 
4.2, at 7144 ppm (literature - 7145 ppm).(20) Upon measurements performed from the freshly 
prepared 1:1 Co:Monomer complexed mixture, distinct shifts were observed due to fast 
interactions, Table 4.1. It is readily apparent that only a small upfield shift of -61 ppm, Figure 4.5 
B. However, pentaamminechlorocobalt(III) and t-dichlorobis(ethylenediamine)cobalt(III) 
produced shifts of -1983 and -4164 ppm respectively, that were considerably greater than the non- 
144 
 
  
Table 4.2. Species detected using 59Co NMR. *charges were omitted for clarity. 
Published chemical shifts were obtained from ref. 20. 
 
A B 
C 
Figure 4.6. ESI-MS of 1:1 adducts of FPX and A) t-
dichlorobis(ethylenediamine)cobalt(III) in the 2- charge state, both covalent and non-
covalent interactions are observed with loss of sulfates, B) 
pentaamminechlorocobalt(III) in the 3- charge state, both covalent and non-covalent 
interactions are observed with loss of sulfate with the parent peak of FPX also 
observed, and C) tris(ethylenediamine)cobalt(III) in the 3- and 4- charge states. Parent 
peak of FPX with loss of sulfates was also observed at the 4- charge state. 
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covalent cobalt complex shifts, Figure 4.5 C. The covalent interactions of the cobalt coordinating 
to the sulfate or any other oxygen on the monomer produced larger shifts. The 
pentaamminechlorocobalt(III) peak was observed at 8885 ppm (8887 ppm),  while the 
pentaammineaquacobalt(III) was shifted downfield to 9155 ppm (9147 ppm).(20) After addition 
of monomer to the solution, the peak representing two monomers, one bound covalently and one 
bound non-covalently to the cobalt complex, is upfield shifted to 6909 ppm, while the peak 
representing a coordinated water with a two non-covalent monomers was observed at 7231 ppm. 
This 1:2 Co:monomer stoichiometry follows the trend observed in the monomer mass 
spectrometry data. Since the t-dichlorobis(ethylenediamine)cobalt(III) rapidly isomerizes in 
aqueous solutions with a greater abundance of cis being formed, we only observed the cis chloride 
isomer at 8961 ppm (8974 ppm). Due to the complexity of the spectra, we used 
tris(ethylenediamine)cobalt(III) as a standard, which agreed to the previous spectra. After addition 
of monomer, we again observed a similar shift of tris(ethylenediamine)cobalt(III). High symmetry 
complexes have narrower lines while low symmetry complexes have broader lines, cis is broader 
than trans, therefore all peaks are attributed to a cis geometry due to the broad nature observed.(20) 
Again, following the mass spectrometry data, there will be a 1:2 binding stoichiometry of 
Co:monomer. An upfield shift was observed at 5400 ppm attributed to c-
diaquabis(ethylenediamine)cobalt(III) with 2 non-covalently bound monomers. Further upfield at 
5200 ppm, a peak was observed of covalently bound water and monomer with another non-
covalent bound monomer. A very broad peak was observed at 4797 ppm, which is likely due to 
both a bidentate bound monomer with a non-covalent bound monomer and bismonomer covalently 
bound.  
The analysis of the NMR spectra are based largely on the chemical shifts of the peaks and the 
quadrupole splitting. The former measures electron density around the 1H nucleus when the 
chloride ligand is replaced by sulfate from the monomer. Furthermore, Co(III) chemical shifts are 
heavily influenced by the nephelauxetic effect in the 59Co NMR spectra.(21) This refers to a 
decrease in the Racah interelectronic repulsion parameter when the cobalt forms a covalent  
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Composition* Formula m/z (charge) 
MW 
Observed Calculated 
FPX+[Co(en3)] C37H70CoN9O49S8 434.77 (4-) 1739.08 1739.04 
FPX+[Co(en3)]-SO3 C37H70CoN9O46S7 414.78 (4-) 1659.12 1659.08 
FPX+[Co(en3)]+Na C37H69CoN9NaO49S8 440.26 (4-) 1761.04 1761.02 
FPX+[Co(en3)] C37H71CoN9O49S8 580.03 (3-) 1740.09 1740.04 
     
FPX+[Co(NH3)5] C31H61CoN8O49S8 410.99 (4-) 1643.96 1643.96 
FPX+[Co(NH3)5]+H2O C31H63CoN8O50S8 415.50 (4-) 1662.00 1661.97 
FPX+[Co(NH3)5] C31H62Co N8O49S8 548.34 (3-) 1645.02 1644.97 
FPX+[Co(NH3)5]-SO3 C31H62CoN8O46S7 521.68 (3-) 1565.04 1565.01 
FPX+[Co(NH3)5]+H2O C31H64CoN8O50S8 554.34 (3-) 1663.02 1662.98 
FPX+[Co(NH3)5] C31H63Co N8O49S8 823.01 (2-) 1646.02 1645.98 
FPX+[Co(NH3)5]+H2O C31H65CoN8O50S8 832.01 (2-) 1664.02 1663.99 
     
FPX+[Co(en2)] C35H63CoN7O49S8 560.00 (3-) 1680.00 1679.98 
FPX+[Co(en2)]-SO3 C35H63CoN7O46S7 533.35 (3-) 1600.05 1600.02 
FPX+[Co(en2)]+H2O C35H65CoN7O50S8 566.01 (3-) 1698.03 1697.99 
FPX+[Co(en2)]+2H2O C35H67CoN7O51S8 571.99 (3-) 1715.97 1715.99 
FPX+[Co(en2)]  C35H64CoN7O49S8 840.51 (2-) 1681.02 1680.98 
FPX+[Co(en2)]-SO3 C35H64CoN7O46S7 800.53 (2-) 1601.06 1601.03 
FPX+[Co(en2)]-2SO3 C35H64CoN7O43S6 760.55 (2-) 1521.10 1521.07 
FPX+[Co(en2)]-3SO3 C35H64CoN7O40S5 720.57 (2-) 1441.14 1441.11 
FPX+[Co(en2)]-4SO3 C35H64CoN7O37S4 680.59 (2-) 1361.18 1361.16 
FPX+[Co(en2)]-5SO3 C35H64CoN7O34S3 640.61 (2-) 1281.22 1281.20 
FPX+[Co(en2)]-6SO3 C35H64CoN7O31S2 600.51 (2-) 1201.02 1201.24 
FPX+[Co(en2)]+H2O C35H66CoN7O50S8 849.51 (2-) 1699.02 1698.99 
FPX+[Co(en2)]+H2O-SO3 C35H66CoN7O47S7 809.84 (2-) 1619.68 1619.04 
FPX+[Co(en2)]+2H2O C35H68CoN7O51S8 858.52 (2-) 1717.04 1717.00 
FPX+[Co(en2)]+2H2O-SO3 C35H68CoN7O48S7 818.52 (2-) 1637.04 1637.05 
FPX+2[Co(en2)] C39H76Co2N11O49S8 928.25 (2-) 1856.50 1856.02 
     
2Monomer+[Co(en3)] C18H48CoN8O16S2 755.19 (1+) 755.19 755.19 
2Monomer+[Co(en2)] C16H40CoN6O16S2 695.12 (1+) 695.12 695.13 
Monomer+[Co(en2)Cl2] C10H28Cl2CoN5O8S 507.26 (1-) 507.26 507.04 
Table 4.3. Species detected on the ESI-MS spectra. *protons and charges were omitted for 
clarity. FPX represent the parent Fondaparinux species and Monomer represents D-
glucosamine-6-O-sulfate.  
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interaction with the monomer, producing less repulsion between two electrons in a doubly 
occupied d-orbital.(19) This repulsion parameter likely arises from one or two causes, the effective 
positive charge on the metal has decreased from a negative bound ligand and/or an increase in 
orbital size from a covalent interaction. The latter is sensitive to the symmetry of the structural 
environment around the transition metal, specifically the symmetrical 
tris(ethylenediamine)cobalt(III) when bound to multiple monomers loses symmetry and multiple 
peaks are observed. The racemic [Co(en)3]
3+ ion pairs with D-glucosamine-6-O-sulfate, resulting 
in the diastereomeric ion pairs having clearly distinct chemical shifts.(22) Comparison of NMR to 
MS gives a clear picture of binding stoichiometry between these cobalt complexes and monomer.  
Negative mode electrospray ionization (ESI) is commonly used for identification and analysis of 
heparin. We have previously shown through ESI-MS studies that FPX undergoes sulfate loss in 
the gas phase.(9) Analysis regarding the retention of labile sulfate groups on the heparin backbone 
has shown metal cations stabilize sulfate groups.(23) In the present work we examine the 
stoichiometry of cobalt complexes bound to FPX and their ability to protect against sulfate loss. 
We again compare the difference in covalent and non-covalent interactions, Table 4.3.  
Peaks corresponding to a hydrogen bonding interaction between tris(ethylenediamine)cobalt(III) 
and FPX were observed at 434.77 m/z (4-) and 580.03 m/z (3-), Figure 4.6. Peaks were also 
observed corresponding to a retained sodium ion at 440.26 m/z (4-) and loss of one sulfate at 
414.78 m/z (4-). The cobalt compounds may coordinate to water resulting in a noncovalent 
interaction, or may coordinate to the sulfates resulting in a covalent interaction since the chloride 
would be dissociated from the compound. Pentaamminechlorocobalt(III) and t-
dichlorobis(ethylenediamine)cobalt(III) have the ability to interact both covalently and non-
covalently, Figure 4.6. Covalent and non-covalent interactions were both observed for 
pentaamminechlorocobalt(III) at the 2-, 3-, and 4- charge states. The cobalt compounds may 
coordinate to water resulting in a noncovalent interaction, or may coordinate to the sulfates 
resulting in a covalent interaction since the chloride would be dissociated from the compound. A 
1:1 binding interaction was observed covalently at 823.01 m/z (2-), 548.34 m/z (3-) along with  
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Kd (µM) ΔG (kJ/mol) ΔH (J/mol) -TΔS (kJ/mol*K) 
[Co(en)3]
3+ 18.6 ± 3.0 -6.5 ± 0.1 -374.8 ± 7.5 -6.1 
[Co(NH3)5Cl]
2+  87.7 ± 17.7 -5.5 ± 0.3 -345.7 ± 20.2 -5.2 
Figure 4.7. A trace of calorimetric titration (upper panel) and integrated isotherms (lower panel). 
The first peak represents a pre-injection that was omitted in the binding calculations. A) ITC 
analysis of FPX by direct titration of tris(ethylenediamine)cobalt(III). B) ITC analysis of FPX 
by direct titration of pentaamminechlorocobalt(III). 
 
Table 4.4. ITC analysis showing the obtained binding parameters: dissociation constants (Kd); 
free energy of binding (ΔG); enthalpy of binding (ΔH); and entropy of binding (-TΔS) 
between cobalt compounds and FPX. The standard error from 3 measurements is indicated. 
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loss of one sulfate at 521.68 m/z (3-), and 410.99 m/z (4-). The non-covalent interaction uses 
hydrogen bonding either between the ammines or coordinated water of the cobalt and the sulfates  
of the FPX. The non-covalent interaction was also observed with a coordinated water at 832.01 
m/z (2-), 554.34 m/z (3-), and 415.50 m/z (4-). Covalent and non-covalent interactions were both 
observed for t-dichlorobis(ethylenediamine)cobalt(III) at the 2- and 3- charge states. The cobalt 
compounds may coordinate to the sulfates producing a covalent interaction since the chlorides are 
dissociated from the compound. Water may also coordinate to one of the free ligand sites, still 
allowing a covalent interaction between cobalt and FPX. The non-covalent interaction uses 
hydrogen bonding either between the ammines or bound water of the cobalt and the sulfates of the 
FPX since water is coordinated to both of the free ligand sites of the cobalt compound. A 1:1 
binding interaction was observed covalently at 560.00 m/z (3-) and with one coordinated water at 
566.01 m/z (3-), and non-covalently with 2 coordinated waters at 571.99 m/z (3-). Loss of one 
sulfate was also observed at 533.35 m/z (3-) with no coordinated water. A 1:1 binding interaction 
was observed covalently at 840.51 m/z (2-) and with one coordinated water at 849.51 m/z (2-), and 
non-covalently with 2 coordinated waters at 858.52 m/z (2-). Loss of one to six sulfates was also 
observed at 800.53, 760.55, 720.57, 680.59, 640.61, and 600.51 m/z (2-) respectively with no 
coordinated water, while at loss of one sulfate was observed both covalently with one coordinated 
water at 809.84 m/z (2-) and non-covalently with two coordinated waters at 818.52 m/z (2-). A 2:1 
binding stoichiometry of Co:FPX was observed at 928.25 m/z (2-) with no coordinated waters. 
We also observed more sulfate loss with covalent interactions, since hydrogen bonding interactions 
allow for sulfate cluster interactions more sulfates are protected. While the covalent interactions 
would only protect one sulfate from loss. Non-covalent interactions protect more sulfates as 
compared to covalent interactions likely due to the non-covalent interaction’s ability to 
“metalloshield” a larger group of sulfate clusters, while the covalent interaction may only protect 
one sulfate through bidentate binding. 
To compare the binding stoichiometry observed in the monomer NMR, monomer binding with 
cobalt complexes was also studied. Peaks were observed for an interaction between  
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IC50 (µM)
a Kd(app) (µM)
b 
[Co(en)3]
3+ 71.0 ± 2.9 33.3 ± 1.4 
[Co(en)2Cl2]
1+ 116.1 ± 1.6 54.4 ± 0.8 
[Co(NH3)5Cl]
2+  75.6 ± 1.2 35.4 ± 0.5 
Figure 4.8. MB competition assay for assessment FPX binding. At a constant concentration 
of FPX (15 μM) in the presence of varying concentrations of A) 
tris(ethylenediamine)cobalt(III) (from bottom to top with 30, 40, 50, 80, 90, 100, 250, 500 
μM), B) t-dichlorobis(ethylenediamine)cobalt(III) (from bottom to top with 40, 50, 60, 70, 
80, 90, 200, 300, 400, 500 μM), and C) pentaamminechlorocobalt(III) (from bottom to top 
with 40, 50, 60, 70, 80, 90, 100, 200 μM); MB binding is inhibited, reflected in the change of 
[AbsMB] at 664 nm. 
 
Table 4.5. IC50 and Kd values of cobalt complexes in competitive inhibition assays using MB. 
aThe IC50 value was determined as the concentration of complex required for half-maximal 
binding of the dye (18.6 μM) to FPX (15 μM). 
bDissociation constants were calculated from the MB assay for cobalt complexes binding to 
FPX using a competitive inhibitor model. 
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tris(ethylenediamine)cobalt(III) and monomer at a 1:2 Co:monomer stoichiometry at 755.19 m/z 
(1+). A 1:2 covalent binding interaction was observed between t-
dichlorobis(ethylenediamine)cobalt(III)  and monomer at 695.12 m/z (1+), while a 1:1 non-
covalent binding interaction was observed at 507.26 m/z (1-) with no dissociated chlorides. 
ITC measures the amount of heat energy released or absorbed into the system upon the interaction 
of two molecules. ITC determines the thermodynamic influences of both the change in enthalpy 
(ΔH) and entropy (ΔS) changes to calculate the free energy of binding (ΔG). ITC assays were 
performed to determine the binding constants between FPX and the cobalt compound library. 
Covalent and non-covalent interactions contribute to the enthalpy term, while conformational 
freedom changes and solvation upon complexation contribute to the entropy term.(24,25)  
While the major contribution for the derived thermodynamic binding parameters arose from the 
entropy term, binding interactions can still be evaluated from the enthalpy binding term, Table 4.4. 
Tris(ethylenediamine)cobalt(III) produced a Kd (18.6 µM) and greatest Gibbs Free energy (-6.5 
kJ/mol), this is likely due to the hydrogen bonding ability and larger overall size compared to other 
ligands, Figure 4.7. Pentaamminechlorocobalt(III) produced a Kd of 87.8 µM and the weakest 
Gibbs Free energy (-5.5 kJ/mol), Figure 4.7. The calculated binding parameters of 
pentaamminechlorocobalt(III) are likely weaker due to its ability to only interact with one sulfate 
covalently. The ITC titrations of t-dichlorobis(ethylenediamine)cobalt(III) to FPX did not give a 
well-defined isothermal trace, perhaps due to the rapid isomerization of t-
dichlorobis(ethylenediamine)cobalt(III) in aqueous solutions. The major contribution arose from 
the entropy term, produced by the release of solvent molecules from FPX upon binding. While the 
enthalpy terms are similar between the two cobalt complexes showing similar strength of hydrogen 
bonding, the difference in the entropy term produces a discrepancy in the dissociation constant. 
Methylene blue (MB) has been used to quantify sulfate content on heparin chains and to examine 
heparin binding interactions.(26-29) The MB absorbance at 664 nm and 614 nm decreases 
proportionally with increasing sulfate concentration from addition of FPX to the solution. We have 
previously shown that with addition of FPX to a solution containing a constant concentration of 
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MB, the absorbance decreases as free MB is bound to increasing concentrations of FPX.(17) The 
association constant between FPX and MB was previously calculated using a Scatchard plot (4.1 
x 104 M-1).(16, 17)  
We again used the MB assay to study the ability of the cobalt library to inhibit MB binding through 
metalloshielding of FPX. With increasing concentrations of cobalt compounds in solution, FPX is 
metalloshielded from MB interacting with the FPX allowing more free-MB to be in solution 
resulting in an increase of absorbance. The ability for these cobalt compounds to “metalloshield” 
was calculated as an IC50 value, the concentration of cobalt compound required to inhibit 50% of 
the MB to bind to the FPX. Pentaamminechlorocobalt(III) and tris(ethylenediamine)cobalt(III) 
both have the ability to ‘metalloshield’ multiple sulfate clusters from binding to MB resulting in 
similar concentrations required (75.6 and 71.0 µM respectively), Table 4.5 and Figure 4.8. Again, 
we observed a higher concentration required for the covalent interaction of t-
dichlorobis(ethylenediamine)cobalt(III) (116.1 µM) which may be due to the one sulfate covalent 
protection over hydrogen bonding cluster interactions or to the rapid isomerization artificially 
increasing the concentration needed, Figure 4.8. By using MB as a reporter, we are able to calculate 
the apparent dissociation constant (Kd(app)) between the cobalt complexes and FPX. 
 
4.4 Conclusions  
 
The focused small library studied here begins to elucidate structure–activity relationships. The 
stark contrast between t-dichlorobis(ethylenediamine)cobalt(III) and 
pentaamminechlorocobalt(III)  in inhibiting the HS cleavage emphasizes the importance of 
hydrogen bonding in sulfate cluster protection. The overall results discussed here suggest 
comparable affinities for cobalt complexes binding to FPX as previously discussed.(16, 17) ITC 
shows that cobalt complexes interacting with FPX, Kds of 18.6 to 90.1 µM, are comparable to a 
mixture of heterogeneous heparin chains complexing with FGF-1, Kds of 1.1 to 3 µM.(30,31) MB 
and MS assays suggest that covalent interactions of these cobalt compounds may only interact 
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with a single sulfate, while non-covalent hydrogen bonding may interact with a cluster of sulfates. 
This was observed using MB as a reporter, requiring a higher concentration of covalently 
interacted cobalt complexes over the non-covalent complexes. This was also observed in the MS 
with a greater number of sulfates lost through the covalent interaction of t-
dichlorobis(ethylenediamine)cobalt(III) with up to six sulfates lost from FPX in the 2- charge state, 
while the non-covalent interaction showed lower abundance of lost sulfates. Therefore 
“metalloshielding” of FPX through sulfate clusters would be greater in the non-covalent 
compounds over the covalent interactions. However, the NMR results show that covalent 
interactions, using application of hard–soft acid–base concepts, occur much stronger than the non-
covalent interactions. These assays give an estimate of the strength of the FPX–cobalt binding and 
provide a relative calculation of affinities. However, given clear disparities in the quantitation of 
dissociation constants, care should be taken in extrapolating across the assays discussed due to the 
inherent differences in the nature of these assays. Thus, whereas ITC is a “two-body” system, the 
MB competition assay becomes a “three-body” system, and is consequently more difficult to 
interpret. Overall, the results validate the importance of the metalloglycomics concept in 
developing new classes of molecules for study of glycan structure and function, further 
emphasizing the need to explore the dual‐ function therapeutic nature of the less cytotoxic cobalt 
complexes. 
 
4.5 Experimental Section 
 
 Synthesis and Materials 
D-glucosamine-6-O-sulfate was purchased from Carbosynth Ltd.(USA). Fondaparinux and 
pentaamminechlorocobalt(III) chloride were purchased from Sigma-Aldrich (USA). Methylene 
blue chloride was purchased from Fisher Scientiﬁc (USA). Tris(ethylenediamine)cobalt(III) 
chloride, t-dichlorobis(ethylenediamine)cobalt(III) chloride, and potassium 
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hexacyanocobaltate(III) were synthesized according to published methods from refs 32, 33, and 
34, respectively.  
 Heparinase Studies 
Colorimetric HPSE activity assay 
The indicated concentration of each compound was incubated for 15 min. at room temperature 
with 50 µM fondaparinux in buffer containing 40mM NaOAc, pH 5. After addition of 0.25U 
heparinase I for 1h at 37°C, the reactions were stopped by adding 100 µl 1.69mM WST-1 
(Dojindo). After heating the plate to 60°C for 30 min., absorbance readings at 584 nm were 
collected using a spectrophotometer (Biotek). The points on the graph represent the mean of two 
independent experiments containing two replicates for each concentration.  
 Matrigel Invasion HPSE assay 
Drug + Heparinase Incubation 
Growth factor reduced matrigel chambers (Corning) were treated with either PBS (-HPSE and 
+HPSE) or 50 µM of cobalt compound for 1 hour. Following treatment, chambers were then 
treated with additional PBS (-HPSE) or 0.3 units of heparinase I (+HPSE and Drug + HPSE). 
Matrigel chambers were then placed in 37°C incubator for 16 hours to allow heparinase digestion 
of matrigel to take place. Following this digestion, matrigel inserts were washed 10x times with 
PBS in order to remove remaining enzyme or drug. Inserts were then filled with DMEM:F12 media 
(Gibco) containing low percentage of FBS (0.2%). Inserts were then placed into new wells 
containing chemoattractant (10%FBS). 
Cell Invasion 
Next, 8x104 serum starved MDA-MB231 cells were seeded into each chamber. Cells were then 
placed into the incubator for 12 hours to allow for invasion to occur. Following this, cells which 
had invaded were fixed and stained using methanol/crystal violet, imaged, and counted manually. 
Percent invasion was determined by normalizing cells invaded through matrigel to cells which 
migrated through control insert. 
Direct Binding Assays:  
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Isothermal Titration Calorimetry 
Calorimetric data was collected using a VP-ITC Microcalorimeter (MicroCal, LLC). All samples 
were degassed for 5 minutes using a ThermoVac (MicroCal, LLC). For all titrations, injections of 
cobalt complexes were pipetted automatically into the reaction cell containing 1.3 mL of FPX at 
300 second intervals from a 300 µL syringe while stirring at 75 rpm. In all experiments, 100 mM 
cacodylate buffer (pH 7.4) was used at 25oC and the thermal reference cell contained 1.3 mL of 
100 mM cacodylate buffer (pH 7.4). Integration of the thermogram peaks were carried out using 
the software supplied with the calorimeter (Origin 7.0). The heats were fitted to a one site model 
using Origin 7.0 to determine Kd, ΔH, and ΔS. ΔG was obtained using Gibbs free energy equation. 
NMR Studies 
1H NMR spectroscopy was performed in an Ascend 400 MHz NMR spectrometer (Bruker), data 
being collected and analyzed with the TOPSPIN software (Bruker). Monomer (23 mM) was pre-
incubated for 10 min with each of the cobalt compounds (23 mM) in the cobalt library (Figure 4.1) 
in deuterated water.  
59Co NMR spectroscopy was performed in an Ascend 400 MHz NMR spectrometer (Bruker), data 
being collected and analyzed with the TOPSPIN software (Bruker). Monomer (23 mM) was pre-
incubated for 10 min with each of the cobalt compounds (23 mM) in the cobalt library (Figure 4.1) 
in deuterated water. Chemical shifts are reported relative to Co(CN)6
3-. 
Mass Spectrometry 
Mass spectra were acquired on a Thermo Electron Corporation Orbitrap Velos mass spectrometer 
(Waltham, MA). Samples were introduced by flow injection at flow rates of 0.5 to 0.7 µL/min 
using a syringe pump. Electrospray source condition were kept constant with a capillary 
temperature of 230oC and capillary voltage between 2.3 and 2.5 kV. FPX and cobalt complexes 
were reconstituted in DI water to a stock concentration of 40 µM. Samples were mixed at a 1:1 
molar ratio and were incubated at room temperature for 20 minutes. Samples were diluted with 
addition of Milli-Q methanol for a final concentration of 1:10 methanol:water. 
 Competitive Binding Assays:  
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Methylene Blue Reporter Method 
A change in absorbance of MB at 664 nm accompanies it binding to the sulfates on FPX. This 
change was used to quantitate the affinity of MB (at a constant final concentration of 21.98 µM) 
for FPX in water. Varying concentrations of cobalt complexes were incubated with constant 
concentration of FPX (at a constant final concentration of 15 µM) for 15 mins at room temp. To 
each sample was added constant concentration of MB. All binding studies were performed in 
triplicate on an Agilent 8453 diode array spectrophotometer in a sub-micro quartz cuvette with a 
path length of 10 mm. 
IC50 and Ka(app) values for binding of cobalt complexes to FPX were calculated by converting the 
MB absorption values to a normalized value (minimum and maximum absorbance) and the Ka(app) 
was determined using the following equation: 
 
1
𝐾𝑎(𝑎𝑝𝑝)
= 𝐼𝐶50𝑥
2𝐾𝑑𝐿[𝑆𝐿−(𝐵𝐿)𝑜] 
[(𝐵𝐿)𝑜
  2
+2𝑆𝐿𝐾𝑑𝐿−3𝑆𝐿(𝐵𝐿)𝑜]
,  
where KdL is the dissociation constant for the labeled ligand (MB) and binding site (FPX), SL is the 
total concentration of the labeled ligand, and (BL)o is the equilibrium of labeled ligand value when 
competitor concentration is zero. 
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Chapter 5: Interactions of Non-covalent Metal Complexes with Fondaparinux 
 
5.1 Results and Discussion 
 
Negative mode electrospray ionization (ESI) is commonly used for characterization of heparin due 
to its highly acidic nature. We have previously shown through ESI-MS studies that FPX undergoes 
sulfate loss in the gas phase. (1) Analysis regarding the retention of labile sulfate groups on the 
heparin backbone has shown metal cations stabilize sulfate groups. (2) In this work we examine 
the stoichiometry of metal complexes bound to FPX and the ability of these metal complexes to 
protect against sulfate loss, Table 5.1.  
Peaks corresponding to a hydrogen bonding interaction between hexaamminecobalt(III) and FPX 
were observed at 415.25 m/z (4-), 554.01 m/z (3-), and 831.52 m/z (2-), Figure 5.1. Peaks were also 
observed corresponding to a retained sodium ion at 561.33 m/z (3-) and one to three retained 
sodium ions at 842.51, 853.50, and 864.49 m/z (2-) respectively. A 2:1 binding stoichiometry of 
Co:FPX was also observed at 910.55 m/z (2-). Continuing with Werner’s complex, one peak 
corresponding to a hydrogen bonding interaction between Werner’s Complex and FPX with a 2:2 
binding stoichiometry was observed at 816.59 m/z (5-), Figure 5.1. Switching to an electrostatic 
compound rather than a hydrogen bonding compound, peaks corresponding to tris(2,2’-
bipyridine)cobalt(III) and FPX were observed at a 1:2 Co:FPX stoichiometry at 620.99 m/z (6-), 
745.39 m/z (5-), 931.98 m/z (4-), and 1242.98 m/z (3-), Figure 5.1. A 1:1 binding stoichiometry 
was also observed 1110.99 m/z (2-). Continuing with tris(2,2’-bipyridine)ruthenium(II), peaks 
corresponding to an electrostatic bonding interaction between tris(2,2’-bipyridine)ruthenium(II) 
and FPX were observed with a 2:1 Ru:FPX stoichiometry at 660.55 m/z (4-), 881.08 m/z (3-), and 
1321.62 m/z (2-), Figure 5.1. A peak was also observed corresponding to a retained sodium ion at 
892.74 m/z (3-). An 1:1 binding stoichiometry was also observed at 517.76 m/z (4-), 690.68 m/z 
(3-), and 1036.52 m/z (2-). Peaks were also observed corresponding to a retained sodium ion at 
698.67 (3-) and to one and two retained sodium ions at 1047.51 and 1058.51 m/z (2-) respectively.  
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Figure 5.1. ESI-MS of 1:1 adducts of FPX and A) hexaamminecobalt(III) in the 2-, 3-, and 4- 
charge states with the parent peak of FPX also observed at the 4- charge state with a 2:1 
Co:FPX stoichiometry at the 2- charge state, B) Werner’s complex in the 5- charge state with 
an observed 2:2 Co:FPX stoichiometry, C) tris(2,2’-bipyridine)cobalt(III) in the 2- through 6- 
charge states with observed 1:1 and 1:2 Co:FPX stoichiometry and loss of 1 sulfate, and D) 
tris(2,2’-bipyridine)ruthenium(II) in the 2- through 4- charge states with observed 1:1 and 2:1 
Co:FPX stoichiometry. 
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A peak was also observed with one retained sodium ion and loss of sulfate at 1007.48 (2-). We 
also observed more sulfate loss with electrostatic interactions, since hydrogen bonding interactions 
allow for sulfate cluster interactions, more sulfates are protected. Cobalt complexes with the ability 
to interact through hydrogen bonding were able to protect the FPX from sulfate loss through sulfate 
cluster interaction with an ability to “metalloshield” a larger group of sulfate clusters where one 
ammine can interact with multiple oxygens. Conversely, sulfate loss was observed after 
interactions with the electrostatic complexes. The compounds using only electrostatic interactions 
will have more of dispersed charge with larger ligands that produces a weaker interaction between 
the metal complexes and FPX. 
ITC measures the amount of heat energy released or absorbed into the system upon the interaction 
of two molecules. ITC determines the thermodynamic influences of both the change in enthalpy 
(ΔH) and entropy (ΔS) changes to calculate the free energy of binding (ΔG). ITC assays were 
performed to determine the binding constants between FPX and the metal compound library. 
Electrostatic and hydrogen bonding interactions contribute to the enthalpy term, while 
conformational freedom changes and solvation changes that occur upon complexation contribute 
to the entropy term. (3, 4) 
While the major contribution for the derived thermodynamic binding parameters arose from the 
entropy term, binding interactions can still be evaluated from the enthalpy binding term, Table 5.2. 
Hexaamminecobalt(III) has an intermediate Kd (59.5 µM) and Gibbs Free energy (-5.8 kJ/mol) 
which is likely due to the hydrogen bonding ability and smaller size of the coordinated ligands, 
Figure 5.2. WC had the greatest Kd and Gibbs Free energy (296 nM and -8.78 kJ/mol, respectively). 
This is due to the overall 6+ charge and largest size, which displaces the most solvent molecules 
and forces a FPX conformational change. Tris(2,2’-bipyridine)cobalt(III) has the lowest Kd (90.1 
µM) and the weakest Gibbs Free energy (-5.5 kJ/mol), Figure 5.2. The less favorable binding 
parameters of tris(2,2’-bipyridine)cobalt(III) likely arise from the lack of hydrogen bonding 
interactions. ITC titrations of tris(2,2’-bipyridine)ruthenium(II) into FPX did not give a well-
defined isothermal trace, perhaps due to weak binding arising from a lack of hydrogen bonding  
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Composition* Formula m/z (charge) 
MW 
Observed Calculated 
FPX+[Co(NH3)6] C31H64CoN9O49S8 415.25 (4-) 1661.00 1660.99 
FPX+[Co(NH3)6] C31H65CoN9O49S8 554.01 (3-) 1662.03 1662.00 
FPX+[Co(NH3)6]+Na C31H64CoN9NaO49S8  561.33 (3-) 1683.99 1683.98 
FPX+[Co(NH3)6] C31H66CoN9O49S8 831.52 (2-) 1663.04 1663.00 
FPX+[Co(NH3)6]+Na C31H65CoN9NaO49S8 842.51 (2-) 1685.02 1684.99 
FPX+[Co(NH3)6]+2Na C31H64CoN9Na2O49S8 853.50 (2-) 1707.00 1706.97 
FPX+[Co(NH3)6]+3Na C31H63CoN9Na3O49S8 864.49 (2-) 1728.98 1728.95 
FPX+2[Co(NH3)6] C31H81Co2N15O49S8 910.55 (2-) 1821.10 1821.07 
     
2FPX+2WC C62H173Co8N30O110S16 816.19 (5-) 4080.95 4080.91 
     
FPX+[Co(bipy)3] C61H73CoN9O61S8 1110.99 (2-) 2221.98 2221.99 
2FPX+[Co(bipy)3] C92H123CoN12O110S16 620.99 (6-) 3725.94 3725.93 
2FPX+[Co(bipy)3] C92H124CoN12O110S16 745.39 (5-) 3726.95 3726.93 
2FPX+[Co(bipy)3] C92H125CoN12O110S16 931.98 (4-) 3727.92 3727.94 
2FPX+[Co(bipy)3] C92H126CoN12O110S16 1242.98 (3-) 3728.94 3728.95 
     
FPX+[Ru(bipy)3] C61H71N9O49RuS8 517.76 (4-) 2071.04 2071.01 
FPX+[Ru(bipy)3] C61H72N9O49RuS8 690.68 (3-) 2072.04 2072.02 
FPX+[Ru(bipy)3]+Na C61H71N9NaO49RuS8 698.67 (3-) 2096.01 2096.02 
FPX+[Ru(bipy)3] C61H73N9O49RuS8 1036.52 (2-) 2073.04 2073.03 
FPX+[Ru(bipy)3]+Na C61H72N9NaO49RuS8 1047.51 (2-) 2095.02 2095.01 
FPX+[Ru(bipy)3]+Na-SO3 C61H72N9NaO46RuS7 1007.48 (2-) 2014.96 2015.05 
FPX+[Ru(bipy)3]+2Na C61H71N9Na2O49RuS8 1058.51 (2-) 2117.02 2116.99 
FPX+2[Ru(bipy)3] C91H96N15O49Ru2S8 660.55 (4-) 2642.20 2642.13 
FPX+2[Ru(bipy)3] C91H97N15O49Ru2S8 881.08 (3-) 2643.24 2643.14 
FPX+2[Ru(bipy)3]+Na C91H109N15O49Ru2S8 892.74 (3-) 2678.22 2678.22 
FPX+2[Ru(bipy)3] C91H97N15O49Ru2S8 1321.62 (2-) 2643.24 2643.14 
Table 5.1. Species detected on the ESI-MS spectra. *protons and charges were omitted for 
clarity. FPX represent the parent Fondaparinux species. 
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interactions, consistent with what was observed in the following MB assay. The major contribution 
arose from the entropy term in the case of the simple cobalt complexes. This was produced by the 
release of solvent molecules from FPX upon binding. The “U”-shaped traces that were observed 
are indicative of a strong conformational change produced by WC interacting with FPX and a 
weaker conformational change produced by hexaamminecobalt(III) with FPX. 
The NMR chemical shift changes of D-glucosamine-6-O-sulfate (monomer) in the presence of 
cobalt complexes were investigated to delineate the binding interactions. Addition of cobalt 
complexes shifted the proton signals of the monomer, Figure 5.3. Upon measurements performed 
from the freshly prepared 1:1 Co:Monomer mixture, distinct shifts were observed due to fast 
interactions. Only small downfield shifts (.000 to .007 ppm) are observed for the non-covalent  
interactions disregarding Werner’s Complex, Table 5.3. Werner’s Complex produced shifts (up to 
.017 ppm) that were at least 2 fold greater than any other non-covalent cobalt complex shift. 
Werner’s Complex produced larger shifts due to the stronger binding of the complex to the 
monomer. Since no considerable shifts were observed in the case of tris(2,2’-bipyridine)cobalt(III) 
due to electrostatic interactions with no hydrogen bonding, tris(2,2’-bipyridine)ruthenium(II) was 
not investigated. The major shifts were observed through the sulfate interaction between Werner’s 
Complex and FPX, while a non-discriminate binding to both sulfate and hydroxy groups were 
observed for hexaamminecobalt(III). 
Methylene blue (MB) has been used to quantify sulfate content on heparin chains and to examine 
heparin binding interactions.(5-8) The MB absorbance at 664 nm and 614 nm decreases 
proportionally with increasing sulfate concentration from addition of FPX to the solution. We have 
previously shown that with addition of FPX to a solution containing a constant concentration of 
MB, the absorbance decreases as free MB is bound to increasing concentrations of FPX. (9) The 
association constant between FPX and MB was previously calculated using a Scatchard plot (4.1 
x 104 M-1). (9, 10) 
We again used the MB assay to study the ability of the metal library to inhibit MB binding through  
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Kd ΔG (kJ/mol) ΔH (J/mol) -TΔS (kJ/mol*K) 
[Co(NH3)6]
3+  59.5 ± 7.8[a] -5.8 ± 0.2 -557.1 ± 15.7 -5.2 
WC6+ 296 ± 34[b] -8.78 ± 0.1 -1336 ± 8 -7.4 
[Co(bipy)3]
3+  90.1 ±  20.3[a] -5.5 ± 0.5 -526.9 ± 51.1 -4.9 
Figure 5.2. ITC analysis of FPX by direct titration with A) hexaamminecobalt(III) B) Werner’s 
complex and C) tris(2,2’-bipyridine)cobalt(III). A trace of calorimetric titration (upper panel) 
and integrated isotherms (lower panel). The first peak represents a pre-injection that was 
omitted in the binding calculations. 
 
Table 5.2. ITC analysis showing the obtained binding parameters: dissociation constants (Kd); 
free energy of binding (ΔG); enthalpy of binding (ΔH); and entropy of binding (-TΔS) between 
cobalt compounds and FPX. The standard error from 3 measurements is indicated. 
[a] Kd measured in µM. 
[b] Kd measured in nM. 
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metalloshielding of FPX. With increasing concentrations of metal compounds, FPX is 
metalloshielded from MB, allowing more free-MB to be in solution, resulting in an increase of 
absorbance at 664 nm. The ability of these metal compounds to “metalloshield” was calculated as 
an IC50 value, the concentration of metal compound required to inhibit 50% of the MB to bind to 
the FPX. Werner’s Complex and tris(2,2’-bipyridine)cobalt(III) required the lowest concentrations 
to inhibit MB binding (41.4 and 36.4 µM respectively), Figure 5.4 and Table 5.4. The similarity 
in concentrations is attributed to the overall larger size of the ligands and their ability to spatially 
inhibit MB binding to the sulfates. A higher concentration was required for the smaller 
hexaamminecobalt(III) compound (64.5 µM). Similarly to the ITC assay, a greater concentration 
of tris(2,2’-bipyridine)ruthenium(II) (676.2 µM) was required to inhibit MB binding to FPX. 
These weak interactions by tris(2,2’-bipyridine)ruthenium(II) arise from the lower charge and lack 
of hydrogen bonding. By using MB as a reporter, we are able to calculate the apparent dissociation 
constant (Kd(app)) between the cobalt complexes and FPX. 
 
5.2 Experimental 
 
Mass Spectrometry 
Mass spectra were acquired on a Thermo Electron Corporation Orbitrap Velos mass spectrometer 
(Waltham, MA). Samples were introduced by flow injection at flow rates of 0.5 to 0.7 µL/min 
using a syringe pump. Electrospray source condition were kept constant with a capillary 
temperature of 230oC and capillary voltage between 2.3 and 2.5 kV. FPX and cobalt complexes 
were reconstituted in DI water to a stock concentration of 40 µM. Samples were mixed at a 1:1 
molar ratio and were incubated at room temperature for 20 minutes. Samples were diluted with 
addition of Milli-Q methanol for a final concentration of 1:10 methanol:water. 
Isothermal Titration Calorimetry 
Calorimetric data was collected using a VP-ITC Microcalorimeter (MicroCal, LLC). All samples 
were degassed for 5 minutes using a ThermoVac (MicroCal, LLC). For all titrations, injections of  
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 Δδ = δ(monomer : Co) – δ(monomer) (ppm) 
αH1 αH2 αH4/βH6’ αH6’ αH5/βH6 αH6 
[Co(NH3)6]3+ 0.007 0.006 0.001 0.006 0.006 0.006 
WC6+ 0.009 0.005 0.005 0.012 0.000 0.017 
[Co(bipy)3]3+ 0.001 0.002 0.000 0.001 0.000 0.002 
Figure 5.3. 1H NMR spectra of 1:1 mixtures of D-glucosamine-6-O-sulfate and various metal 
complexes from top to bottom: hexaamminecobalt(III), Werner’s complex, tris(2,2’-
bipyridine)cobalt(III), and D-glucosamine-6-O-sulfate. 
 
Table 5.3. 1H chemical shift changes (Δδ = 
δ(monomer : Co) – δ(monomer)) after incubation 
of metal complexes with D-glucosamine-6-O-
sulfate. 
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cobalt complexes were pipetted automatically into the reaction cell containing 1.3 mL of FPX at 
300 second intervals from a 300 µL syringe while stirring at 75 rpm. In all experiments, 100 mM 
cacodylate buffer (pH 7.4) was used at 25oC and the thermal reference cell contained 1.3 mL of 
100 mM cacodylate buffer (pH 7.4). Integration of the thermogram peaks were carried out using 
the software supplied with the calorimeter (Origin 7.0). The heats were fitted to a one site model 
using Origin 7.0 to determine Kd, ΔH, and ΔS. ΔG was obtained using Gibbs free energy equation. 
NMR Studies 
1H NMR spectroscopy was performed in an Ascend 400 MHz NMR spectrometer (Bruker), data 
being collected and analyzed with the TOPSPIN software (Bruker). Monomer (23 mM) was pre-
incubated for 10 min with each of the cobalt compounds (23 mM) in the cobalt library (Figure 5.5) 
in deuterated water. 
Methylene Blue Reporter Method 
A change in absorbance of MB at 664 nm accompanies it binding to the sulfates on FPX. This 
change was used to quantitate the affinity of MB (at a constant final concentration of 21.98 µM) 
for FPX in water. Varying concentrations of cobalt complexes were incubated with constant 
concentration of FPX (at a constant final concentration of 15 µM) for 15 mins at room temp. To 
each sample was added constant concentration of MB. All binding studies were performed in 
triplicate on an Agilent 8453 diode array spectrophotometer in a sub-micro quartz cuvette with a 
path length of 10 mm. 
IC50 and Ka(app) values for binding of cobalt complexes to FPX were calculated by converting the 
MB absorption values to a normalized value (minimum and maximum absorbance) and the Ka(app) 
was determined using the following equation: 
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IC50 (µM)
a Kd(app) (µM)
b 
[Co(NH3)6]
3+  64.5 ± 1.1 30.2 ± 0.5 
WC6+ 41.4 ± 0.1 20.1 ± 0.2 
[Co(bipy)3]
3+  36.4 ±  0.9 17.7 ± 0.4 
[Ru(bipy)3]
2+ 676.2 ± 17.3 316.8 ± 8.1 
Figure 5.4. MB competition assay for assessment FPX binding. At a constant concentration of 
15 μM FPX in the presence of varying concentrations of A) hexaamminecobalt(III) (from 
bottom to top with 30, 40, 50, 60, 70, 80, 90, 100 μM), B) Wener’s complex (from bottom to 
top with 10, 20, 30, 40, 50 μM), C) tris(2,2’-bipyridine)cobalt(III) (from bottom to top with 
10, 20, 30, 40, 50, 60, 70, 80, 90, 100 μM) D) tris(2,2’-bipyridine)ruthenium(II) (from bottom 
to top with Ruthenium only (1 mM), 10, 20, 40, 60, 80, 100, 500, 1000 μM); MB binding is 
inhibited, reflected in the change of [AbsMB] at 664 nm. 
 
Table 5.4. IC50 and Kd(app) Values of metal compounds in the competitive inhibition assay using 
MB as a reporter. 
a) The IC50 value was determined as the concentration of complex required for half-maximal 
binding of the dye (21.98 μM) to FPX (15 μM) for the MB binding assay. 
b) Dissociation constants were calculated from the MB assay for metal compounds binding to 
FPX using a competitive inhibitor model.  
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Hexamminecobalt(III) 
Tris(2,2'-bipyridine)cobalt(III) 
Werner’s hexol 
Tris(2,2'-bipyridine)ruthenium(II) 
Figure 5.5. Library of cobalt complexes used. Counterions omitted for clarity. 
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where KdL is the dissociation constant for the labeled ligand (MB) and binding site (FPX), SL is the 
total concentration of the labeled ligand, and (BL)o is the equilibrium of labeled ligand value when 
competitor concentration is zero. 
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6.1 Abstract 
 
The interaction between simple metal cations and fondaparinux leads to sulfate cluster binding, 
thus providing a simple platform to investigate “metalloshielding” of sulfates using a reporter dye, 
stabilization of sulfates using ESI-MS, and cleavage inhibition of glycosidic linkages using 
bacterial heparinase. 
 
6.2 Introduction 
 
Heparan sulfate proteoglycans (HSPGs) are found in the extracellular matrix or on the cell surface 
once proteins associate with heparan sulfate (HS), a sulfated glycosaminoglycan. HSPGs play a 
major role in the cell recognition process, adhesion, and migration.(1,2) Cancer cells over-express 
HSPGs on their cell surface. HS sulfate residues are the recognition site for many different protein 
substrates including pro-angiogenic growth factors, interacting similar to the phosphate clamp-
arginine fork motif. Fibroblast growth factors (FGFs) directly stimulate the growth, metastasis and 
survival of cancer cells.(3) HSPG enzymatic cleavage at glycosidic linkages by heparanase 
(HPSE) causes release of angiogenic growth factors initiating the angiogenic cascade. HPSE is 
also over-expressed in tumors with significant correlation between metastatic potential and 
heparanase activity.(4-7) HS is, thus, an attractive drug target to inhibit tumor cell progression 
through “metalloshielding” or sulfate cluster masking of HS by metal complexes protecting HS 
from enzymatic cleavage by the mammalian heparanase, and preventing growth factors from 
binding to HS and/or preventing release of bound growth factors.  
The highly anionic nature of HSs means they are associated with physiologically relevant 
cations.(8-10) Cation association aﬀ ects the biomolecule conformation and can facilitate 
heparin−protein interactions such as Ca2+-dependent heparin−annexin A2 binding.(11) Growth 
factors are also copper-dependent, with a slightly higher aﬃnity of HS for FGF-1 compared to 
FGF-2.(12-15) Aquated Ca2+, Mg2+, Fe3+, and Zn2+ ions, at higher than physiological  
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Figure 6.1. MB competition assay for assessment FPX binding. At a constant concentration of 15 μM 
FPX and 21.98 μM MB in the presence of varying concentrations of A) Manganese(II) chloride (from 
bottom to top with 10, 20, 30, 50, 60, 70, 80, 200, 300, 400, and 500 μM), B) Vanadium(III) chloride 
(from bottom to top with 10, 20, 30, 70, 80, 90, 200, 300, 400, and 500 μM), C) Vanadyl(III) sulfate 
(from bottom to top with 50, 60, 70, 80, 90, 100, 250, 300, and 400 μM) and D) absorption spectrum 
of MB and Vanadyl(III) sulfate (from bottom to top with 100, 250, and 500 μM); MB binding is 
inhibited, reflected in the change of [AbsMB] at 664 nm. 
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concentrations, reduce FGF-1 interactions with HS.(8) In order to determine the importance of 
hard-soft acid-base concepts on the “metalloshielding” potential of the metal complex library, 
binding and cleavage inhibition studies were performed using Fondaparinux as a model HS-like 
substrate. Fondaparinux (FPX) is a well-defined octasulfated pentasaccharide with a single point 
of cleavage for bacterial HPSE. New patterns of metal-heparin binding can be achieved by the 
application of hard–soft acid–base concepts. 
To develop the HSAB concepts, we have chosen a small library of metal complexes to examine 
their effects with FPX.  This communication describes cleavage inhibition studies in the presence 
and absence of Manganese(II) chloride using bacterial HPSE. A competition assay was 
implemented using methylene blue (MB) as a reporter to measure the “metalloshielding” of MB 
for each compound. Sulfate stability was examined using mass spectrometry (MS). The overall 
results emphasize the importance of understanding the properties of glycan interactions with metal 
complexes, to expand bioinorganic chemistry into this important class of biomolecules. 
 
6.3 Results and Discussion 
Methylene blue (MB) has been used to quantify sulfate content on heparin chains and to examine 
heparin binding interactions.(16-18) With increasing sulfate concentration from addition of FPX 
to the solution, the MB absorbance at 664 nm and 614 nm decreases proportionally. It has been 
previously shown that upon addition of FPX to a solution of MB, the absorbance decreases as more 
MB is bound to FPX.(19) The association constant between FPX and MB was previously 
calculated using a Scatchard plot (4.1 x 104 M-1).(19)  
The MB assay was used to study the ability of the metal library to inhibit MB binding through 
“metalloshielding” of FPX. Varying concentrations of metal complexes were incubated with 
constant concentration of FPX (15 µM) for 15 mins at room temperature. MB was added to each 
(to a constant final concentration of 21.98 µM). With increasing concentrations of metal 
compounds in solution, FPX is “metalloshielded” from MB, preventing interaction with FPX. The 
additional free-MB in solution resulting in an absorbance increase, Figure 6.1. The ability of these  
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IC50 (µM)
a IC50 (µM)
b 
MnCl2 333 ± 1 354 ± 78 
VCl3 264 ± 1 NA 
VOSO4 535 ± 1 NA 
Composition* Formula m/z (charge) 
MW 
Observed Calculated 
FPX+Mn+Na C31H47MnN3NaO49S8 526.28 (3-) 1578.87 1578.83 
FPX+Mn C31H49MnN3O49S8 778.94 (2-) 1557.88 1557.86 
FPX+Mn-SO3 C31H49MnN3O46S7 738.98 (2-) 1477.96 1477.90 
     
FPX+V C31H46N3O49S8V 387.72 (4-) 1550.88 1550.84 
FPX+V+Na C31H47N3NaO49S8V 787.43 (2-) 1574.86 1574.84 
FPX+V C31H48N3O49S8V 776.44 (2-) 1552.88 1552.86 
FPX+V-SO3 C31H48N3O46S7V 736.46 (2-) 1472.92 1472.90 
     
FPX+VO+Na C31H48N3NaO50S8V 530.63 (3-) 1591.89 1591.84 
FPX+VO+Na-SO3 C31H48N3NaO47S7V 503.97 (3-) 1511.91 1511.88 
FPX+VO C31H49N3O50S8V 523.30 (3-) 1569.90 1569.86 
FPX+VO-SO3 C31H49N3O47S7V 496.65 (3-) 1489.95 1489.90 
FPX+VO-2SO3 C31H49N3O44S6V 496.99 (3-) 1490.97 1409.95 
FPX+VO-3SO3 C31H49N3O41S5V 443.34 (3-) 1330.02 1329.99 
FPX+VO+Na C31H49N3NaO50S8V 796.45 (2-) 1592.90 1592.85 
FPX+VO+Na-SO3 C31H49N3NaO47S7V 756.47 (2-) 1512.94 1512.89 
FPX+VO+Na-2SO3 C31H49N3NaO44S6V 716.49 (2-) 1432.98 1432.94 
FPX+VO+Na-3SO3 C31H49N3NaO41S5V 676.51 (2-) 1353.02 1352.98 
FPX+VO C31H50N3O50S8V 785.46 (2-) 1570.92 1570.87 
FPX+VO-SO3 C31H50N3O47S7V 745.48 (2-) 1490.96 1490.91 
FPX+VO-2SO3 C31H50N3O44S6V 705.50 (2-) 1411.00 1410.95 
FPX+VO-3SO3 C31H50N3O41S5V 665.52 (2-) 1331.04 1331.00 
Table 6.1. IC50 values of metal compounds in the competitive inhibition assay using MB as a reporter. 
a) The IC50 value was determined as the concentration of complex required for half-maximal 
binding of the dye (21.98 μM) to FPX (15 μM) for the MB binding assay. 
b) The IC50 value was determined as the concentration of complex required to inhibit 50% of 
HPSE cleavage on FPX. 
 
Table 6.2. Species detected on the ESI-MS spectra. *protons and charges were omitted for clarity. FPX 
represent the parent Fondaparinux species. 
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metal compounds to “metalloshield” was calculated as an IC50 value, the concentration of metal 
compound required to inhibit 50% of MB binding, Table 6.1. The higher charged Vanadium(III) 
requires the lowest concentration, 264 µM, while Vanadyl(III) requires the highest concentration, 
535 µM, due to the decrease in overall charge of the complex due to the presence of negatively 
charged oxygen. Manganese(II) requires an intermediate concentration, 333 µM. While the V(III) 
and Mn(II) complexes interact covalently with protection proportional to the charge of each metal; 
the VO, while still covalent, requires a higher concentration due to the oxygen being retained, both 
lowering the overall charge of the complex and limiting the number of available interaction sites 
on the Vanadium. Due to MB’s ability to interact with sulfates, we also measured the absorbance 
change of MB in the presence of Vanadyl(III) sulfate. An analogous change in absorbance was 
observed using similar concentrations of Vanadyl(III) sulfate to those used in the inhibitory MB 
assay. This would artificially decrease the absorbance requiring a higher concentration of metal 
required to inhibit MBs binding to FPX. 
Negative mode electrospray ionization (ESI) is commonly used for identification and analysis of 
heparin. We have previously shown through ESI-MS studies that FPX undergoes sulfate loss in 
the gas phase.(19) Analysis regarding the retention of labile sulfate groups on the heparin backbone 
has shown metal cations stabilize sulfate groups.(20) In the present work, the stoichiometry of 
metal complexes bound to FPX and their ability to protect against sulfate loss. FPX and metal 
complexes were reconstituted in DI water to a stock concentration of 40 µM. Samples were mixed 
at a 1:1 molar ratio and were incubated at room temperature for 20 minutes. Samples were diluted 
with addition of Milli-Q methanol for a final concentration of 1:9 methanol:water. Peaks 
corresponding to a covalent interaction between Manganese(II) and FPX were observed at 
778.9447 m/z (2-) with loss of one sulfate at 738.9751 m/z (2-), Table 6.2. A Peak was also 
observed corresponding to the previous interaction with a retained sodium ion at 526.2888 m/z (3-
). Peaks corresponding to a covalent interaction between Vanadium(III) and FPX were observed  
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Figure 6.2. Structure of Fondaparinux, and cleavage products by P. heparinus heparinase I. In the 
presence of Manganese(II) chloride, cleavage was inhibited. 
0
20
40
60
80
100
120
0 0.08 0.15 0.31 0.63 1.25
%
 H
ep
ar
in
as
e 
ac
ti
v
it
y
[MnCl2] (mM)
Figure 6.3. Inhibition of heparinase I through 
interaction of Manganese(II) chloride with FPX. Data 
are expressed as percentages relative to controls 
containing no Manganese(II) chloride. 
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at 387.7184 m/z (4-) and 776.4411 m/z (2-) with loss of one sulfate at 736.4632 m/z (2-), Table 6.2. 
A Peak was also observed corresponding to a retained sodium ion at 787.4316 m/z (2-). Peaks 
corresponding to a covalent interaction between Vanadyl and FPX with a retained sodium were 
observed at 398.22067 m/z (4-) with loss of one sulfate at 378.2310 m/z (4-), Table 6.2. Peaks of 
the previous interaction were also observed at 523.6379 m/z (3-) and loss of sulfate at 496.9847 
m/z (3-), along with peaks corresponding to a retained sodium ion at 531.2971 m/z (3-) and loss of 
one sulfate at 504.6441 m/z (3-). Peaks were also observed corresponding to Vanadyl and FPX 
covalent interaction at 785.9596 m/z (2-) with loss of one, two, and three sulfates at 745.9811, 
706.0016, and 666.0220 m/z (2-), respectively. Again, retained sodium was observed at 797.4489 
m/z (2-) with loss of one to three sulfates at 757.4705, 717.4907, and 677.5122 m/z (2-), 
respectively. 
The interaction peaks observed were relatively weak compared to the parent FPX peaks. Greater 
sulfate loss was observed in the case of Vanadyl, since the negative oxygen was retained. The 
oxygen was retained due to the strong interaction between Vanadium and oxygen using HSAB 
chemistry. The positive charge of the Vanadium complex would be lowered concomitantly 
inhibiting the Vanadium from interacting with a greater number of sulfates.  
The cleavage patterns for the interactions between FPX and mammalian heparanase or bacterial 
heparinase I (often used as a model for the mammalian enzyme) are shown in Figure 6.2.(21) A 
colorimetric assay was adapted to examine the inhibitory effect of metal complexes on the 
enzymatic heparinase degradation of FPX. Manganese(II) chloride was incubated for 15 min at 
room temperature with 50 µM FPX in 40mM NaOAc buffer, pH 5. After addition of 0.25 U 
heparinase I for 1 hour at 37 °C. The reactions were stopped by adding 100 µL 1.69 mM WST-1 
(Dojindo), and absorbance readings were recorded at 584 nm. The pentasaccharide substrate was 
incubated with metal complex prior to enzyme exposure and cleavage was 
measured versus control in absence of added complex. Inhibition of heparinase cleavage is 
effective in a concentration-dependent manner for Manganese(II) chloride, Figure 6.3 and Table 
6.1. Time course studies show that Manganese(II) chloride instantly inhibited activity with little 
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or no variation with time, while the Vanadium(III) complexes interacted with the assay and did 
not produce reportable results.  
 
Overall, these results emphasize that the study of simple cations with oligosaccharides has 
substantial potential in the new area of metalloglycomics. Simple metal cations such as Zn2+ and 
Ca2+ affect the activity and conformation of heparin mimetics. Our results highlight the potential 
“metalloshielding” effect by metal complexes of heparin mimetics through modification of metal 
oxidation state and substitution lability of ligands, and use of HSAB concepts. Vanadium, a hard 
acid, reacts with oxygen, a hard base, forming a stronger bond than Manganese, an intermediate 
acid, with oxygen. Vanadium also produces a stronger interaction than Manganese due to a higher 
overall charge of the complex and due to its ability to interact with more sulfate groups. Vanadyl, 
containing oxygen, lowered the overall charge of the metal complex and limited the amount of 
“metalloshielding”. The study of simple metal cations extends the application of bioinorganic 
chemistry from protein and DNA-RNA interactions into the new era of metalloglycomics. 
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Chapter 7: Synthesis and Characterization of Werner’s Complex 
 
7.1 Synthesis 
 
Ammonium carbonate (7.0 g, 0.0728 mol) was dissolved in 20.0 mL of water, 20.0 mL of 
concentrated aqueous ammonia was then added. In a second container, cobalt (II) nitrate 
hexahydrate (5.0 g, 0.017 mol) was dissolved in 10.0 mL of water. The two solutions were 
combined with stirring. Slowly, 3.0 mL of the 30% hydrogen peroxide solution was added. Once 
the hydrogen peroxide has been added, the solution was evaporated to a volume of 30 mL. During 
the evaporation time, ammonium carbonate (1.7 g, 0.0173 mol) was added to the solution. When 
the solution volume was about 30 mL, the solution was filtered and the filtrate was cooled on ice.  
Red/purple crystals of product formed. These crystals were collected and washed with a few 
milliliters of ice-cold water and then ethanol, and dried. 2.0 g of the product was dissolved in 55 
mL of 0.6 M nitric acid. The solution was then treated with 25 mL of ethanol, slowly. The resulting 
precipitate was filtered off. 2.0 g of the product was dissolved in 25 mL of 0.2 M aqueous 
ammonia. After 24 hours purple/black crystals began to form. After 3 days the crystals were 
collected. 2.0 g, 40.8% recovered.  
 
 
 
 
 
 
 
 
 
 
Figure 7.1. Werner’s Complex 
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7.2 Characterization 
 
1H NMR: 
Theoretical:  
2.49ppm DMSO 
2.95 and 4.29 ppm (3:3) axial and equatorial NH3 
3.34 ppm (1.2) waters of crystallization 
-1.69 ppm (1) OH 
Experimental:  
2.49ppm DMSO 
2.9 and 4.3 ppm (3.02:3) axial and equatorial NH3 
3.3 ppm (6.56) waters of crystallization 
-1.7 ppm (.98) OH 
 
Figure 7.2. 1H NMR of Werner’s Complex in DMSO. 
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UV:  
Theoretical: 
311(4.95x10^3), 504(212), 627(126) wavelength (mol-1 cm-1) 
Experimental: 
311(4.79x10^3), 504(204), 627(127) wavelength (mol-1 cm-1) 
 
Figure 7.3. UV spectra of Werner’s Complex in water. 
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IR:  
Present: 
OH stretch 3600-3300 
NH4 stretch 2375 and 3169, 1626, 817 
NO3 stretch 1329 
Co-N stretch 462 
Co-O stretch 543 
Not present: 
SO4 stretch 1115 
CO3 stretch 1715, 1240 
 
 
 
Elemental Analysis: 
Theoretical for Co4H42N18O24: C 0.00, H 5.19, N 25.24.  Experimental: C <0.10, H 4.78, N 25.24 
 
Figure 7.4. IR spectra of Werner’s Complex. 
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Chapter 8: Conclusions 
 
The results on heparin and Fondaparinux interactions with metal complexes can be extrapolated 
to glycosoaminoglycans such as HS. This emphasizes the relevance of glycan interactions in 
understanding the biological properties of coordination compounds and the utility of the 
metalloglycomics concept for extending bioinorganic chemistry to this class of important 
biomolecules.  
The focused small library of PPCs studied here begins to elucidate structure–activity relationships. 
The stark contrast between [Pt(NH3)4]
2+ and MonoplatinNC in inhibiting the HS cleavage 
emphasizes the importance of dangling amine moieties as well as increased charge dispersion. The 
relative efficacy of the polynuclear set again shows that positive charge dispersion through 
dangling amines and Pt coordination spheres play important roles in masking the HS fragments 
and protecting them against enzymatic cleavage. The ability to form a “sulfate clamp” from the 
interaction of am(m)ines in a Pt coordination unit are likely to be more effective in masking than 
the single positive charge of the dangling amine—nevertheless the two structural features do 
contribute to the overall effect. Trends were assessed, affinity is related to charge and in general 
these substitution‐ inert complexes show broadly similar affinity to FPX and DNA. The 
approaches to inhibition of HS or DNA function are formally analogous since both protect the 
“substrate” from enzyme and/or protein processing. High‐ affinity DNA binding through the 
phosphate clamp efficiently inhibits transcription factors such as TBP (TATA box binding 
proteins) and restriction enzymes. While, the Kd values found for PPC–FPX interactions are 
broadly similar to those found for growth factor–oligosaccharide interactions in the nM range. This 
suggests that metalloshielding will also be effective in inhibition of oligosaccharide‐ protein 
function as shown for the effect of TriplatinNC on FGF‐ heparin interactions. 
The small library of simple metal ammine complexes, along with the lead compound TriPtNC, 
confirmed the generality of metal complexes and their affinity for HS. The Kd values found for 
metal ammine–FPX interactions are broadly similar to those found for growth factor–
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oligosaccharide interactions in the µM range. Again, the overall results suggest comparable 
affinities for heparin relative to DNA for charged metal compounds, regardless of their intrinsic 
nucleic acid affinity. The presence of HS on the cell surface and its relatively similar affinity to 
DNA would suggest that glycan binding is thus a competitive cellular event for many coordination 
compounds. These results extend our understanding of the importance of the interactions of 
physiologically relevant aquated metal cations with heparin to defined coordination compounds. 
The available coordinating moieties on HS–heparin are the oxygen-donor atoms of the hard 
carboxylate and sulfate bases. Therefore, new patterns of metal-ion binding can be achieved by 
the interplay and application of hard–soft acid–base concepts. Further, in considering the concept 
of metalloglycomics, coordination compounds can be manipulated to modify the oxidation state, 
ligand lability, and coordination number and geometry to produce a diverse inorganic library. 
These studies also confirm the affinity of simple coordination complexes with heparin, using a 
series of mononuclear cobalt, ruthenium, and platinum compounds with affinity for heparin 
ordered Co > Ru > Pt. This suggests that cobalt complexes may be more effective at 
metalloshielding oligosaccharide‐protein function. 
Simple cobalt compounds bind with relatively high affinity to heparin, even greater than that of 
the simple platinum compound, tetraammineplatinum(II), extending this work into a library of 
cobalt complexes. The contrast between t-dichlorobis(ethylenediamine)cobalt(III) and 
pentaamminechlorocobalt(III)  in inhibiting HS cleavage of FPX and matrix emphasizes the 
importance of hydrogen bonding in sulfate cluster protection. The overall results discussed here 
suggest comparable affinities for cobalt complexes binding to FPX as previously discussed. ITC 
shows that cobalt complexes interacting with FPX, Kds of 18.6 to 90.1 µM, are comparable to a 
mixture of heterogeneous heparin chains complexing with FGF-1, Kds of 1.1 to 3 µM. MB and 
MS assays suggest that covalent interactions of these cobalt compounds may only interact with a 
single sulfate, while non-covalent hydrogen bonding may interact with a cluster of sulfates. This 
was observed using MB as a reporter, requiring a higher concentration of covalently interacted 
cobalt complexes over the non-covalent complexes. This was also observed in the MS with a 
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greater number of sulfates lost through the covalent interaction of t-
dichlorobis(ethylenediamine)cobalt(III) with up to six sulfates lost from FPX in the 2- charge state, 
while the non-covalent interaction showed lower abundance of lost sulfates. Therefore 
“metalloshielding” of FPX through sulfate clusters would be greater in the non-covalent 
compounds over the covalent interactions. However, the NMR results show that covalent 
interactions, using application of hard–soft acid–base concepts, occur much stronger than the non-
covalent interactions. These assays give an estimate of the strength of the FPX–cobalt binding and 
provide a relative calculation of affinities. This suggests that cobalt complexes with hydrogen 
bonding ability will be more effective at metalloshielding oligosaccharide‐protein function. 
Interactions between non-covalent cobalt complexes and FPX were also studied. More sulfate loss 
was observed with electrostatic interactions, while cobalt complexes with the ability to interact 
through hydrogen bonding were able to protect the FPX from sulfate loss through sulfate cluster 
interaction with an ability to “metalloshield” a larger group of sulfate clusters where one ammine 
can interact with multiple oxygens. The compounds using only electrostatic interactions will have 
more of dispersed charge with larger ligands that produces a weaker interaction between the metal 
complexes and FPX. Further, electrostatic interactions between cobalt and FPX were stronger as 
compared to electrostatic interactions between ruthenium complexes and FPX. ITC titrations of 
tris(2,2’-bipyridine)ruthenium(II) into FPX did not give a well-defined isothermal trace, perhaps 
due to weak binding arising from a lack of hydrogen bonding interactions, consistent with what 
was observed in the MB assay. The multinuclear Werner’s Complex exhibited similar association 
as the PPCs for FPX. Again, this suggests that multinuclear cobalt complexes with hydrogen 
bonding ability will be more effective at metalloshielding oligosaccharide‐protein function. 
In addition, simple metal complexes interact with Fondaparinux and may be considered in the 
development of future antimetastatic drugs in application of hard-soft acid-base concepts. 
Vanadium, a hard acid, reacts with oxygen, a hard base, forming a stronger bond than Manganese, 
an intermediate acid, with oxygen. Vanadium also produces a stronger interaction than Manganese 
due to a higher overall charge of the complex and due to its ability to interact with more sulfate 
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groups. Vanadyl, containing oxygen, lowered the overall charge of the metal complex and limited 
the amount of “metalloshielding”. New patterns of metal-ion binding can be achieved by the 
interplay and application of hard–soft acid–base concepts. 
Further studies should be performed using the less cytotoxic cobalt complexes to confirm their 
strength of interactions to HS. Assays using ITC would show the competitive binding of cobalt 
complexes vs growth factors binding to FPX. Linear, multinuclear cobalt complexes should also 
be studied, mimicking the lead compounds TriplatinNC or BBR3464. These linear cobalt 
complexes should interact relatively similarly as the PPCs with the anionic HS while maintaining 
the low cytotoxic profile. A BBR3464 mimic would allow strong covalent interactions between 
the hard acid of cobalt and the hard base of oxygen, while the non-covalent hydrogen bonding 
would allow sulfate cluster interactions for strong metalloshielding. Furthermore, the poor 
pharmacokinetic results that plagued BBR3464 should be overcome by limiting the inactivation 
of sulfur containing biomolecules and producing a target that is overexpressed on cancer cells.  
Overall, these results demonstrate the utility of the metalloglycomics concept in developing new 
classes of molecules for study of glycan structure and function. It is clear that oligosaccharides 
represent a viable alternative cellular target to oligonucleotides and these results further emphasize 
the unique dual-function nature of metal complexes. 
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Appendix 
 
Synthesis and Characterization 
 
trisethylenediaminecobalt(III) chloride 
Cobalt(II) chloride hexahydrate (6.0 g, 25.0 mmol) was dissolved in 17.5 mL of water. Another 
solution was prepared by dissolving 4.51 mL of anhydrous ethylenediamine (2.7 eq, 67.5 mmol) 
in 12.5 mL of water and cooled to 0 °C on ice and neutralized partially with 4.35 mL of 6 M HCl 
(25.5 mmol). Both solutions were mixed together and 5 mL of 30% hydrogen peroxide was added 
with stirring. The solution was then boiled to a volume of approximately 30.0 mL.  30 mL of 12 
M HCl was added, followed by addition of 60 mL of ethanol and allowed to cool to room 
temperature for 30 mins. The solution was cooled to 0 °C and the precipitate was collected and 
washed with ice-cold ethanol and ether (10 mL each). The final product was dried in air. Yellow 
crystals collected 4.3 g 61.7%. 
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1H NMR: 
Theoretical:  
4.80 ppm D2O 
5.2 and 4.8 ppm (6:6) NH2 
2.8 ppm (12) CH2 
Actual: 
5.2 ppm (6) NH2 and 4.8 ppm (under D2O) 
2.8 ppm (12) CH2 
 
 
 
 
 
 
 
Figure A.1. 1H NMR of Co(en)3Cl3 in water. 
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trans-dichlorobis(ethylenediamine)cobalt(III) chloride 
300 mL of water was heated in a 600 mL beaker and maintained at a moderate boil. In an 
evaporating dish, 4.0g of Cobalt (II) Chloride Hexahydrate (16.6 mmol) was combined with 10 
mL of water. To this was added 15 mL of 10% ethylenediamine (en) (0.23 mmol). The evaporating 
dish was placed on top of the beaker of boiling water. The mixture was stirred over this steam bath 
for 40 minutes; the volume of the solution was maintained at about 5 mL by occasionally adding 
small portions of water. During this process, the Co2+ was oxidized to Co3+ by the oxygen in the 
air. Good agitation was necessary to promote solvation of the oxygen. To the solution, 12 mL of 
Concentrated 12 M HCl was added. Heating and stirring was continued without addition of water 
until a thin slurry of crystals was formed. The slurry was cooled to Room Temperature by setting 
the evaporating dish on the lab bench and stirred occasionally for 15 minutes. The mixture was 
collected using a Buchner funnel with Side-Arm Flask attached to an aspirator. The precipitate 
was washed with a minimal amount of 6 M HCl (2 mL) and air dried. 1.19 g collected green 
precipitate (20.8%). 
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1H NMR: 
Theoretical:  
4.80 ppm D2O 
5.2 (1) NH2 
2.8 ppm (1) CH2 
Actual: 
5.2 ppm (1) NH2 
2.8 ppm (1) CH2 
 
 
 
 
 
Figure A.2. 1H NMR of Co(en)2Cl2Cl in water. 
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UV-VIS λmaz: 
Theoretical 
cis: 390, 530 nm 
trans: 450, 625 nm 
Actual 
cis: 380, 520 nm 
trans: 450, 625 nm 
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Figure A.3. UV-VIS spectra of isomerization  of Co(en)2Cl2Cl in water. 
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Isothermal Titration Calorimetry 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.4. ITC of isomerization  of Co(en)2Cl2Cl in water. 
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